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ABSTRACT
Lung cancer is the leading cause of cancer-related deaths in the United States with
a 5-year survival rate of only 18%. Differences in access to care and treatment utilization
may play a role in observed survival disparities among rural patient populations. This
dissertation aimed to examine rural disparities in all-cause and lung-cancer specific
survival, time to treatment initiation, and utilization of surgical treatment among nonsmall cell lung cancer cases.

We utilized comprehensive cancer registry data from the Surveillance,
Epidemiology, and End Results program linked with Medicare billing claims (SEERMedicare) for non-small cell lung cancer (NSCLC) patients diagnosed between 20032011. We compared differences in all-cause survival and lung cancer-specific survival
based on urban and rural residence while controlling for demographic and clinical
characteristics of patients. We examined differences in the time between diagnosis and
treatment initiation for urban and rural NSCLC patients and furthermore the impact of
time to treatment on survival. We also implemented multilevel modeling techniques to
assess the associations of county-level neighborhood and patient-level demographic and
clinical characteristics with utilization of surgical treatment in early-stage NSCLC
patients.
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Our results showed that rural NSCLC patients had worse all-cause and lung
cancer-specific survival than their urban counterparts. Our adjusted Cox PH model results
found that differences in the time between diagnosis and treatment initiation may not
contribute to rural disparities in lung cancer survival. However, utilization of surgical
treatment at any time point was related with high survival probability. More than 50% of
the patients who received surgery survived longer than 5 years following diagnosis.
When examining differences in surgical utilization, factors related to decreased
likelihood of surgical treatment for lung cancer included living in higher poverty
counties, enrollment in Medicaid, and black race. When controlling for county-level
poverty and patient characteristics, rurality was not significantly related to differences in
surgical utilization among NSCLC patients.

This dissertation identified persisting rural disparities in all-cause and lung
cancer-specific survival in the United States. Observed rural disparities may be due to
sociodemographic factors more common among rural cancer patients such as public
insurance or being uninsured, and low incomes. In concordance with previous research,
black NSCLC patients were also less likely than white patients to receive surgical
treatment. Targeted interventions are needed to improve lung cancer survival in rural, low
income, and black patient populations, particularly focusing on improving utilization of
surgical treatment in early-stage cases among these groups.

Keywords: Non-small cell lung cancer, lung cancer survival, survival analysis, multilevel
modeling, health disparities
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CHAPTER 1
INTRODUCTION
Among all cancer types, lung cancer is the leading cause of cancer-related death
in the United States (U.S.), for both men and women, killing approximately 156,000
people in 2017.1 In comparison, an estimated 134,000 people died from the next three
deadliest cancers combined (colorectal, pancreatic, breast) in the same year.1 The
American Cancer Society estimates that there will be 234,030 newly diagnosed cases of
lung cancer in 2018, making up 13% of the total cancer cases in the U.S.,2 creating a
financial burden of over $12.12 billion for treatment costs.3 Lung cancer survival varies
depending on patient and environmental factors such as stage at diagnosis, smoking
history, treatment approaches, and access to care. Such factors differ by racial and ethnic
groups, sex, rurality, and geographic region, creating observed disparities in lung cancer
survival.

Black and Native American populations have the highest lung cancer-specific
mortality rates when compared to all other racial and ethnic groups.4–7 The causes of
these racial disparities are complex and multifactorial, including differences in access to
care and risk factors for lung cancer. Existing data points to distrust of the medical
community, perceived discrimination, and a predominately white medical workforce as
possible contributing factors.4,8,9 Black lung cancer cases are also diagnosed at later
stages and less likely to receive surgery than white cases (even in early stages).4–6,10–13
1

Similarly, black and Native American cases are less likely to receive smoking cessation
counseling (a crucial component of lung cancer prevention) and more likely to be
diagnosed with lung cancer at late stages than whites.7,14–18 In contrast, Hispanic and
Asian American lung cancer patients have longer survival times that whites.4

A sex disparity in survival from lung cancer has been observed with men having
shorter survival than women.19–22 Historically, the population of lung cancer patients in
the US has been predominately male, though the proportion of female cases has increased
in recent years with incident cases in 2017 being 52.5% male and 47.5% female.2,12
While the incidence of large cell and squamous cell lung cancers has decreased over time
for both men and women, adenocarcinoma incidence rates in men have remained steady
and increased among women.12 In fact, higher overall lung cancer incidence rates among
women than men were observed for those born between 1965-1980.23 The smoking
prevalence among women in this age group was higher than their predecessors but lower
than the smoking prevalence in men of the same age and does not fully account for the
observed increase in the incidence rates.23 Sex differences in lung cancer incidence and
survival need to be examined continuously in the future.

In the U.S., rural residents have a higher smoking prevalence, higher overall
incidence rates of lung cancer, and higher rates of late-stage lung cancer diagnoses than
urban residents.24–27 When examining lung cancer mortality rates from 1999-2016 by
region and rurality, the highest mortality rates existed in the rural South at 63.0 per
100,000 population.28 Rural residents with lung cancer are also less likely to receive
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treatment than urban residents with lung cancer.29 Late-stage diagnoses and limited
treatment options for late-stage cases are contributing factors to the higher observed
mortality rates for rural Americans with lung cancer.29 Combined with the sheer disease
burden, rural residents also face higher poverty rates, lower education, and a higher
proportion of uninsured and elderly adults than urban residents.30,31

Early detection is integral in improving survival from lung cancer.32 Over 65% of
lung cancer cases are diagnosed in stage III or IV.33 When detected at stages I and II, the
survival rate for lung cancer is 54%, and when detected after metastasis to other organs,
the survival rate drops to 4%.2,34 Annual screening by low-dose computed tomography
(LDCT) for patients deemed high risk for lung cancer began being covered by most
private health insurance providers and Medicare in 2015.35 In randomized clinical trials,
LDCT screening among high-risk individuals was shown to reduce the risk of lung
cancer death by 20-40%, providing a promising avenue to improving survival rates for
smoking-related lung cancers in the future.36–38 Equal access to LDCT screening centers
among rural residents of the screening-eligible population needs to be prioritized to close
the gaps in disparities in early detection of lung cancer.39,40

Regional differences in lung cancer survival exist as well.41–44 Southeastern states
have the highest mortality-to-incidence ratios for lung cancer.42 Disparities in accessing
care for rural and black populations are most pronounced in the South where smoking
prevalence, lung cancer incidence rates, and poverty are also the highest in the nation.31,45
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The largest proportion of the lung cancer screening-eligible population also resides in the
South.39

1.1 Statement of the Problem
First, the goal of this research was to identify existing disparities in lung cancer
outcomes (i.e., survival and treatment utilization) among persons of different racial/ethnic
backgrounds, sex, rurality, and geographic locations. Identifying persistent (or
increasing) disparities may aid in the development of targeted public health interventions
and policies for at-risk populations or regions. While lung cancer incidence and mortality
rates among black and Native American races and rural residents are higher in
comparison to their white and urban counterparts, estimates of these disparities need
updating. The available data is largely based on non-generalizable datasets (e.g., single
state cancer registries, single health care system), restricted to rare types of lung cancer
(e.g., small cell lung cancer), data from the early 1990s to early 2000s, or survival not
adjusted by race, sex, and/or rurality in modeling approaches.11,46 Lung cancer survival
data is highly cited in the field but is based on data from as far back as 1991 with the
most recent publications utilizing data on non-small cell lung cancer only up to 2006.6,47–
53

We anticipate that our results will be highly cited data on lung cancer survival.

Second, significant changes have been made in the prevention and control of lung
cancer in recent years with respect to lung cancer screening guidelines, tobacco control
policies, declining smoking rates, genetic testing availability, oncology telemedicine
(teleoncology), pharmaceutical development, and personalized/precision medicine.
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Screening reduces mortality via early detection, while tobacco control and declining
smoking prevalence have driven down lung cancer incidence.54–56 Enhanced treatment
approaches including genetic testing, teleoncology, evolving first-line drugs, and
personalized medicine improve survival and expansion of these treatment approaches
have the potential to change the disease progression.57–59 Improved health insurance
coverage through the Affordable Care Act (ACA) may also play a role in closing gaps in
survival disparities between black and white populations. The percentage of black adults
without health insurance decreased from 21% to 11% from 2010 to 2015.60 A reference
point for lung cancer survival among different racial groups is needed as we move into
this new era to measure the impact, if any, that new screening and treatment efforts may
have on the survival of lung cancer patients at the population-level.

Third, continuing expansion of rural oncology providers and early detection of
lung cancer via annual LDCT screening provide possible avenues for reducing rural and
racial disparities. The results of this project allow for monitoring of temporal changes in
disparities when compared with results from earlier cohorts from SEER-Medicare data.
Additionally, the National Cancer Institute’s (NCI) stated research emphasis areas
currently includes a focus on health disparities and rural cancer control current research.61
This work contributes to their research agenda61 by identifying geographic areas of high
need or disparities among rural populations, providing formative data needed to develop
and/or target future research projects.

5

1.2 Aims and Hypotheses
To address these known gaps in the field, we implemented a comprehensive
registry and claims-based analysis of lung cancer patients in the U.S. using the existing
2003-2011 SEER-Medicare database for all aims. Specifically, we:

Aim 1: Investigated disparities in lung cancer-specific and all cause survival by
race/ethnicity, sex, and geography and identify patient-level and county-level factors
associated with survival
Hypothesis 1a: We hypothesized that lung cancer survival and overall survival would be
lower among black and Native American races vs. whites, men vs. women, and rural vs.
urban residence.
Hypothesis 1b: We further hypothesized that these disparities would be most pronounced
in the South Census region (SEER locations in Louisiana, Kentucky, Georgia).
Methods: We used Cox Proportional Hazards models for primary lung cancer cases

Aim 2: Examined differences in lung cancer-specific survival at differing thresholds
of treatment initiation
Hypothesis 2: We hypothesized that lung cancer survival would be highest among those
initiating treatment within 4 weeks of diagnosis.
Methods: We used three time dependent and stratified Cox Proportional Hazards models,
one for each treatment type (surgery, chemotherapy, radiation), comparing survival of
those (with the same stage at diagnosis) initiating treatment after diagnosis at five
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differing thresholds: 4 weeks or less, 5-6 weeks, 7-9 weeks, 9-12 weeks, greater than 12
weeks.

Aim 3: Explored disparities in utilization of lung cancer surgical treatment and
related patient and county predictors among lung cancer patients
Hypothesis 3a: We hypothesized that county-level factors would impact surgical
treatment utilization among lung cancer patients
Hypothesis 3b: We further hypothesized that Medicaid enrollees (low income) and black
patients would be less likely to receive surgery when compared to those not on Medicaid
and white patients
Methods: We performed a multilevel logistic regression examining patient factors nested
within counties (and county-level factors) associated with utilization of surgical treatment
for lung cancer

1.3 Significance and Rationale
The goals of this project were to identify potential disparities in lung cancer
survival along with access, utilization, and timely receipt of treatment for lung cancer.
There is currently no standard guideline for appropriate time intervals between the data of
diagnosis and treatment initiation for the of lung cancer. Time may play a role in lung
cancer survival as lung cancer is an aggressive disease that metastasizes to other organs.
Differences in time to treatment initiation may be an important mechanism driving
observed disparities in lung cancer mortality, especially among black and Native
American races, and rural residents. Empirically based guidelines for timeliness of
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treatment could provide a valuable measure for patients interested in seeking second
opinions or for those concerned about time delays in scheduling required appointments
following initial diagnosis.

A better understanding of disparities in survival and access to surgical cancer
treatment is a crucial step in improving lung cancer survival. Patient race/ethnicity, sex,
and residential location impacts the course of cancer treatment received.4–6,11,13,62 Our
results provide insight necessary to develop targeted interventions aimed at improving
access to treatment and survival of lung cancer by identifying areas with the greatest need
of expanded healthcare services, including but not limited to teleoncology, mobile LDCT
screening units, and hospital partnerships (e.g., local tumor boards, physician sharing
arrangements). This also lays the groundwork for potential interventions aimed at
advancing patient navigation for racial minorities or rural patients, patient education
initiatives improving surgical acceptance among black and Native American patients, as
well as physician education on discrimination, bias, and cultivating trusting relationships
with patients.

Race and ethnicity, rurality, and region may be social determinants of patient
experience in navigating cancer care, influencing potential differences in survival rates.
Residents of rural counties may have longer travel times to cancer treatment facilities and
decreased likelihood of receiving care from specialist physicians, such as thoracic
surgeons. This could contribute to differences observed in urban and rural outcomes as
utilization of surgical treatment can greatly improve survival among early stage cases.
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Our examination of urban-rural differences in timely treatment and lung cancer survival
also provides insight into how space and place impact receipt of healthcare. Examining
factors for potential intervention is imperative in addressing the multifaceted mechanisms
driving healthcare decisions. The growing focus by federal agencies on multilevel
intervention research points to the importance of researching various sources of impact
on patient outcomes. Projects such as ours, which help pinpoint predictors of survival, the
timeliness of cancer treatment, and the utilization of surgical treatment open the door for
future changes to health care policy and interventions aimed at improving equity to
access to care, and ultimately survival rates.
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CHAPTER 2
LITERATURE REVIEW
This chapter provides a brief overview of the existing data related to lung cancer
survival including environmental exposures, histology, disease staging, treatment types
and timeliness, cancer treatment centers and patient characteristics (e.g., race/ethnicity,
sex, rurality, and residential location). An understanding of lung cancer history, causes,
treatment, and related disparities is crucial to comprehension of the evolving landscape of
the disease.

2.1 Epidemiology of Lung Cancer
Several environmental exposures have been directly linked to lung cancer through
epidemiologic research dating back to the 1950s.56 Lung cancer incidence in the U.S.
began increasing in the 20th century with increased popularity and mass production of
cigarettes containing addictive materials, particularly nicotine. In the 1950s, U.S. and
British researchers published numerous studies demonstrating a probable link between
cigarette smoking and lung cancer.63–73 Subsequently in 1964, the U.S. Surgeon
General’s Advisory committee released a report compiling the existing evidence warning
that smoking causes lung cancer, citing retrospective studies with relative risks ranging in
magnitude from 2.0 to 25.5 for the relationship of smoking and lung cancer. Since that
report, tobacco smoke has emerged as the most profound factor impacting lung cancer
incidence and premature death, with an estimated 80-90% of cases directly attributed to
10

active smoking and second-hand smoke exposure.74 Despite this, approximately 40
million Americans currently smoke.75 Time trends in the occurrence of lung cancer
closely follow smoking prevalence rates. Lung cancer mortality peaked among men in
approximately 1990 at 70 cases per 100,000 population and has since decreased every
year, closely tracking with declining smoking prevalence.55,56,76,77 Relatively high
smoking prevalence among black adults, men, residents of rural areas, and in the South
drive high lung cancer incidence and mortality in these populations.60,75,78

Approximately 10-20% of lung cancer cases are not linked to smoking.79,80
Chemical exposures such as radon, asbestos, nickel, and chromates are also strongly
linked to lung cancer.56,81,82 In 1970, asbestos was recognized as a hazardous chemical
and thus began being regulated by the Environmental Protection Agency (EPA). Radon,
the second leading cause of lung cancer, was first linked to lung cancer in mine workers
in 1989, the same year that the EPA issued a full ban on asbestos use.56,82 Moreover, high
levels of arsenic exposure are established as causing lung, liver, kidney, prostate, and
bladder cancer.82 Additional lung cancer risk factors include outdoor air pollution,
occupational smoke inhalation (e.g., firefighters) and smoke inhalation from cooking on
an open fire.56,83 Rarely, lung cancer occurs in those with no smoking history and no
known exposures to chemicals or smoke. These cases are often attributed to genetic
mutations or possibly unidentified environmental exposures.56,79,80

2.2 Low Dose Computed Tomography (LDCT) Screening
Annual LDCT screening significantly reduces lung cancer mortality by 20-40%.54
Following the National Lung Screening Trial in 2011, national organizations including
11

the U.S. Preventive Services Task Force (USPSTF) and the American Cancer Society
released recommendations for annual LDCT screening to individuals at high risk for lung
cancer.54,84–86 Although eligibility criteria vary by organization, the USPSTF classifies
high risk individuals as current and former smokers who quit within the last 15 years,
persons aged 55 to 80 years, and those with 30+ pack-years smoking history.35,84,87
Medicare began covering LDCT screening for high risk individuals (including a shared
decision-making visit with a qualified health care provider) in 2015.35 Although LDCT
screening for lung cancer increased from 3.3% in 2010 to 3.9% in 2015 following the
publication of the NLST results in 2011 and updated USPSTF recommendations in 2013,
national LDCT screening rates remain very low.88,89 Screening utilization significantly
varies by region with the highest utilization in Northeast (10.1%) compared to the
Midwest (2.2%), the South (3.5%), and the West (1.6%).39 Utilization does not mirror
the size of the LDCT screening eligible population, as the largest proportion of those
eligible (40.3%) resides in the South.39

Many factors contribute to low screening rates. Screening eligible smokers are
less likely to have a usual source of care than the general population and therefore less
likely to be referred for LDCT screening.90 However, eligible individuals who are
identified as smokers and have a usual health care provider appear to miss opportunities
to learn about LDCT screening from their healthcare providers. Previous research has
reported both physician barriers,91–93 and patient factors contribute to these missed
opportunities. For example, patients who smoke have reported barriers in discussing lung
cancer screening with their health care providers due to feelings of discrimination based
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on their smoking history.94,95 Furthermore, patients eligible for screening with
comorbidities may experience more harm than benefit, thus motivating the patient and
physician to decide against screening during a shared decision-making counseling
session.94 Screening among high-risk populations provides an opportunity to diagnosis
more cases at early stages. More research is needed to understand and improve low
screening utilization in an effort to further improve lung cancer survival.

2.3 Histology and Staging
Lung cancer histology and staging are associated with survival, as both play
prominent roles in defining the clinical characteristics of a case and choosing the
appropriate treatment approach following a lung cancer diagnosis. Lung cancer histology
is divided into two categories: non-small cell lung cancer (NSCLC) and small cell lung
cancer (SCLC). NSCLC accounts for 85-90% of all cases and includes three subtypes:
large cell, adenocarcinomas and squamous cell carcinomas.12 Adenocarcinoma is the
most common histologic type and is the most common type among never smokers.96 The
remaining 10-15% are SCLC, which is almost exclusively observed among smokers and
former smokers. SCLC is considered the most aggressive form of lung cancer since it is
the least responsive to chemotherapy.97 Small cell, squamous cell, and large cell
incidence rates have decreased over time while the incidence of adenocarcinomas has
increased in women and remained constant among men.12,98

The American Joint Committee on Cancer defines lung cancer stages 0-IV by
three combined categories, referred to as TNM classifications, including: primary tumor
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size (TX, T0-T4), regional lymph node involvement (NX, N0-N3), and distant metastasis
(M0, M1, M1a, M1b).99 Tumor size (T score) defines the greatest dimension in
centimeters and the physical location of the primary tumor.99 Determining the
involvement of lymph nodes (N score) has been cited as the most important piece to
staging the disease and determining the proper course of treatment.100 Conversely,
improper nodal detection can lead to treatment failure and decreased survival.101 Nodal
involvement can be determined through various methods (invasive/surgical approaches or
non-invasive scans: CT or PET).100 Surgical systematic nodal sampling is preferred by
the American College of Chest Physicians, with a detection rate almost twice that of
surgical selective sampling of lymph nodes and non-invasive scans.102 Cases with
metastasis (M1, M1a, M1b) are defined as Stage IV. Approximately 40% of lung cancer
cases are diagnosed with stage IV disease, with a 5-year survival rate between 010%.99,103

2.4 Treatment Options
Treatment approaches for lung cancer are highly variable depending on histologic
type, stage at diagnosis, genetic profile, overall health of a patient, and location of
cancerous nodule(s). Cancer-directed treatment is defined as any treatment approach
intended to control, remove, or destroy cancer cells in the body.104 Cancer-directed
treatment approaches may include surgery to resect the tumor, chemotherapy, radiation,
immunotherapy, or a combination of all four. Non-cancer-directed therapies are given for
clinical reasons such as pain management, nutrition supplementation, and diagnostic
tests. Cancer registries are required to differentiate between cancer-directed and non-
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cancer-directed treatments in patient records. For this project, we only considered the use
of cancer-directed treatment.

In otherwise healthy adults diagnosed with lung cancer before metastasis, surgery
is the most effective treatment approach to improve survival.100 Staging, tumor size,
tumor location(s), and patient comorbidities (i.e., medical operability) are collectively
considered when determining if surgical resection is appropriate and is often reserved for
patients diagnosed in early stages.100,105 Surgery to remove tumors from the lungs can be
complex, depending on the location of the nodules in proximity to crucial blood vessels
and surrounding organs.100

Lung resection for the treatment of lung cancer may be performed in various ways
(e.g., lobectomy, sleeve lobectomy, or pneumonectomy) through a traditional open
approach or via minimally invasive thoracic surgery (MITS), which includes videoassisted thoracic surgery (VATS) or robotic VATS (RVATS).100,106 Lobectomy (removal
of a lobe of the lung) is the preferred surgical approach for the surgical management of
lung cancer, recommended by the American College of Surgeons due to the lower rates
of tumor recurrence and longer survival in comparison to the use of segmentectomy
(removal of a segment of a lung lobe).100 Patient outcomes further improve when
lobectomy is performed by MITS rather than by an open surgical approach.106–108 In fact,
research has demonstrated increased 5-year survival, shorter hospital stays, better postoperative pulmonary function, and lower reported levels of pain in comparison to open
surgical approaches.106–108 Despite these advantages, MITS approaches have not been
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adopted uniformly as the standard approach to lung resection.109 Thoracic surgeons have
been shown to adopt recommended surgical guidelines more readily than general
surgeons and have better patient outcomes including improved survival.110,111 However,
thoracic surgeons are not widely accessible in rural areas, potentially resulting in unequal
access to high-quality surgery for early-stage lung cancer cases.112,113

In late-stage cases and/or people with poor health, surgery may not be an option.
Hence, chemotherapy and/or radiation is the next best treatment approach. Depending on
the stage at diagnosis, chemotherapy for lung cancer can be given prior to surgery, after
surgery (adjuvant therapy), or at the same time as radiation treatment (concurrent
therapy). Most patients receive a combination of two chemotherapy drugs given in cycles
lasting one to three days, with breaks in between over a three to four-week period.87 All
chemotherapy drugs recommended for use in the treatment of NSCLC are included in
Appendix A of this document.114

In the same way as chemotherapy, radiation may be given before surgery, after
surgery, and in some cases alone.87 Radiation prior to surgery is often an attempt to
shrink tumors to make them easier to remove. Radiation alone may be recommended for
late-stage patients as a palliative care approach. The two main types of radiation for the
treatment of NSCLC are external beam radiation therapy and brachytherapy (also
referred to as internal radiation therapy). Subtypes of external beam radiation therapy are
three-dimensional conformal radiation therapy (3D-CRT), intensity modulated radiation

16

therapy (IMRT), and stereotactic body radiation therapy (SBRT).87,115 Radiation therapy
is often given five days a week for up to seven weeks.

Lung cancer treatment is constantly evolving through the development of new
medications, novel genetic testing techniques, and advanced treatment protocols from
clinical trials. Immunotherapy drugs work to stimulate the immune system to destroy
cancer cells and can be given along with, after, or in place of chemotherapy. The first
immunotherapy drug for NSCLC, Opdivo, was approved in 2015 followed by Keytruda,
Tecentriq, and Imfinzi.116 Targeted therapy drugs are commonly used for late-stage
patients and are coupled with genetic testing to pinpoint when they are appropriate for
each patient. These drugs work to inhibit tumor development differently than
chemotherapy drugs through processes such as altering proteins, hindering chemical
signals, and blocking blood vessel production in tumors. In 2018 there were ten FDA
approved targeted treatments.114,117 Epidermal growth factor receptor (EGFR) mutation
testing was the first approved in 2013 following recommendations by the National
Comprehensive Cancer Network for EGRF testing for late-stage NSCLC patients in
2007.118 However, disparities may exist in the use of targeted therapies. An examination
of utilization of EGFR testing from 2011-2013 found it was being underutilized in all
practice settings and most commonly performed in urban areas and among Asians. On the
contrary, Medicaid recipients, Hispanics and black cases were the least likely groups to
be tested, potentially leading to missed opportunities for use of targeted therapies and
improved treatment outcomes for these populations.118
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Clinical trials provide opportunities to understand the efficacy of new treatment
approaches. Clinical trials are sometimes considered a last option in survival for latestage lung cancer patients when approved treatment options have failed or are not
considered appropriate. In December 2018, there were 149 NIH funded clinical trials
active in the U.S. focusing on innovative approaches to lung cancer treatment.119
However, it may be difficult for all eligible patients to access clinical trial locations. The
NCI and FDA have acknowledged the underrepresentation of racial minorities and rural
residents in past clinical trials.120,121 New initiatives such as the National Community
Oncology Research Program sponsored by NCI focus on bringing more clinical and
intervention trials to diverse communities serving minority and rural patients at local
community-based hospitals.121

2.5 Time to treatment initiation
Choosing the appropriate treatment approach varies depending on patient
characteristics and provider tendencies, which can impact the time between diagnosis and
treatment initiation. An appropriate time interval between diagnosis and treatment
initiation is defined as timely treatment and is one of six domains of health care quality
recommended by the Institute of Medicine.122 However, optimal timing of treatment
initiation and the impact of timely treatment on lung cancer survival is not well
defined.123–126 Recommendations from agencies such as the American Cancer Society
and American Lung Association suggest starting treatment “very soon” or “within a few
weeks” after a cancer diagnosis. These vague recommendations ideally could be more
precise.123 Because a cancer diagnosis can cause anxiety and depression that delay patient
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action to seek immediate follow-up care and plan a course of treatment, clearly defined
recommendations for timely treatment are needed to encourage prompt delivery of
guideline-concordant treatment.

2.6 Factors driving treatment delays
Previous research has reported multiple factors driving delays in treatment
including medical system processes, patient comorbidities, stage at diagnosis, and
diagnostic testing approaches. Medical system processes, including long referral periods,
have contributed to treatment delays in early-stage patients diagnosed in community
settings127 and time spent scheduling PET scans contributed to treatment delays in a
diverse population of Medicare patients.124 In a single health system in Texas, patients
treated at public hospitals experienced longer delays in treatment than those treated in
private hospitals (76 days vs. 45 days, p<0.01.128 Among a sample of veterans, the
median time to surgery was 98 days and waiting for smoking cessation significantly
delayed treatment for almost a third of the study sample (29%).125 In this same
population, time spent on evaluation and staging (a median wait time of 71 days for
scans) also contributed to delays in treatment.125 Missed diagnoses was reported as
causing delays in patient interviews from cancer centers, outpatient settings, and
community treatment centers.125,127,129 Late-stage diagnosis (versus early-stage) and
treatment in non-academic settings versus a VA hospital have been associated with
improved timely treatment in some studies.130,131 However, treatment for late-stage
disease at academic centers was associated with delays in a diverse population of patients
from the National Cancer Data Base as were urban location, having an income less than
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$35,000 and increasing Charlson comorbidity scores were all associated with delays in
treatment.132

2.7 Timely treatment and survival
Timely treatment and its association with lung cancer survival is not well
understood. Publications on the topic have used a range of definitions for treatment itself
(surgery, chemotherapy, or radiation) and timely treatment (e.g., median time from study
sample, arbitrarily 6 weeks). Few studies have identified a positive association between
timely treatment and improved survival in lung cancer patients. A study of early-stage
lung cancer patients at John Hopkins cancer center reported an average referral time of
61.2 days following diagnosis. They found that increasing weeks from diagnosis to first
surgery (measured continuously) predicted worse survival (HR=1.04, 95%CI:1.001.09).127 However, these results were not statistically significant after adjusting for
patient demographics and clinical factors. Findings from a 12-year sample of stage I
patients from the National Cancer Database found that surgery initiation before 8 weeks
post-diagnosis resulted in significantly higher survival rates.132 Similarly, a review among
Medicare patients found a median time-to-treatment of 27 days. In early-stage cases,
treatment initiation within 35 days was associated with improved survival. There was no
association between treatment time and survival for distant-stage cases.124

Others have reported conflicting findings, showing worse survival or no
association between timely treatment and lung cancer. In a small sample of veterans
(n=129) from a single health care system, the median time to treatment was longer than
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that reported in other settings at 84 days.133 They defined timely treatment as less than the
median, 84 days, and found that patients receiving timely treatment were more likely to
die than patients receiving care after 84 days (HR=1.6, 95%CI: 1.3-1.9). After stratifying
by severity, the results were not significantly different.133 A study of privately insured
lung cancer patients in South Carolina found patients who received treatment within 6
weeks of diagnosis had shorter median survival at all stages (36.9, 27.1, 12.4 months for
localized, regional, and distant) when compared to cases who received treatment in more
than 6 weeks (39.4, 33.8, 25.2 months for localized, regional, distant).134 Likewise, an
investigation of 482 stage I-III NSCLC patients in a single medical network in Texas
from 2000-2005 found a median diagnosis to treatment time of 33 days.128 They defined
timely treatment as less than the median 33 days and reported no association between
timely treatment and survival using Kaplan Meier survival analysis (p=0.42).128 An
examination of SEER-Medicare records from 2002-2007 showed a substantial proportion
of patients waiting over 300 days to initiate treatment.126 Timely treatment was defined
using guidelines published by the RAND corporation and the British Thoracic Society:
less than 8 weeks for surgery, 7 weeks for radiation, and 4 weeks for chemotherapy.126,135
In their survival analysis among 16,747 patients diagnosed in 2003 or 2004, they found
lower mortality risk for patients receiving delayed care (HR=0.68, 95%CI:0.66-0.71)
compared to patients receiving more rapid care.126

2.8 Disparities in timely treatment
There are also conflicting findings related to disparities in the time to treatment
initiation for lung cancer; however, overall studies found disparities relating to race, sex

21

and rurality. A study of the association between race and time to treatment initiation for
lung cancer among veterans found only slight racial differences in time to treatment
between black and white patients (72 days vs. 65 days, p=0.80).53 Using a Cox PH model
adjusting for patient and disease characteristics, black cases had significantly better
survival than whites (HR=0.30, p<0.01).53 A SEER-Medicare analysis of lung cancer
patients from 2000-2002 reported black patients had 1.4 times the odds of treatment
delays when compared with white patients (p<0.01).136 Other factors associated with
delays in treatment were Medicaid and Medicare dual enrollment (vs. Medicare alone),
being divorced or widowed (vs. married), and late-stage diagnosis (vs. early stage).136 A
SEER analysis using records from 2002-2007 reported differences in timely treatment by
race and sex where females were 25% less likely to receive timely treatment compared to
men and black patients were 66% less likely to receive timely treatment compared to
white patients.47

2.9 National Cancer Institute and Commission on Cancer Treatment Centers
Treatment center type is related to patient outcomes including survival.137–140
National Cancer Institute (NCI) designation and Commission on Cancer (CoC)
accreditation are two of the highest standards for cancer treatment centers. Patients
treated at these centers have better survival than those treated at non-accredited
centers.137–140 A study of 69,579 cancer patients in Los Angeles County found lung
cancer patients who did not receive their first treatment at a NCI-designated
comprehensive cancer center had worse survival than those treated at other cancer centers
after adjusting for demographic and clinical factors (HR=1.4, 95% CI, 1.3-1.6).137 More
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research is needed to understand the factors associated with patient utilization of these
centers in comparison to non-accredited treatment centers. NCI designation results from a
peer-review process through the National Cancer Institute. There are currently 14 NCIDesignated Cancer Centers and 49 NCI Comprehensive Cancer Centers located in 36
states, primarily in urban areas.141 Most NCI centers are part of high-volume university
medical centers. High patient volume and academic settings have been shown to have
better survival in lung cancer patients where post operation morality was 3.2% in highvolume settings (more than 90 operations per year) compared to 4.8% in low-volume
settings (p < 0.01)142 and are the primary locations of clinical trials testing new cancer
treatments.141

The Commission on Cancer (CoC), an accreditation program from the American
College of Surgeons, provides accreditation to high-quality treatment centers. The
proportion of hospitals with CoC accreditation changes per year and varies widely across
states. For example, in 2009 the proportion of CoC-accredited hospitals in Wyoming was
0% and 100% in Delaware.143 CoC accreditation requires treatment centers to meet
standards on prevention, research, education, and quality care aimed at improving
survival.144 When compared with non-CoC-accredited hospitals, CoC hospitals are larger,
more commonly in urban areas, and have more available services for cancer patients such
as patient navigation, financial counselors, and advanced surgical approaches.143,145
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2.10 Race and Ethnicity
Racial disparities in lung cancer incidence, treatment, and thus survival,
particularly among black vs. white race, are well documented.2,12,49,50,146–151 Observed
racial disparities in lung cancer survival may be a complex function of socioeconomic
differences, access to care, treatment disparities, comorbidities, smoking behavior, or
other factors. Statistically controlling for covariates such as socioeconomic status (SES),
stage at diagnosis, and comorbidities has been shown to reduce or remove survival
differences in survival observed between black and white lung cancer patients.146–149

2.11 Racial Differences in Incidence and Survival
Lung cancer incidence is higher in black adults than any other racial/ethnic group
in the U.S.2,12,50,150,151 Smoking functions as major contributor to the observed incidence
of lung cancer in black adults.150 The 2017 smoking prevalence for black adults in the US
was 14.9% compared to 15.2% among whites.152 Furthermore, black smokers are less
likely to use smoking cessation assistance and less likely to stop smoking than
whites.153,154 Even among never smokers, lung cancer incidence is higher in blacks than
whites.96,155 Black lung cancer patients also tend to be younger and diagnosed at a later
stage than their white counterparts.6,148

Like the overall U.S. population, cancer is the second leading cause of death
among Native Americans.156 Lung cancer mortality from 2009-2013 for Native American
men was lower than the incidence for white and black men but higher than Asian men.77
However, Native Americans in Oklahoma experience higher lung cancer incidence rates
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than whites.157 Native American women had the highest lung cancer incidence as
compared to white, black, and Asian women. Despite the higher incidence rates, Native
American women had lower mortality rates than white and black women.77

Lung cancer mortality rates are also highest among black men, followed by white
men, white women and black women, respectively.2 Research on racial differences in
lung cancer survival using small cohorts, state cancer registries, and SEER data similarly
report worse survival among black lung cancer cases than all other race
categories.4,5,146,149,158,159 Conversely, Asians have better survival than whites.4,155

Lung cancer survival among Hispanics is not well understood. In some
populations, the survival of Hispanics is cited as better than whites.4,155,160 Researchers
point to potential differences in histologic type, social support, or exposures (e.g., wood
burning smoke) as reasons for better survival in Hispanics, while others argue that
detection bias and diversity among Hispanics may play a role.161–163 An examination of
Florida and Texas cancer cases from 1995-2003 reported high missingness among
foreign-born Hispanics in the sample that can explain the previous observed rates of high
survival.162,163 In a study among stage I SEER registry patients from 1991-2000,
Hispanics had worse survival than whites.164 However, after adjusting for surgery and
stage at diagnosis, the difference was not statistically significant suggesting that
differences in surgical resection by race may explain observed survival differences
between Hispanics and whites.164
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The data related to Native American disparities in lung cancer mortality and
survival is sparse and presents conflicting results. An analysis of lung cancer cases
between 1999-2009 recorded by Indian Health Services found death rates among Native
Americans living in Contract Health Service Delivery Area (CHSDA) counties higher
than whites in the same CHSDA counties, citing disparities in tobacco control and
interventions as contributing factors.165 Kaiser Permanente Northern California reported
significantly higher comorbidities among Native American lung, breast, colorectal, and
prostate cancer patients compared to whites.156 However, after adjusting for
comorbidities and disease characteristics, all-cause mortality and cancer-specific
mortality were not significantly higher in Native Americans than whites.156 Similarly,
Indian Health Services records in Florida spanning 1996-2007 examining 148,140
patients found no difference in lung cancer survival between whites and Native
Americans.166

2.12 Racial differences in treatment
Racial differences in lung cancer treatment are also well documented. Black lung
cancer patients are less likely than white patients to receive timely treatment (within 6
weeks of diagnosis), receive radiation therapy, undergo surgical staging, and receive
surgical resection.8,10,11,13,47,155,164 When choosing to undergo surgical resection, black
patients are less likely than white patients to use high-volume hospitals, a metric
associated with better surgical outcomes such as survival.167 Black patients are also more
likely to refuse treatment all together, even when diagnosed at an early stage.8 Treatment
delays among Medicare beneficiaries were reported where Native Americans experienced
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significantly longer treatment delays and lower receipt of treatment than whites.168 Native
Americans were less likely to receive guideline concordant treatment, less likely to have
surgical resection, and had lower rates of follow-up surveillance than whites.168 Survival
was significantly lower among those who did not receive optimal treatment and surgery.
Minority groups’ potential distrust in medical providers, fatalism, and negative surgical
beliefs have been cited as contributing factors to differences in lung cancer treatment
utilization.155,164,169,170

2.13 Sex
More lung cancer cases are male than female, as the smoking prevalence among
men has historically been much higher than that of females. However, the gap between
males and females in lung cancer incidence is narrowing at 52.2% male and 47.5%
female in 2017.12,60,171,172 Of note, more lung cancer cases among never smokers are
female than male.22,23 and a higher proportion of adenocarcinoma lung cancer cases are
female than male.173–175 There is concern over biological differences, specifically higher
susceptibility to cigarette carcinogens in women than in men.173,176–178 Additionally,
women have a harder time quitting smoking compared to men.179

Female lung cancer cases tend to be younger and have better survival than men
even after controlling for age, stage, and treatment type.19,21,23,173,180,181 A meta-analysis
reported sex differences in targeted therapy and immunotherapy, where females benefited
more than males from EGFR inhibitors.182 Sex differences in histology and treatment
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response may need to be considered with greater magnitude when choosing the treatment
approach for lung cancer.22,182

2.14 Rurality
At least 46 million people live in rural areas of the U.S. and often face higher
rates of poverty, smoking, and overall poor access to healthcare in comparison to urban
areas.48,183 Most rural areas have a smoking prevalence twice that of large urban areas
contributing to higher lung cancer incidence and mortality rates in rural areas.24,48,184
Rural areas also have 1.15 (95%CI: 1.15-1.16) times the risk of lung cancer diagnosed at
late-stage compared to those in urban areas, making treatment decisions more
complicated and limiting.185 Even among stage I patients, rural residents have higher
odds of receiving no treatment than their urban counterparts (RUCA 9 vs. RUCA 1
OR=1.40, 95%CI: 1.09-1.80).48

The rural population is dispersed over 97% of the nation’s land area, often making
it difficult for rural residents to access healthcare resources needed to diagnosis and treat
lung cancer.186 Rural residents must travel farther to access care, specifically to access
specialty physicians.187 Access to specialists is important as treatment by specialists is
associated with receipt of cancer-directed therapy even among late-stage lung cancer
patients and improved survival.110,111,188,189 In a geographic analysis of drive times to
cancer treatment centers, researchers found that 45.2% of the population live less than a
one-hour drive to an NCI-designated center and 69.4% live within a one-hour drive to
academic centers.187 However, Native Americans, rural residents, and those living in the
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South had the longest drive times to any cancer treatment centers.187 When examining the
association of the interaction between race and rurality on access to cancer care, urban
black cancer patients had shorter travel times than urban white patients,190 yet rural black
patients had longer travel times than rural whites to NCI-designated Cancer Centers.
Rural black patients were also 58% less likely than rural whites to receive care at an NCIdesignated cancer center.191 On the other hand, in an analysis of self-reported quality of
care among rural breast, lung, colorectal, and prostate cancer patients, the rural cancer
patients reported getting cancer care quickly more so than urban cancer patients.192

2.15 Regional differences
The South bears the burden of the highest smoking rates and lung cancer
incidence in the country.50,193 Kentucky has the highest incidence rate of lung cancer
cases for both men and women.193 In 2015, the age-adjusted lung cancer incidence rates
in for men was 105.6 per 100,000 and 77.5 per 100,000 for women in Kentucky. In
comparison, Utah had the lowest age-adjusted cancer incidence rates at 29.6 per 100,000
for men and 22.1 per 100,000 for women. In Kentucky, 24.5% of adults currently smoke,
placing them the second highest in the nation in 2016 behind West Virginia at 24.8% of
adults.193 An examination of regional differences in racial disparities of lung cancer
incidence in 2016 reported that lung cancer incidence among black men in Kentucky is
twice that of Colorado, further illustrating the differences in the burden of lung cancer
between the two populations.150 A review of SEER and National Program of Cancer
Registries (NPCR) lung cancer data from 2004-2006 also reported differences in lung
cancer incidence by region where those living in the South had the highest lung cancer
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incidence.50 They also described racial differences in incidence by region; the highest
lung cancer incidence rates among whites were in the South, among Asians in the West,
among Hispanics in the Northeast and among blacks and Native Americans in the
Midwest.50 Based on these results, the authors recommended tailoring prevention
messages to fit regional culture.50

2.16 Socioeconomic Status
Socioeconomic status (SES) is an important factors influencing survival,
potentially working through mechanisms of low smoking rates, better access to care,
improved health literacy, and overall better health among high SES populations when
compared to low SES populations.51,146,194–196 Among lung cancer patients, low SES is
linked to lower likelihood of surgical resection, guideline-concordant treatment, and
lower survival.6,51,195,197,198 Even after adjusting for comorbidities, patients of the lowest
SES continue to have worse survival outcomes compared to those of higher SES
(HR=1.05, p<0.01).6 Differences in SES may be a contributing factor to the observed
cancer disparities among rural and black populations. While some have shown that
adjusting for SES eliminates rural and racial disparities,53,195 others have demonstrated
that these disparities are reduced, but not eliminated, after adjusting for SES.146,195,196

2.17 Martial Status
Marital status has also been associated with cancer survival, perhaps functioning
through improved SES and social support.146,195,196 Married individuals are less likely to
have late stage at diagnosis (OR=0.83, 95%CI:0.82-0.84), more likely to undergo cancer-
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directed treatment (OR=1.53, 95%CI: 1.51-1.56), and experience improved survival
when compared to non-married individuals (single, divorced, widowed) (HR=0.80,
95%CI: 0.79-0.80).196 The protective result of marital status may be stronger for men
than women.146

2.18 Summary
An understanding of disparities in survival and access/utilization of high-quality
lung cancer treatment facilities is a crucial step in reducing lung cancer mortality. Patient
race/ethnicity, sex, and location impacts cancer treatment and thus survival. The results
of our proposed project add to existing data on lung cancer disparities and our results
identifying barriers in surgical utilization among low income and black patient
populations provide necessary insight for the development of future interventions.
Further research aimed at improving surgical utilization among early stage cases may
improve survival of lung cancer among low income and black patient populations.
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CHAPTER 3
METHODS
To address the aforementioned gaps in the literature, we used the National Cancer
Institute’s Surveillance, Epidemiology and Ends Results (SEER) cancer registry data
linked with fee-for-service Medicare billing data from the Centers for Medicare and
Medicaid Services (CMS), referred to as SEER-Medicare.199 We used the SEERMedicare linked database to address all three of our research aims.

3.1 Description of SEER-Medicare Dataset
The SEER-Medicare data set provides population-based cancer registry data from
the SEER program and comprehensive Medicare billing data for fee-for-service (FFS)
Medicare beneficiaries. We utilized twelve years of linked SEER-Medicare claims data
from 2003-2014. SEER-Medicare data is fitting for our population of interest because it
covers nearly 26% of the U.S. population and two-thirds of lung cancer patients in the
U.S. are over the age of 65 (the age at which most individuals qualify for Medicare
coverage).200 SEER provides cancer registry information on patient disease
characteristics such as primary cancer site, stage at diagnosis, and tumor behavior.
Medicare FFS billing data provides information on all procedures and visits billed to
Medicare including the treatment(s) received and the associated dates and locations of
treatment receipt.
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The geographic coverage of the SEER-Medicare linked dataset is limited to that
of SEER registry sites in the United States: New Jersey, Connecticut, Iowa, Wisconsin,
Detroit, Michigan, Louisiana, Kentucky, Georgia, Seattle (Washington), California,
Hawaii, Utah, Idaho, New Mexico, Alaska Natives.

3.2 Description of the SEER Program
The main objective of SEER is to reduce the mortality of morbidity of cancer in
the US through research using cancer registry data. SEER began collecting cancer
registry data in 1973 in Connecticut, Hawaii, Iowa, New Mexico, Utah, Detroit, and San
Francisco/Oakland and has since expanded to include twenty registries representing a
diverse population of US residents.201 In addition to clinical data, SEER also provides
information on the cause of death, survival time, demographics, and county-level urban
versus rural designation. To address generalizability, NCI has shown that the
characteristics of the geographic areas covered by SEER registries are similar to that of
the overall US population in terms of education and poverty. The SEER registry
population does, however, have a higher proportion of foreign-born residents that the
general US population (17.9% vs. 13.2%). The racial coverage of the registry is 31.9% of
whites, 30.0% of blacks, 44.0% of Hispanics, 57.5% of Asians, 49.3% of American
Indians or Alaskan Natives, and 68.5% of Hawaiians or Pacific Islanders.201

3.3 Description of Medicare Fee for Service Claims
The Medicare portion of the dataset provides health care billing claims for
covered expenditures for enrollees in fee-for-service (FFS) Medicare. Those covered
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under Medicare Advantage (MA) do not have detailed billing claims available in the data
files, restricting analytic capabilities to the FFS population only. Medicare is limited to
those age 65 and older, those with disabilities, and patients with End Stage Renal
Disease.202

NCI and CMS perform the SEER-Medicare linkage process before releasing the
data files to researchers. This process occurred every 4 years between 1991-2003, every 3
years from 2006-2012, and now biennially since 2014 with the most recent linkage
available from 2016. The most recent files released in 2016 cover SEER data for patients
diagnosed with cancer through December 31, 2013 and their accompanying Medicare
billing claims through December 31, 2014. The linkage itself includes matching SEER
registry patient identifiers with corresponding identifying variables in Medicare master
enrollment files with a reported successful match rate of 93%.200

3.4 Study Sample
Our sample included subjects identified with a first primary diagnosis of nonsmall cell lung cancer lung cancer confirmed by a biopsy procedure on record. Receipt of
treatment was identified in claims data using CPT and ICD9 codes for chemotherapy,
radiation, and/or surgical resection. Our inclusion criteria are: 1) a first primary lung
cancer tumor diagnosed between 2003-2011, 2) a diagnosis of non-small cell lung cancer
(NSCLC) only, which accounts for approximately 85% of lung cancer cases, and 3) age
66 years and older. We excluded lung cancer patients who were diagnosed postmortem.
Patients undergoing surgical resection of the lung for reasons not related to treatment of
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lung cancer (e.g., to treat collapsed lung, removal of blood clots, removal of damaged
tissue from emphysema) or with Kaposi’s sarcoma of the lung (this disease has a unique
prognosis/associated complications) were also excluded (ICD-9 Codes in Figure 3.1 and
Appendix). Patients eligible for Medicare due to a diagnosis of End Stage Renal Disease
(ESRD) and/or disability were excluded from our study sample. These patients are often
younger and coping with complex medical conditions as compared with Medicare
beneficiaries who have aged into eligibility (65 and older).

3.5 Independent Variables
Patient-level variables were drawn from the SEER component of the data base
and included age of patient (66-69, 70-74, 75-79, 80-84, 85+), sex (male vs female), and
race with categories white, black, Asian and Pacific Islander, Native American/Alaskan
Native. SEER provides four different variables for patient rurality, also a main exposure
of interest. We used county-level U.S. Department of Agriculture defined Rural-Urban
Continuum Codes (RUCC) for all three aims.203 RUCC codes are based on metropolitan
population densities and adjacency to metro areas.203 We used primary RUCC codes, nine
whole number categories indicating population sizes, with three metro classifications and
six nonmetro classifications: 1) Metro county of over 1,000,000 population, 2) Metro
county of 250,000-1,000,000 population, 3) Metro county of under 250,000 population,
4)Nonmetro county of 20,000 or more population and adjacent to a metro area, 5)
Nonmetro county of 20,000 or more population and not adjacent to a metro area
6)Nonmetro county of 2,500 to 19,999 population and adjacent to a metro county, 7)
Nonmetro county of 2,500 to 19,999 population and not adjacent to a metro county, 8)
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Completely rural or less than 2,500 population and adjacent to a metro area, 9)
Completely rural or less than 2,500 population and not adjacent to a metro area.203 We
used SEER registry location to assign Census regions in the following four categories:
1.

Northeast: New Jersey, Connecticut

2.

Midwest: Iowa, Wisconsin, Detroit, Michigan

3.

South: Louisiana, Kentucky, Georgia

4.

West: Seattle, California, Utah, Idaho, New Mexico, Alaska Natives, Hawaii

Covariates included marital status, year of diagnosis, and Medicaid enrollment (as
a patient level measure of low income). We used clinical data from SEER on data of
diagnosis, cause of death, date of death, survival time, stage at diagnosis, and histology
type (with NSCLC as an inclusion criteria)

All statistical analyses were conducted with SAS software, version 9.4 (SAS
Institute Inc., Cary, NC). This research contained only deidentified secondary data
analyses and was deemed exempt from IRB review at the University of South Carolina.
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3.6 Paper 1 Methods
Investigate disparities in lung cancer-specific and overall survival by race/ethnicity,
sex, and geography and identify patient and geographic factors associated with
survival
Hypothesis: We hypothesized that lung cancer survival would be lowest among black,
rural, and male cases. We further hypothesized that these disparities would be most
pronounced in the South Census region.

3.6.1 Measures
Lung cancer disease characteristics and patient demographics were derived from
the SEER component of our SEER-Medicare data. Our main independent variable of
interest was rurality. Patient residence at county-level at the time of diagnosis was used to
assign levels of rurality using RUCC codes.203 The USDA 2003 RUCC designation,
based on 2000 Census data, were used for cases diagnosed between 2003-2009. The 2013
RUCC codes, based on 2010 Census data, were used to define rurality for cases
diagnosed in 2010-2011. We collapsed RUCC codes into three categories as follows: 1)
Large urban=Metro counties over 250,000 population, 2) Small urban =Metro counties
under 250,000 population, 3) Rural=All Nonmetro counties

We controlled for race (white, black, Asian, Native American, other), sex (male
or female), Census region (Northeast, Midwest, South, West) and stage at diagnosis
(localized, regional, distant) in our model. Cause of death was used to define lung cancerspecific and overall survival. Our outcome variables, vital status and survival time in
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months, are reported by SEER. The following covariates were also tested with the main
variables of interest for model selection based on literature reviews: year of diagnosis,
patient age at diagnosis, Charlson Comorbidity Index, treatment type (chemotherapy,
radiation, surgery, combination, all of the above), marital status, and Medicaid enrollment
(yes or no).

3.6.2 Analyses
We produced descriptive statistics for our study sample demographics and
performed between-group comparisons by rurality and stage at diagnosis using t-tests for
continuous variables and chi-square tests for categorical variables. We used the Kaplan
Meier method and the Log-Rank test to examine the unadjusted differences of all-cause
and lung cancer-specific survival by levels of rurality. We used the logrank trend test to
investigate a possible trend in survival with increasing rurality. We implemented
multivariable survival analyses through two Cox Proportional Hazards (PH) models, one
for all-cause survival and one for lung cancer-specific survival, with rurality as our
primary exposure of interest. Before performing model selection, we tested the
Proportional Hazard (PH) assumption for our model variables using log-log plots and
Schoenfeld residual plots across time with =0.05. Two of our variables violated the PH
assumption, race and receipt of radiation therapy. Through Likelihood Ratio testing, we
determined that the best approach was to use a stratified Cox PH model, stratified by
race. After examining the interaction of time with the variable for radiation therapy,
which also violated the proportional hazards assumption, we recognized a clear crossover
in all-cause survival probability at 12 months post diagnosis. We implemented a time-
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dependent model using a heavy side function at 12 months post diagnosis for the allcause model. In the lung cancer-specific model, the crossover of survival curves occurred
earlier at month 8, and a heavy side function was implemented at 8 months post
diagnosis. We selected variables in our final model through backward selection with
removal level of p≤0.05 and then examined potential significant interactions between 1)
rurality and sex, 2) rurality and Census region by performing additional Likelihood Ratio
Tests. Once our final models were selected, we produced hazard ratios with 95%
confidence intervals. We produced Kaplan Meier curves for levels of rurality in each
region since the use of time-dependent Cox Ph models does not allow for estimation of
final adjusted survival curves.

Figure 3.1 Conceptual Framework of Paper 1 Survival Analysis
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Table 3.1 Study Variable Definitions and Sources
Study Variable

Definition

Source

Aim(s)

Age at diagnosis

65-69, 70-74, 75-79, 80-84, 85+

SEER

1,2,3

Race

White, Black, Native American, Asian, Other

SEER

1,2,3

Sex

Male or female

SEER

1,2,3

Marital status

Married, not married, unknown

SEER

1,2,3

Comorbidity

Charlson Index

Medicare

1,2,3

Income level

Low income (Yes or No) provided as Medicaid recipient or
not

Medicare

1,2,3

End Stage Renal
Disease

Yes or No (exclusion criteria) ICD9 585.6

Medicare

1,2,3

Kaposi sarcoma

Yes or No (exclusion criteria) ICD9 176.4

Medicare

1,2,3

Date of diagnosis

Month and year; first biopsy

SEER,
Medicare

2

Vital status

Dead or alive

SEER

1,2,3

Cause of death

ICD codes

SEER

1,2

Date of death

Date of death agreement

SEER,
Medicare

1,2

Survival time

Survival time in months (from date of diagnosis)

SEER

1,2

Stage at diagnosis

I, II, III, IV

SEER

1,2,3

Histology type

Non-small cell vs other (inclusion criteria) ICD-O-3 C34

SEER

1,2,3

Patient characteristics
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Tumor factors

Geographic factors

Patient location at
diagnosis

State and county FIPS code

SEER

1,2,3

Rurality

County level Rural Urban Continuum Codes 2003 and 2013 SEER

1,2,3

Census region

Northeast, South, Midwest, West (defined from patient
registry location via SEER registry ID)

1,2,3

County Median
Income

Continuous measure of median income of a county to gauge Census
the socioeconomic status

Medically Underserved County MUA designation (Yes or No)
Areas

SEER, GIS

3

HRSA

3

Treatment factors
Yes, No, Unknown

SEER,
Medicare

1,2,3

Radiation therapy

Yes, No, Unknown

SEER,
Medicare

1,2,3

Chemotherapy

Yes, No, Unknown

Medicare

1,2,3

Time to treatment

First surgery, chemotherapy, or radiation – date of diagnosis SEER,
Medicare

2

Thoracic surgeries
other than removal of
malignant neoplasms

Benign neoplasms ICD9 211.0-235.8
Cystic fibrosis IDC9 277.02
Primary pulmonary hypertension ICD9 416.0
Emphysema ICD9 492.0-494.1
COPD ICD9 496
Pneumonia ICD9 486, 513, 516
Pleurisy ICD9 511.0-511.9
Abscess of the lung ICD9 513.0-513.1

1,2,3
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Surgery

Medicare

3.7 Paper 2 Methods
Examine differences in lung cancer-specific survival at differing thresholds of
treatment initiation
Hypothesis: We hypothesized that survival would be highest among those initiating
treatment within 4 weeks of diagnosis

Figure 3.2 Conceptual Framework of Paper 2 Survival Analysis

3.7.1 Measures
The outcome of lung cancer-specific survival time will be assessed from SEER
data on vital status and survival time in months. Our main independent variable will be
time from initial diagnosis to treatment defined at five differing thresholds: 4 weeks or
less, 5-6 weeks, 7-9 weeks, 10-12 weeks, greater than 12 weeks. Time to treatment will
be calculated by the weeks between the date of diagnosis (from SEER) to the time of the
first treatment billing code in Medicare. Treatment is defined as first surgery,
chemotherapy, or radiation and will be identified from Medicare billing codes using
42

HCPCS and CPT codes. A full list of the CPT, HCPCS, and ICD-9 codes for surgery and
radiation are listed in the appendix.204,205 To identify chemotherapy initiation, we will use
codes associated with a comprehensive list of chemotherapy drugs approved by the Food
and Drug Administration (FDA) for the treatment of NCSLC.204 HCPCS codes for this
list of drugs is available from the National Cancer Institute.205 Since our data set does not
include Medicare Part D (prescription drug billing codes), we will not be able to capture
chemotherapy medications taken at home by prescription. We will control for age, stage
at diagnosis, race/ethnicity, sex, rurality, and Census region. Rurality will be
dichotomous (urban vs rural) based on rural urban continuum codes (RUCC).

3.7.2 Analyses
For each treatment type, we produced frequencies for all variables included in the
model and performed between group comparisons by time to treatment using chi-square
tests with =0.05. We tested the unadjusted relationship between time to treatment and
lung cancer-specific survival with Kaplan Meier curves and the logrank test. We then
tested the Proportional Hazards (PH) assumption using log-log of survival probability
over time for all variables included in the model. We calculated univariate Hazards
Ratios (HRs) for all variables tested for inclusion and performed a backwards selection
with removal levels of 0.05 coupled with likelihood ratio tests to assess model fit. Using
our final models, we produced hazards ratios with 95% confidence intervals for survival
of NSCLC patients by categories of time to treatment.

43

For surgical treatment, two variables of interest violated the PH assumption: time
to surgery initiation and radiation treatment. Time to surgery initiation showed a clear
crossover in survival probability at 16 months post diagnosis. To account for these
violations in our model, we incorporated a variable for the interaction between time to
surgery initiation and survival time at 16 months post diagnosis and stratified by radiation
treatment.

When stratifying by a radiation in survival analysis, the stratified Cox PH models
constructs separate partial likelihood functions for each radiation group. The multiplies
the two functions are multiplied together and use values of the coefficient that maximize
the function. Therefore, the effect of radiation is absorbed into the time function and we
can no longer make comparisons on this variable. Time-dependent Cox PH models allow
us to account for the PH assumption of a variable, when deemed appropriate, and retain
the ability to draw conclusions on that variable. Further explanations on time-dependent
and stratified Cox PH models can be found elsewhere.206,207

For our sample of patients who received chemotherapy treatment, the variable for
radiation treatment also violated the PH assumption; thus, we applied a time-dependent
PH model. Specifically, we created and incorporated a time dependent variable into the
Cox PH model representing radiation 12 months post diagnosis or not.

`For the model of time to radiation treatment initiation, Census region violated the
PH assumption. We chose to use a stratified Cox PH model, stratified by region. As
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described above, using a stratified Cox PH model accounts for the effect of region in the
final model but does not allow for comparisons between regions.206

3.8 Paper 3 Methods
Explore disparities in utilization of surgical lung cancer treatment across county
characteristics (urban/rural, medically underserved areas, and by percent of
population 65 and over in poverty) and related patient and county predictors among
lung cancer patients seeking treatment
Hypothesis 3a: County-level factors would impact surgical treatment among early stage
lung cancer patients
Hypothesis 3b: Patients in rural counties, Medically Underserved Areas (MUAs), or in
high poverty counties would be less likely to receive surgical treatment for early stage
lung cancer

This study design incorporated multilevel logistic regression modeling techniques
to account for patient fixed effects nested within counties as well as county fixed effects.
Multilevel modeling was performed to identify patient and county factors influencing the
utilization of surgical treatment for lung cancer. We expected a clustering of
characteristics within levels of our data by county. For example, patients from the same
residential area (county) tend to be more alike than patients residing different counties in
terms of access to care and income. Multilevel modeling allowed us to account for these
non-independent responses at each level of the model.
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Nesting structure

Levels of Influence
County

Patients

County: Rurality, Percent of Population over 65
in Poverty, Medically Underserved Areas,
Random Effect

Utilization
of
Surgical
Treatment

Age, Race, Sex, Marital Status, Medicaid
Eligibility, Stage at Diagnosis, Grade, Laterality

Conceptual multilevel model of patients nested within geographic factors associated with utilization of surgical
treatment

Figure 3.3 Conceptual Framework of Multilevel Model

3.8.1 Measures
The dependent variable in our model, utilization surgical treatment center
(yes/no), was defined from SEER records on patient treatment type. The first level of our
multilevel logistic regression contained patient demographics and clinical characteristics
from SEER data: age at diagnosis, race/ethnicity, sex, marital status, Medicaid
enrollment, stage at diagnosis, grade, and laterality. We used a binary definition for
rurality in this model (urban versus rural) by collapsing RUCC codes into Metro/urban
versus Nonmetro/rural categories. Level-one patient factors were nested within level-two
county factors including rurality, percent of the population over 65 in poverty (as a
measure of socioeconomic status of the county), and Medically Underserved Area
designation (MUA). MUAs are county-level assignments for counties with too few
primary care providers for the population in the county.208
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3.8.2 Analyses
We employed a multilevel modeling approach for this aim, specifically a basic
random intercept logistic regression. This model allows the intercept to vary randomly
across clusters (counties) by incorporating cluster-specific (county) random effects. First,
we calculated descriptive statistics for patient-level factors across counties and test for
differences by chi-square tests (=0.05). We then estimated the null model predicting
surgery utilization from only county-level random effects. We then calculated the median
odds ratio (MOR) and intraclass correlation coefficient (ICC). The MOR explains the
median magnitude of the odds ratio between a randomly chosen high-risk county (rural,
low SES, MUA) versus a low-risk county (urban, high SES, not MUA), providing an
estimate of the amount of individual probability of surgical utilization attributed to
county characteristics.209 An MOR not equal to 1.0 indicates that the multilevel model is
an appropriate statistical approach for the data being used.209 The ICC provides a measure
of the total variation in the outcome that is attributed to clustering by groups (clustering
by county in our analysis). A significant ICC indicates that a multilevel modelling
approach should be used for the data.210 We then selected county-level predictors of
surgical treatment for our level-two model also backward selection. After our level-two
model was complete, we estimated our level-one model with patient characteristics
predicting surgical utilization. Variable selection was based on coefficients with
significant p-values less than or equal to 0.05 or deemed to be significant based on
literature related to our research question. We assessed model fit using pseudo R-squared.
After fitting our final model, we produced the estimated variance of the distribution of
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random effects and odds ratios with 95% confidence intervals for predictors associated
with utilizing surgical treatment among early stage lung cancer patients.
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CHAPTER 4
RURAL DISPARITIES IN ALL-CAUSE AND LUNG CANCERSPECIFIC SURVIVAL IN THE UNITED STATES: A SEER-MEDICARE
ANALYSIS1

1

Odahowski CL, Alberg A, Schootman M, Zhang J, Eberth JM. To be submitted to Lung Cancer
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4.1 Abstract
Introduction
Despite declining smoking rates nationwide, lung cancer remains the leading
cause of cancer-related death among both men and women in the United States. When
examining stage at diagnosis, those diagnosed at distant stage have the highest risk of
death with a 5-year survival of 4% compared to 54% among localized cases. For all
stages combined, the five-year survival is 18%. Lung cancer survival differs by race, sex,
and stage at diagnosis. Black and Native American lung cancer cases have worse survival
when compared to white cases while men have worse survival than women. However,
research regarding lung cancer survival differences by rurality is limited. Our objective
was to investigate the relationship of rurality with all-cause survival and lung cancerspecific survival, adjusting for clinical and demographic factors.
Methods
We examined 135,627 cases of non-small cell lung cancer diagnosed between
2003-2011 from SEER-Medicare and defined rurality using Rural Urban Continuum
Codes from the US Department of Agriculture. We used the Kaplan Meier estimator and
Log Rank test to examine the relationship of rurality with all-cause survival and lung
cancer-specific survival. We used the trend test to investigate a possible trend in survival
with increasing rurality. We implemented a stratified, time-dependent Cox Proportional
Hazards (PH) model to examine the relationship of rurality, stratified by race, with allcause survival and lung cancer-specific survival controlling for patient and clinical
characteristics. Based on our final models, we produced hazard ratios and 95%
confidence intervals stratified by race.
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Results
The log rank and trend test were significant for decreasing survival with
increasing rurality for both all-cause and lung cancer-specific survival (p<0.01). The
interaction of race and Census region was also significant in our final Cox PH model,
stratified by race. In the South and West regions, small urban and rural areas had worse
all-cause and lung cancer-specific survival than large urban areas, stratified by race. In
the South, the all-cause hazard ratio was 1.07 (95%CI: 1.03-1.10) for small urban and
1.10 (95%CI: 1.06-1.14) for rural, compared to large urban. The South lung cancerspecific hazard ratio for small urban was 1.09 (95%CI: 1.05-1.15) and 1.10 (95%CI:
1.06-1.15) for rural in comparison to large urban. The hazard ratios were slightly higher
for the West small urban (All-cause HR:1.13, 95%CI: 1.10-1.16; Lung cancer-specific
HR:1.12, 95%CI: 1.08-1.15) and rural (All-cause HR:1.11, 95%CI: 1.06-1.15; Lung
cancer-specific HR:1.12, 95%CI: 1.07-1.18) as compared to large urban, stratified by
race. In the Midwest, all-cause and lung cancer-specific survival was worse for only rural
areas compared to large urban with marginal significance, stratified by race (All-cause
HR: 1.07, 95%CI: 1.01-1.12; Lung cancer-specific HR: 1.07, 95%CI: 1.01-1.14). In the
Northeast, hazard ratios based on rurality were not significant for small urban (All-cause
HR: 1.01, 95%CI: 0.97-1.05; Lung cancer-specific HR: 0.99, 95%CI: 0.95-1.03) or for
rural (All-cause HR: 0.97, 95%CI: 0.87-1.08; Lung cancer-specific HR: 0.94, 95%CI:
0.83-1.06)
Conclusions
Rural residence was associated with lower all-cause and lung cancer-specific
survival. Future research should focus on identifying factors for intervention to improve
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health equity between urban and rural populations such as improvements in access to care
and receipt of guideline-concordant lung cancer treatment.

Keywords: Lung cancer survival; Rurality; Cox Proportional Hazards Model; Cancer
Registry

4.2 Introduction
Lung cancer is the leading cause of cancer-related death among both men and
women in the United States with a five-year survival of only 18%.2 However, survival
improves dramatically if the cancer is detected at an early, localized stage, with an
improved five-year survival rate of 54%, compared to 4% for distant stage at diagnosis.1,2
Many factors are related to survival, including socioeconomic status and clinical
characteristics such as comorbidities and histology type.103,181,43 Racial disparities are
documented for survival with black and Native American cases having lower survival
compared to whites, due in part to differences in comorbidities, increased likelihood of
late-stage diagnosis, and lower utilization of surgical treatment.4,49,146,148,149,156,166
Similarly, differences by sex have shown that women fare better than men with lung
cancer in terms of survival.19,181

Geographic variation in lung cancer survival by rurality and region needs to be
further examined. Rural areas of the US have higher smoking prevalence, higher lung
cancer incidence, and higher lung cancer mortality than their urban counterparts.27,78,211
Rural cancer patients are also more likely to live in low-income areas, have a limited
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supply of health care providers, and experience longer drive times to providers.78,187,190
These factors contribute to more late-stage diagnoses and lower utilization of surgical
treatment in rural patients than urban patients, both determinants of cancer
survival.185,190,211 Data from the Utah Cancer Registry showed that the 5-year survival of
rural residents was 5.2% lower than for urban residents.212 However, a similar study
using Georgia Comprehensive Cancer Registry data found no significant differences in
urban and rural survival after controlling for treatment.213 Rural-urban differences in
lung cancer survival may differ from across regions in the US, as many of the factors
related to lung cancer survival differ by region (such as race/ethnicity, income, education,
access to care, and smoking prevalence).78,214 In the context of lung cancer, the South has
the longest drive times to reach medical providers and the largest population deemed
high-risk for lung cancer (defined by LDCT screening eligibility)39,187as well as the states
with the highest lung cancer mortality-to-incidence ratios.42 Further research is needed to
examine survival disparities by rurality and region. Our objective was to examine
differences by rurality and region in all-cause and lung cancer-specific survival time in a
cohort of non-small cell lung cancer patients using SEER-Medicare linked data.

4.3 Methods
Data Source
We examined comprehensive cancer registry from the Surveillance,
Epidemiology, and End Results program linked with Medicare billing data (SEERMedicare)199 to examine cases of non-small cell lung cancer with a first primary tumor
diagnosed between 2003 and 2011. We excluded cases under age 66 to ensure at least 12
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months of Medicare billing claims prior to any cancer diagnosis. We also excluded cases
diagnosed post-mortem and any Medicare receipts with end stage renal disease as this
condition is associated with unique clinical challenges and short life expectancy. Lung
cancer clinical characteristics, survival time, and patient demographics were taken from
SEER. Our main independent variable of interest, patient rurality, was defined using the
patient residence at county-level at the time of diagnosis using Rural Urban Continuum
Codes (RUCC). RUCC codes, developed by the US Department of Agriculture (USDA)
Economic Research Service (ERS), are based on metropolitan population densities and
adjacency to metro areas.203 We collapsed the nine primary RUCC codes into the
following 3 categories: 1) Large urban - Metro county of 1,000,000 population or higher,
2) Small urban - Metro county under 1,000,000 population, 3) Rural – All nonmetro
counties. We used 2003 RUCC designation (based on 2000 Census data) for cases
diagnosed between 2003-2009 and 2013 RUCC codes (based on 2010 Census data) to
define rurality for cases diagnosed in 2010-2011. We defined regions by SEER registry
locations within 4 Census regions: Midwest (Iowa, Wisconsin, and Detroit, Michigan),
Northeast (New Jersey, Connecticut), South (Louisiana, Kentucky, Georgia) West (Utah,
Idaho, New Mexico, Alaska Natives, all California registries, and Seattle, Washington).
Cause of death from SEER records was used to define all-cause and lung cancer-specific
survival and has been previously assessed for validity.215 Our outcome variables, vital
status and survival time in months, were taken also taken from SEER. We controlled for
race/ethnicity (white, black, Asian, Native American, other). We did not include Hispanic
ethnicity in our race/ethnicity categories as it is not self-reported in SEER, but rather
assigned based on surname.216 We also controlled for sex (male or female), Census
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region (Midwest, Northeast, South, West) and stage at diagnosis (localized, regional,
distant) in our model. The following covariates were tested as main exposures of interest
(rurality) for model selection: year of diagnosis, patient age at diagnosis, Charlson
Comorbidity Index, marital status, Medicaid enrollment at the time of diagnosis (yes or
no), and treatment types (chemotherapy, radiation, surgery). Receipt of radiation and
surgery were reported by SEER. We used a validated SAS macro to pull chemotherapy
use from linked Medicare billing codes.217

Data Analyses
We produced descriptive statistics for our study sample demographics and
performed between-group comparisons by rurality and stage at diagnosis using t-tests for
continuous variables and chi-square tests for categorical variables. We used the Kaplan
Meier method and the Log-Rank test to examine the unadjusted differences of all-cause
and lung cancer-specific survival by levels of rurality. We used the logrank trend test to
investigate a possible trend in survival with increasing rurality. We implemented
multivariable survival analyses through two Cox Proportional Hazards (PH) models, one
for all-cause survival and one for lung cancer-specific survival, with rurality as our
primary exposure of interest. Before performing model selection, we tested the
Proportional Hazard (PH) assumption for our model variables using log-log plots and
Schoenfeld residual plots across time with =0.05. Two of our variables violated the PH
assumption, race and receipt of radiation therapy. Through Likelihood Ratio testing, we
determined that the best approach was to use a stratified Cox PH model, stratified by
race. After examining the interaction of time with the variable for radiation therapy,
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which also violated the proportional hazards assumption, we recognized a clear crossover
in all-cause survival probability at 12 months post diagnosis. We implemented a timedependent model using a heavy side function at 12 months post diagnosis for the allcause model. In the lung cancer-specific model, the crossover of survival curves occurred
earlier at month 8, and a heavy side function was implemented at 8 months post
diagnosis. We determined variables necessary to include in our final model to control for
confounding based on significance in our literature review and through development of a
Directed Acyclic Graph (DAG). We then examined potential significant interactions
between 1) rurality and sex, 2) rurality and Census region by performing additional
Likelihood Ratio Tests. Once our final models were selected, we produced hazard ratios
with 95% confidence intervals. We produced Kaplan Meier curves for levels of rurality in
each region since the use of time-dependent Cox PH models does not allow for
estimation of final adjusted survival curves.

4.4 Results
Patient Characteristics
Our final sample size included 135,627 NSCLC cases with over half (57.3%)
living in large urban areas, 28% in small urban areas, and 14.8% in rural areas (Table
4.1). All patient characteristics differed significantly by level of rurality (p<0.01). Onethird of the cases (31.2%) were 80 or more years old and the majority were white
(85.0%), males (50.6%), married (50.1%), and diagnosed at a distant stage (52.7%). With
respect to treatment, more than half (56.8%) received chemotherapy (defined from billing
codes) while most cases did not receive surgery (76.1%) or radiation therapy (66.2%),
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although recommended treatment varies depending on patient clinical factors (data not
available). In the total sample 13.4% were enrolled in Medicaid, 44.7% were in the West
Census region, and 30.2% had no comorbidities detected through billing data (i.e.,
Charlson comorbidity score=0). Missing or unknown responses were noted for race
(0.2%), marital status (3.4%), and receipt of surgery (0.6%),

Survival by Levels of Rurality
In large urban areas, 82.2% of cases died from all-causes and 69.3% died from
lung cancer during follow-up (Table 4.2). In small urban areas, 83.9% died from any
cause compared to 70.8% for lung cancer, and for rural areas, 85.4% died from all-causes
and 72.3% from lung cancer during follow-up. All-cause median survival was 8 months
for large urban areas and 7 months for both small urban and rural areas. Lung cancerspecific median survival was 10 months for large urban areas and 9 months for both
small urban and rural areas.

The Kaplan Meier and corresponding Log rank test showed significant differences
for both all-cause survival and lung cancer-specific survival by levels of rurality with
p<0.01. The logrank trend test was also significant at p<0.01 by decreasing levels of
rurality (large urban>small urban>rural). A multiple comparison test with Bonferroni
adjustment revealed significant differences in both all-cause and lung cancer-specific
survival with large urban vs. small urban (p<0.01) and large urban vs. rural (p<0.01). The
unadjusted survival for small urban compared to rural was not statistically different for
both all-cause and lung cancer-specific survival (p=0.05).
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Time-Dependent Cox Proportional Hazards Model, Stratified by Race
All covariates tested in addition to rurality (age, sex, region, marital status,
Medicaid enrollment, year of diagnosis, stage at diagnosis, and treatment types) were
statistically significant and retained in our final time-dependent Cox PH models, stratified
by race.

Geographic Factors
All variables tested for inclusion in final stratified time-dependent model were
statistically significant. We also found a significant interaction for region and rurality.
Due to this interaction, we calculated hazard ratios for each level of rurality by Census
regions (Table 4.3). In the South and West regions, small urban and rural areas had worse
all-cause and lung cancer-specific survival than large urban areas, stratified by race. In
the South, the all-cause hazard ratio was 1.07 (95%CI: 1.03-1.10) for small urban and
1.10 (95%CI: 1.06-1.14) for rural, compared to large urban. The South lung cancerspecific hazard ratio for small urban was 1.09 (95%CI: 1.05-1.15) and 1.10 (95%CI:
1.06-1.15) for rural in comparison to large urban. The hazard ratios were slightly higher
for the West small urban (All-cause HR:1.13, 95%CI: 1.10-1.16; Lung cancer-specific
HR: 1.12, 95%CI: 1.08-1.15) and rural (All-cause HR:1.11, 95%CI: 1.06-1.15; Lung
cancer-specific HR:1.12, 95%CI:1.07-1.18) as compared to large urban, stratified by
race. In the Midwest, all-cause and lung cancer-specific survival was worse for only rural
areas compared to large urban with marginal significance, stratified by race (All-cause
HR: 1.07, 95%CI: 1.01-1.12; Lung cancer-specific HR: 1.07, 95%CI: 1.01-1.14). In the
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Northeast, rurality was not significantly associated with all-cause or lung cancer-specific
survival with hazard ratios either very close to or less than 1.0.

Demographic Factors
A five-year increase in age was associated with decreased all-cause and lung
cancer-specific survival, stratified by race (All-cause HR: 1.10, 95%CI: 1.10-1.11; Lung
cancer-specific HR:1.08, 95%CI: 1.07-1.09). Females and Medicaid enrollees had more
favorable all-cause and lung cancer-specific survival compared to males (All-cause HR:
0.83, 95%CI: 0.81-0.84; Lung cancer-specific HR: 0.84, 95%CI: 0.82-0.85) and those not
on Medicaid (All-cause HR: 0.96, 95%CI: 0.94-0.99; Lung cancer-specific HR: 0.94,
95%CI: 0.92-0.96), stratified by race. Unmarried patients had a higher risk of all-cause
and lung cancer-specific death than their married counterparts (All-cause HR:1.12,
95%CI:1.10-1.14; Lung cancer-specific HR: 1.12, 95%CI:1.09-1.14).

Clinical factors
Compared with localized stage, distant stage at diagnosis had the highest
magnitude HR in our results for lung cancer-specific survival at 3.73 (95% CI: 3.62-3.83)
and all-cause at 2.96 (95%CI: 2.29-3.03), stratifying by race. Regional stage was also
associated with increased risk of death for both all-causes and lung cancer when
compared to localized stage and stratifying by race (All-cause HR:1.65, 95%CI:1.611.69; Lung cancer-specific HR:1.95, 95%CI:1.89-2.00). The association of comorbidities
differed for all-cause and lung cancer-specific survival. Comorbidities showed a doseresponse relationship for all-cause survival stratified by race, where each one-unit
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increase in the Charlson score corresponded with an increase in the all-cause hazard ratio
(Table 4.3). For lung cancer-specific survival, there was a slight increase in the risk of
death for patients with a Charlson score of 3 or higher compared to those with a score of
0-2 (HR: 1.18, 95%CI: 1.15-1.21). Among treatment options, those not receiving surgery
had the highest hazard ratios for both all-cause and lung cancer-specific survival (Allcause HR:3.01, 95%CI: 2.93-3.09; Lung cancer-specific HR:3.28, 95%CI:3.18-3.38)
compared to those who received surgery. Those who did not receive chemotherapy also
had higher hazard ratios than those who did receive chemotherapy for both outcomes
(All-cause HR:1.55, 95%CI:1.52-1.58; Lung cancer-specific HR:1.55, 95%CI:1.52-1.58).
Receipt of radiation therapy was associated with significant differences in all-cause
survival at 6 months post-diagnosis (HR:1.40, 95%CI:1.37-1.43) and marginally
significant at 12 months post diagnosis (HR:1.04, 95%CI:1.01-1.07). The relationship
was similar for lung cancer-specific survival at 6 months post diagnosis (HR:1.45,
95%CI:1.42-1.49). However, receipt of radiation therapy was not associated with
significant differences in lung cancer-specific survival at 12 months post diagnosis
(HR:0.97, 95%CI:0.95-1.00).

There was no difference in all-cause or lung cancer-specific survival for those
diagnosed between 2006-2008 compared to those diagnosed in 2009-2011. However,
those diagnosed between 2003-2005 had a lower hazards ratio for both outcomes (Allcause HR:0.58, 95%CI:0.56-0.59; Lung cancer-specific HR:0.56, 95%CI:0.55-0.58).
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4.5 Discussion
Our large-scale study to assess differences in all-cause and lung cancer-specific
survival found significantly worse survival for rural patients when compared to those in
large urban areas. Furthermore, the association of rurality on survival differed by region,
with worse survival in the South and West Census regions after adjusting for
demographic and clinical factors. These results are consistent with findings from previous
studies.211,212 Atkins et al found a dose-response relationship between rurality and
mortality when examining 348,002 lung cancer cases diagnosed between 2000 and 2006,
where lung cancer mortality increased with increasing levels of rurality. Regional
differences in access to care, screening utilization, environmental exposures, and
smoking behavior contribute to observed regional differences in survival.24,39,187

Comorbidities appears to be a stronger factor behind observed disparities in allcause survival. However, controlling for comorbidities did not mitigate the observed
differences in survival by rurality in our results. Our data lacked a measurement of
smoking status. Approximately 90% of lung cancer cases are caused by smoking.74
Furthermore, smoking causes other chronic conditions that can make cancer treatment
difficult for a patient to tolerate such as heart disease, chronic obstructive pulmonary
disorder (COPD), and peripheral vascular disease. The role of smoking in rural lung
cancer survival disparities should also be considered as the smoking prevalence among
rural residents is higher than in urban residents183,211,78 and the South has the highest
regional smoking prevalence in the US.39,214
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Similar to other studies, women also fared better for both all-cause and lung
cancer-specific survival after adjusting for covariates in the stratified model.19,173,180,182
Distant stage at diagnosis had a high hazard ratio (HR=3.73) compared to localized stage
at diagnosis for lung cancer-specific survival. Early diagnosis should continue to be a
focus of improvement in lung cancer interventions, and pursuit of equal access to LDCT
screening may play a role in improving stage at diagnosis among rural populations,
especially in the South with a high at-risk population based on USPSTF screening
recommendations.39 The time-dependent relationship we observed for radiation therapy
(with poor survival in the first year following diagnosis) fits with the standard treatment
recommendations for distant stage cases given radiation for pain management and not for
curative intent. Surgery is considered the most effective treatment for NSCLC when
deemed appropriate for patients.218,219 Our findings of a high HR=3.28 for lung cancerspecific survival in those who did not receive treatment compared to those who did is
likely an artifact of surgery occurring more frequently in cases with early stage at
diagnosis. Over forty percent of the cases in our sample did not receive chemotherapy
(43.2%), associated with 55% higher risk of all-cause and lung cancer-specific death
(HR=1.55). Except for radiation therapy received in the first year, treatment of any type
was associated with improved all-cause and lung cancer specific survival.

Strengths and Limitations
Our study had many strengths. The use of SEER-Medicare, a large populationbased cohort of lung cancer patients, provides high quality data from areas covering
approximately 26% of the US. The large sample size provided the statistical power to
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detect small differences. The SEER component of the data provides comprehensive
cancer registry data on patient clinical factors with follow-up of patients’ survival.
Medicare billing data also allowed us to capture existing comorbidities before diagnosis
with lung cancer and chemotherapy treatment after diagnosis. Expanded research on rural
health disparities is a recognized priority of the National Cancer Institute,61 and to our
knowledge, this is the first study assessing the relationship of rurality and region for both
all-cause and lung cancer-specific survival.

This study is not without limitations. While SEER-Medicare is the best available
data source for our research question, it is limited it in geographic coverage of the United
States, particularly for rural areas. Rural underrepresentation in national data is a
documented concern for rural health research and needs improvement in the future.220–222
Rural areas in the South, particularly in Alabama, Mississippi, and Arkansas, experience
particularly high state-level mortality for lung cancer.39 Not representing these areas of
documented rural disparities in our data may introduce a bias towards the null (i.e.
underrepresent the magnitude of the rural survival disparity) as these states have some of
the worst lung cancer mortality in the US.223 SEER data also does not contain
information on patient smoking history.222 Approximately 90% of lung cancer cases are
linked to smoking and the largest proportions of high-risk current and former smokers are
in rural areas and the South.39,55,56,78 Findings that rural lung cancer patients have worse
survival could be driven by higher smoking prevalence which is directly related to higher
comorbidities prevalence (e.g., COPD, heart disease) and histology that is less responsive
to treatment.224 Our definition of patients’ urban or rural designation was based on the
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patients’ residence at the time of diagnosis. It is possible that patients move before
diagnosis or following diagnosis which we were unable to measure. We also did not
examine use of targeted therapy and immunotherapy given that our cohort was diagnosed
between 2003-2011, before the US Food and Drug Administration (FDA) approved such
drugs in 2015.116 Our modeling approach, a time-dependent Cox PH model stratified by
race, does not allow us to make direct comparisons on race, a documented disparity in
lung cancer survival not captured here.

4.6 Conclusions
All-cause and lung cancer-specific survival were lowest among lung cancer
patients in rural counties compared with urban residents. When examined by rurality and
region, lung cancer cases in the South and West had the highest hazard ratios for both allcause and lung cancer-specific survival. Comorbidities and receipt of surgery appear to
be driving factors behind observed survival disparities. Future research should focus on
identifying effective intervention strategies to improve health equity between urban and
rural populations such as improvements in early detection, prevention and control of
comorbid conditions, and receipt of guideline-concordant lung cancer treatment,
especially in the South and West regions of the US.
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Table 4.1 Demographics of Non-Small Cell Lung Cancer Cases by Urban/Rural Designation,
SEER-Medicare 2003-2011

Total N
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Age
Mean (std)
Sex
Male
Female
Race
White
Black
Asian or Pacific Islander
Native American or
Alaskan Native
Other/Unknown
Census Region
Midwest
Northeast
South
West
Marital Status
Married
Not married
Unknown/Missing
Medicaid Enrollment
Yes
No
Surgery
Yes

Large Urban
77685

Small Urban
37920

Rural
20022

Total
135627

76.5 (6.7)

76.2 (6.6)

75.6 (6.5)

76.3 (6.7)

p-value

<.01
<.01
48.9%
51.1%

51.3%
48.7%

55.8%
44.2%

50.6%
49.4%
<.01

80.4%
9.7%
2.6%
5.7%

85.6%
7.2%
2.8%
3.0%

90.9%
6.3%
1.4%
0.9%

85.0%
8.3%
6.2%
0.3%

1.6%

1.4%

0.5%

0.2%
<.01

11.8%
22.2%
15.4%
50.6%

9.3%
17.5%
29.6%
43.6%

17.2%
3.4%
55.3%
24.1%

11.9%
18.1%
25.3%
44.7%

48.8%
47.7%
3.5%

50.9%
46.0%
3.2%

53.6%
43.2%
3.2%

50.1%
46.6%
3.4%

10.3%
89.7%

9.2%
90.8%

11.4%
88.6%

24.2%

22.7%

21.1%

<.01

<.01

<.01
23.3%
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No
Unknown/Missing
Radiation
Yes
No
Unknown/Missing
Chemotherapy
Yes
No
Charlson Comorbidity
Score
0
1
2
3
4
5
6
Missing/Unknown
Year of diagnosis
2003-2005
2006-2008
2009-2011
Stage at diagnosis
Localized
Regional
Distant

75.5%
0.3%

76.8%
0.5%

77.0%
1.8%

76.1%
0.6%
<.01

31.4%
67.4%
1.2%

34.0%
64.8%
1.2%

32.6%
64.2%
3.2%

32.3%
66.2%
1.5%
<.01

52.8%
47.2%

58.9%
41.1%

68.2%
31.8%

56.8%
43.2%
<.01

28.7%
22.7%
12.1%
6.2%
3.3%
1.9%
1.9%
23.7%

31.8%
25.0%
13.0%
6.4%
3.4%
1.9%
1.6%
16.9%

33.1%
28.1%
14.3%
7.1%
3.6%
1.9%
1.6%
10.2%

30.2%
23.9%
12.7%
6.4%
3.4%
1.9%
1.8%
19.8%

30.8%
34.5%
34.8%

32.3%
34.1%
33.6%

32.7%
34.7%
32.6%

31.5%
34.4%
34.1%

22.2%
24.7%
53.1%

22.0%
26.1%
52.0%

21.9%
25.9%
52.3%

22.1%
25.2%
52.7%

<.01

<.01

Table 4.2 Death Rates by Levels of Rurality among SEER-Medicare NSCLC Cases, 2003-2011
Among patients diagnosed with lung cancer:
Percentage who died from any cause
Percentage who died from lung cancer

Large Urban
82.2%
69.3%

Small Urban
83.9%
70.8%

Rural
85.4%
72.3%

Table 4.3 Time-Dependent Cox Proportional Hazards Results of All-Cause Survival, Stratified by Race,
SEER-Medicare NSCLC Cases 2003-2011
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Geographic Factors
Region by Rurality
Midwest
Large Urban
Small Urban
Rural
Northeast
Large Urban
Small Urban
Rural
South
Large Urban
Small Urban
Rural
West
Large Urban
Small Urban
Rural
Demographic Factors

Unadjusted All-Cause
HR (95% CI)

Adjusted All-Cause
HR (95% CI)

1.00 (Reference)
1.00 (0.96-1.05)
1.07 (1.03-1.12)

1.00 (Reference)
1.02 (0.97-1.08)
1.07 (1.01-1.12)

1.00 (Reference)
0.97 (0.94-1.00)
0.98 (0.94-1.00)

1.00 (Reference)
1.01 (0.97-1.05)
0.97 (0.87-1.08)

1.00 (Reference)
1.07 (1.04-1.10)
1.10 (1.07-0.14)

1.00 (Reference)
1.07 (1.03-1.10)
1.10 (1.06-1.14)

1.00 (Reference)
1.08 (1.06-1.10)
1.08 (1.04-1.11)

1.00 (Reference)
1.13 (1.10-1.16)
1.11 (1.06-1.15)
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Age, 5-year increase
Sex
Male
Female
Marital Status
Married
Not married
Medicaid Enrollment
Yes
No
Clinical Factors
Stage at Diagnosis
Localized
Regional
Distant
Charlson Comorbidity Score
0
1
2
3
4
5
6 or higher
Year of diagnosis
2003-2005
2006-2008
2009-2011
Surgery
Yes
No
Chemotherapy
Yes

1.18 (1.18-1.19)

1.10 (1.10-1.11)

1.00 (Reference)
0.85 (0.84-0.86)

1.00 (Reference)
0.83 (0.81-0.84)

1.00 (Reference)
1.21 (1.19-1.22)

1.00 (Reference)
1.12 (1.10-1.14)

1.08 (1.06-1.10)
1.00 (Reference)

0.96 (0.94-0.99)
1.00 (Reference)

1.00 (Reference)
1.78 (1.75-1.81)
47.45 (4.37-4.52)

1.00 (Reference)
1.65 (1.61-1.69)
2.96 (2.89-3.03)

1.00 (Reference)
1.07 (1.05-1.08)
1.18 (1.15-1.20)
1.31 (1.28-1.34)
1.42 (1.37-1.47)
1.53 (1.47-1.60)
1.69 (1.62-1.77)

1.00 (Reference)
1.14 (1.12-1.16)
1.25 (1.22-1.28)
1.35 (1.31-1.39)
1.43 (1.38-1.49)
1.61 (1.53-1.69)
1.70 (1.61-1.78)

1.02 (1.00-1.04)
1.06 (1.05-1.08)
1.00 (Reference)

0.58 (0.56-0.59)
1.01 (0.99-1.03)
1.00 (Reference)

1.00 (Reference)
4.647 (4.56-4.72)

1.00 (Reference)
3.01 (2.93-3.09)

1.00 (Reference)

1.00 (Reference)

No
Radiation, less than 12 months following
diagnosis
Yes
No
Radiation, 12 months or more following
diagnosis
Yes
No

1.37 (1.36-1.39)

1.55 (1.52-1.58)

1.00 (Reference)
1.14 (1.12-1.16)

1.00 (Reference)
1.40 (1.37-1.43)

1.00 (Reference)
0.56 (0.55-0.58)

1.00 (Reference)
1.04 (1.01-1.07)
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Table 4.4 Time-Dependent Cox Proportional Hazards Results of Lung Cancer-Specific Survival,
Stratified by Race, SEER-Medicare NSCLC Cases 2003-2011
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Geographic Factors
Region by Rurality
Midwest
Large Urban
Small Urban
Rural
Northeast
Large Urban
Small Urban
Rural
South
Large Urban
Small Urban
Rural
West
Large Urban
Small Urban
Rural
Demographic Factors
Age,
5-year increase
Sex
Male
Female
Marital Status
Married

Unadjusted Lung CancerSpecific
HR (95% CI)

Adjusted Lung CancerSpecific
HR (95% CI)

1.00 (Reference)
1.03 (0.99-1.08)
1.11 (1.06-1.16)

1.00 (Reference)
1.03 (0.97-1.10)
1.07 (1.01-1.14)

1.00 (Reference)
0.95 (0.92-0.98)
0.96 (0.88-1.05)

1.00 (Reference)
0.99 (0.95-1.03)
0.94 (0.83-1.06)

1.00 (Reference)
1.08 (1.05-1.12)
1.10 (1.07-1.14)

1.00 (Reference)
1.09 (1.05-1.15)
1.10 (1.06-1.15)

1.00 (Reference)
1.08 (1.05-1.10)
1.09 (1.06-1.13)

1.00 (Reference)
1.12 (1.08-1.15)
1.12 (1.07-1.18)

1.15 (1.15-1.16)

1.08 (1.07-1.09)

1.00 (Reference)
0.86 (0.85-0.87)

1.00 (Reference)
0.84 (0.82-0.85)

1.00 (Reference)

1.00 (Reference)
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Not married
Medicaid Enrollment
Yes
No
Clinical Factors
Stage at Diagnosis
Localized
Regional
Distant
Charlson Comorbidity Score
0-2
3 or higher
Year of diagnosis
2003-2005
2006-2008
2009-2011
Surgery
Yes
No
Chemotherapy
Yes
No
Radiation, less than 8 months following diagnosis
Yes
No
Radiation, 8 months or more following diagnosis
Yes
No

1.18 (1.17-1.20)

1.12 (1.09-1.14)

0.98 (0.96-1.00)
1.00 (Reference)

0.94 (0.92-0.96)
1.00 (Reference)

1.00 (Reference)
2.15 (2.10-2.20)
5.80 (5.69-5.92)

1.00 (Reference)
1.95 (1.89-2.00)
3.73 (3.62-3.83)

1.00 (Reference)
1.18 (1.16-1.20)

1.00 (Reference)
1.18 (1.15-1.21)

1.08 (1.07-1.10)
1.05 (1.03-1.06)
1.00 (Reference)

0.56 (0.55-0.58)
1.02 (1.01-1.04)
1.00 (Reference)

1.00 (Reference)
5.58 (5.46-5.69)

1.00 (Reference)
3.28 (3.18-3.38)

1.00 (Reference)
1.37 (1.36-1.39)

1.00 (Reference)
1.55 (1.52-1.58)

1.00 (Reference)
1.18 (1.16-1.20)

1.00 (Reference)
1.45 (1.42-1.49)

1.00 (Reference)
0.55 (0.54-0.56)

1.00 (Reference)
0.97 (0.95-1.00)
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Figure 4.1 Kaplan Meier Curves of 5-year All-Cause Survival by Rurality and Region, SEER-Medicare NSCLC Cases
2003-2011
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Figure 4.2 Kaplan Meier Curves of 5-year Lung Cancer-Specific Survival by Rurality and Region, SEER-Medicare NSCLC
Cases 2003-2011

CHAPTER 5
TIME TO TREATMENT INITIATION AND LUNG CANCER
SURVIVAL IN THE UNITED STATES: A SEER-MEDICARE
ANALYSIS2

2

Odahowski CL, Alberg A, Schootman M, Zhang J, Eberth JM. To be submitted to Cancer Epidemiology
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5.1 Abstract
Introduction
Rural patients must travel farther for cancer care than their urban counterparts,
perhaps putting them at higher risk of delayed treatment initiation. The relationship
between time to treatment initiation and survival is not well characterized and there are
currently no standard recommendations or quality metrics for the time between diagnosis
and treatment initiation for lung cancer patients. Our aim was to examine urban/rural
differences in time to treatment initiation and the relationship of time to treatment
initiation (for surgery, chemotherapy and radiation separately) and lung cancer-specific
survival.
Methods
We used SEER-Medicare linked data for non-small cell lung cancer (NSCLC)
patients diagnosed between 2003-2011. We excluded patients under age 66 (to ensure at
least 12 months of Medicare data prior to diagnosis) and those with Medicare eligibility
due to end-stage renal disease. We created three treatment-specific cohorts (cancerrelated surgery, chemotherapy, and radiation) using Medicare billing codes. Claims were
used to identify the first treatment date and time from diagnosis to treatment initiation
was examined continuously and categorized as follows: 0-4 weeks, 5-6 weeks, 7-8
weeks, 9-12 weeks, and greater than 12 weeks. We also explored a binary comparison of
treatment time: 0-12 weeks versus greater than 12 weeks. We used the Kaplan Meier and
logrank test to assess the unadjusted relationship of time to treatment initiation and
survival for each treatment type. We then used Cox Proportional Hazards (PH) models to
estimate the adjusted survival by time to treatment initiation after testing the PH
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assumption for all variables included. We produced univariate and adjusted Hazards
Ratios (HR) with 95% confidence intervals (CI) based on our final models by stage at
diagnosis.
Results
The majority of NSCLC patients received all treatment types in 12 weeks or less.
The proportion of rural residents starting treatment after 12 weeks was significantly less
than the proportion starting treatment in 0-12 weeks, and the opposite was true for urban
residents (surgery p<0.01, chemotherapy p<0.01, radiation p<0.01). Earlier treatment
(within 12 weeks of diagnosis) did not results in a survival advantage in the adjusted
models for chemotherapy and radiation for any stage. In the time-dependent Cox PH
model for surgery, those who had surgery later than 12 weeks post diagnosis had better
survival than those who had surgery in 0-12 weeks, in the first 16 months of follow up
time when stratifying by radiation for all stages (HR: 0.83, 95% CI: 0.75-0.91). Beyond
16 months of follow-up, localized and regional cases who had surgery after 12 weeks had
worse survival than those who had surgery in 0-12 weeks (localized HR:1.20,
95%CI:1.06-1.33; regional HR:1.18, 95%CI:1.06-1.32). The difference in survival was
not significantly different for distant cases beyond 16 months of follow-up for different
times to surgery initiation (distant HR:0.61, 95% CI:0.46-0.82).
Conclusions
Lung cancer treatment decisions are complex, often requiring time for diagnostic
testing and consultations with many specialist physicians. Time to treatment initiation
may not be an important factor for improving lung cancer survival. However, receipt of
surgical treatment is most effective treatment in terms of improved survival time. Among
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all of those who received treatment, a higher proportion of rural residents initiated
treatment within 12 weeks of diagnosis. However, rural residents had worse survival than
urban residents. Future research is needed to better understand time to treatment initiation
and lung cancer survival.

5.2 Introduction
Treatment approaches for lung cancer vary based upon many factors including
stage at diagnosis, tumor histology and location, and overall health of a patient.105 Lung
cancer treatment may include surgery, radiation, chemotherapy, or a combination thereof.
Treatment approaches such as targeted therapies and immunotherapy are continuing to
expand, with FDA approval starting in 2015.116 In spite of the many treatment options
available for lung cancer, in healthy adults diagnosed before metastasis, surgery is the
most effective treatment approach for improved survival.100 Staging, tumor size, tumor
location(s), and patient comorbidities (i.e., medical operability) are collectively
considered when determining if surgical resection is appropriate, yet surgery is often
reserved for patients diagnosed in early stages.100,218,102 In late-stages and/or people with
poor health, surgery may not be an option. Hence, chemotherapy and/or radiation are
considered the next best treatment approaches.87 Depending on the stage at diagnosis,
chemotherapy for lung cancer may be given prior to surgery, after surgery (adjuvant
therapy), or at the same time as radiation treatment (concurrent therapy).87,100 Similarly to
chemotherapy, radiation may be given before surgery, after surgery, and in some cases
alone.87,100 Radiation prior to surgery is often an attempt to shrink tumors for easier
removal. Stereotactic Body Radiation Therapy (SBRT) is high doses of radiation given in
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the precise location of tumors.115 SBRT is mostly given to patients who are not eligible
for surgery and have small, well differentiated tumors. Radiation alone may also be
recommended for late-stage patients as a palliative care approach.87

Timely treatment is one of six domains of health care quality recommended from
the Institute of Medicine introduced in 2015.122 However, as choosing the appropriate
treatment approach varies from one patient to the next, the time between diagnosis and
treatment initiation also varies. Additionally, optimal timing of treatment initiation and
the impact of timely treatment on lung cancer on survival is not well defined in previous
studies.123–127,133,225 Recommendations from agencies such as the American Cancer
Society and American Lung Association suggest starting treatment “very soon” or
“within a few weeks” after a cancer diagnosis218,226 while other organizations recommend
starting treatment within 14 days (Danish Lung Cancer Registry) or 6 weeks regardless of
the stage or treatment type (RAND Corporation).126,135 The British Thoracic Society
recommends surgical treatment in less than 8 weeks, radiation in less than 7 weeks, and
chemotherapy in less than 4 weeks following diagnosis.126 While some view quicker
treatment initiation as superior for patient outcomes, data supporting this stance is scarce.

Timely treatment and survival outcomes
Timely treatment and its association with lung cancer survival is not well
understood.9–15 Publications on the topic have used a range of definitions for treatment
itself (surgery, chemotherapy, or radiation) and timely treatment (e.g., median time from
study sample, arbitrarily 6 weeks).9-16 Few studies have investigated the association
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between timely treatment and improved survival in lung cancer patients. A study of earlystage lung cancer patients reported an average referral time of 61.2 days following
diagnosis.127 They found that increasing weeks from diagnosis to first surgery (measured
continuously) predicted worse survival.127 However, these results were not statistically
significant after adjusting for patient demographics and clinical factors. A nested casecontrol study of 762 lung cancer patients found shorter time intervals between diagnosis
and surgical treatment to be associated with improved survival through a Kaplan-Meier
analysis.225 However, after adjusting for patient symptoms and smoking status, the results
were no longer significant. Findings from a large, 12-year sample of stage I lung cancer
patients from the National Cancer Database found that surgery initiation before 8 weeks
post-diagnosis resulted in significantly higher survival rates.227 A review among
Medicare patients found a median time-to-treatment of 27 days.124 In early-stage cases,
treatment initiation within 35 days was associated with improved survival. There was no
association between treatment time and survival for distant-stage cases.124

Others have reported conflicting findings, showing worse survival or no
association between for timely treatment and lung cancer. In a small sample of veterans
(n=129) from a single health care system, the median time to treatment was 84 days.133
Using the median, timely treatment was defined as less than 84 days. They found that
patients receiving timely treatment were more likely to die than patients receiving care
after 84 days, but after stratifying by disease severity (advanced stage, non-solitary
pulmonary nodules), the results were not significantly different.133 A study of privately
insured lung cancer patients in South Carolina found no association between treatment
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and survival when patients received treatment within 6 weeks of diagnosis.134 Likewise,
an investigation of 482 stage I-III NSCLC patients in a single medical network in Texas
from 2000-2005 found a median diagnosis to treatment time of 33 days.128 They defined
timely treatment as less than 33 days and reported no association between timely
treatment and survival using Kaplan Meier survival analysis.128 An examination of
SEER-Medicare records from 2002-2007 showed a median time interval of 180 days with
most patients waiting over 300 days to initiate treatment.126 Timely treatment was
defined using guidelines published by the RAND corporation and the British Thoracic
Society: less than 8 weeks for surgery, 7 weeks for radiation, and 4 weeks for
chemotherapy.126,135 In their survival analysis among 16,747 patients diagnosed in 2003
or 2004, they found worse survival in patients receiving timely care as compared to those
receiving care after their defined time periods.126 The relationship between time to
treatment initiation and survival in lung cancer patients remains unclear and needs further
investigation.

Disparities in Time to Treatment Initiation
There are conflicting findings related to racial and rural disparities in the timely
treatment of lung cancer. A study of the association between race and timely treatment of
lung cancer among veterans found no racial differences in time to treatment, palliative
care, or hospice referrals between black and white patients.53 Conversely, a SEERMedicare analysis of lung cancer patients from 2000-2002 reported delays in treatment
were more likely among black cases than white cases.136 Other factors associated with
delays in treatment were Medicaid and Medicare dual enrollment (vs. Medicare alone),
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being divorced or widowed (vs. married), and late-stage diagnosis (vs. early stage).136 A
SEER analyses using records from 2002-2007 also reported differences in time to
treatment by race where non-white patients were less likely to receive timely treatment
compared to white patients.126 Rural residents with lung cancer are also less likely to
receive treatment than urban residents with lung cancer.228 Thoracic surgeons are not
widely available in rural areas, potentially resulting in unequal access to high-quality
surgery for rural lung cancer cases.112,113 Rurality and region may dictate patient
experiences in navigating cancer care, influencing potential differences in survival. We
are interested in investigating the potential contribution of time to treatment on this rural
survival disparity. Our objective was to compare the time between diagnosis and
treatment initiation by rurality and region, then to examine the association of time to
treatment with lung cancer-specific survival at differing thresholds of treatment initiation
for surgery, chemotherapy, or radiation.

5.3 Methods
Data Source
We utilized data from the Surveillance, Epidemiology, and End Results (SEER)
program linked with comprehensive Medicare fee-for-service (FFS) billing data (SEERMedicare) for cases diagnosed with non-small cell lung cancer (NSCLC) from 2003 to
2011.199 SEER-Medicare provides population-based cancer registry data from the SEER
registry sites covering New Jersey, Connecticut, Iowa, Wisconsin, Louisiana, Kentucky,
Georgia, California, Hawaii, Utah, Idaho, New Mexico, Detroit (Michigan), Seattle
(Washington), and Alaska Natives. We excluded cases under age 66 to ensure at least 12
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months of Medicare FFS billing data prior to diagnosis. We also excluded those with
Medicare eligibility due to end-stage renal disease, patients with a missing date of
diagnosis, and those who did not receive cancer-directed surgery, chemotherapy, or
radiation.

Time to Treatment Initiation
We created three separate cohorts based on treatment type (surgery,
chemotherapy, radiation). Receipt of surgery and/or radiation was reported through SEER
and confirmed through Medicare billing codes with the corresponding date of services.
Chemotherapy receipt and the date of services are not reported by SEER and were pulled
from Medicare billing codes alone. The appendix includes the list of CPT, HCPCS, and
ICD-9 billing codes used to identify cancer-directed surgery, chemotherapy, and radiation
from the National Cancer Institute.204 Diagnostic procedures, such as biopsy and surgical
staging were excluded. Treatment initiation was defined by the earliest date for cancerdirected surgery, chemotherapy, and radiation following the diagnosis date. Month of
diagnosis and year of diagnosis are reported by SEER. The National Cancer Institute
suggests using the first day or the fifteenth day as the day of diagnosis.229 To ensure that
the diagnosis date always preceded the first treatment, the first of the month was assigned
to all cases for the day of diagnosis We examined time between diagnosis and first
treatment continuously and in five categories in an effort to identify the timing threshold
at which survival is affected. The five categories we tested were: 0-4 weeks, 5-6 weeks,
7-8 weeks, 9-12 weeks, and greater than 12 weeks then in two categories 0-12 weeks
versus greater than 12 weeks.
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Survival and Covariates
Lung cancer-specific survival time was assessed from SEER data using vital
status and survival time in months. We assessed differences in time to treatment initiation
for factors in the following categories: 1) geographic factors, 2) demographic factors, and
3) clinical factors. Geographic factors included urban/rural residence, and Census region.
Urban/rural status was defined by collapsing metropolitan categories and
nonmetropolitan categories of Rural Urban Continuum Codes (RUCC) where
metropolitan=urban and nonmetropolitan=rural.203 We grouped registry locations into
Census regions as follows:
1.

Northeast: New Jersey, Connecticut

2.

Midwest: Iowa, Wisconsin, Detroit, Michigan

3.

South: Louisiana, Kentucky, Georgia

4.

West: Seattle, California, Utah, Idaho, New Mexico, Alaska Natives, Hawaii

Demographic factors included age at diagnosis, sex, race, marital status, and
Medicaid enrollment (yes/no). Clinical factors included stage at diagnosis (localized,
regional, distant), Charlson comorbidity score (0-2 or 3+), year of diagnosis, and receipt
of other treatment types. Charlson comorbidity score was calculated from Medicare
billing codes from the 12 months prior to diagnosis using a validated SAS macro
available from the National Cancer Institute.230 We chose our reference groups as the
most advantaged group in terms of survival, based on existing epidemiology data (e.g.,
white race, localized stage at diagnosis)
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Analyses
For each treatment type, we produced frequencies for all variables included in the
model and performed between group comparisons by time to treatment using chi-square
tests with =0.05 by stage at diagnosis. We tested the unadjusted relationship between
time to treatment and lung cancer-specific survival with Kaplan Meier curves and the
logrank test. We then tested the Proportional Hazards (PH) assumption using log-log of
survival probability over time for all variables included in the model. We calculated
univariate Hazards Ratios (HRs) for all variables tested for inclusion and performed a
backwards selection with removal levels of 0.05 coupled with likelihood ratio tests to
assess model fit. Using our final models, we produced hazards ratios with 95%
confidence intervals for survival of NSCLC patients by categories of time to treatment.

Time to Surgical Treatment Model
For surgical treatment, two variables of interest violated the PH assumption: time
to surgery initiation and radiation treatment. Time to surgery initiation showed a clear
crossover in survival probability at 16 months post diagnosis. To account for these
violations in our model, we incorporated a variable for the interaction between time to
surgery initiation and survival time at 16 months post diagnosis and stratified by radiation
treatment.

When stratifying by a radiation in survival analysis, the stratified Cox PH models
constructs separate partial likelihood functions for each radiation group. The multiplies
the two functions are multiplied together and use values of the coefficient that maximize
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the function. Therefore, the effect of radiation is absorbed into the time function and we
can no longer make comparisons on this variable. Time-dependent Cox PH models allow
us to account for the PH assumption of a variable, when deemed appropriate, and retain
the ability to draw conclusions on that variable. Further explanations on time-dependent
and stratified Cox PH models can be found elsewhere.206,207

Time to Chemotherapy Treatment Model
For our sample of patients who received chemotherapy treatment, the variable for
radiation treatment also violated the PH assumption; thus, we applied a time-dependent
PH model. Specifically, we created and incorporated a time dependent variable into the
Cox PH model representing radiation 12 months post diagnosis or not.

Time to Radiation Treatment Model
Census region violated the PH assumption among our sample of patients who
received radiation treatment. We chose to use a stratified Cox PH model, stratified by
region. As described above, using a stratified Cox PH model accounts for the effect of
region in the final model but does not allow for comparisons between regions.206

5.3 Results
Surgery Patient Characteristics
A final sample size of 26,365 patients were identified as receiving surgical
treatment with 22,021 (83.5%) within 12 weeks of diagnosis and 4,344 (16.5%) after 12
weeks (Table 5.1). Time to surgery differed significantly by urban/rural residence
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(p<0.01) where 85.7% of those receiving treatment within 12 weeks were urban residents
and 14.3% were rural residents. In those receiving surgical treatment more than 12 weeks
after diagnosis, the proportion was higher proportion for urban residents (87.5%) and
12.5% were rural residents. Time to surgery was significantly different by regions as well
(p<0.01). The West was the only region that had a higher proportion of residents
receiving surgery after 12 weeks compared to 0-12 weeks (West 0-12 weeks: 40.2%;
West >12 weeks: 48.2%). Differences existed by age groups as well (p<0.01). Those over
the age of 75 had higher proportions treated with surgery in 0-12 weeks compared to after
12 weeks (75+, 0-12 weeks: 46.0% 75+, >12 weeks: 43.1%). A higher proportion of nonwhite patients received surgery after 12 weeks compared with within 12 weeks (13.1%
vs. 10.0%, p<0.01). A higher proportion of Medicaid enrollees were treated with surgery
after 12 weeks (14.1%) than in 0-12 weeks (10.8%) (p<0.01), and a higher proportion of
those receiving radiation received surgery after 12 weeks (21.7% vs. 8.9%, p<0.01). A
higher proportion of married individuals received surgery after 12 weeks than 0-12 weeks
(>12 weeks: 42.5% vs. 0-12 weeks: 37.8%, p<0.01), and a lower proportion of unmarried
individuals received surgery after 12 weeks (55.0%) compared to those who received
surgery within 12 weeks (59.3%, p<0.01). The majority of patients treated in 12 weeks or
less were localized stage (55.8%) while the highest percent of those treated after 12
weeks were regional stage (47.8%, p<0.01). Sex was not significantly different by time to
surgery (p=0.32). However, the majority of subjects that received surgery regardless of
time were female (0-12 weeks: 52.7%; >12 weeks: 51.8%). Chemotherapy receipt also
did not significantly differ by time to surgery (p=0.24).
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Time to Surgery and Survival
There were no significant differences in survival for time categories less than 12
weeks (Table A.1). However, the unadjusted difference in survival with surgery initiation
in 0-12 weeks versus greater than 12 weeks was significantly different in the first 16
months of follow up (logrank test, p <.0001; Kaplan Meier depicted in Figure 5.1) where
those receiving surgery in less than 12 weeks had worse survival. The median survival
for those who received surgical treatment was greater than our follow time (greater than
60 months), regardless of the time to initiation. Our final stratified time-dependent Cox
PH model included time to surgery initiation, urban/rural residence, age, sex, Charlson
comorbidity score, year of diagnosis, and stage at diagnosis, stratified by radiation.
Medicaid enrollment (p=0.68), race (p=0.81), region (p=0.84) and chemotherapy
(p=0.77) were dropped from the model. Surgical patient characteristics by stage at
diagnosis are shown in Table 5.2.

Based on our final model, within 16 months of follow up, those who had surgery
later than 12 weeks post diagnosis had better survival than those who had surgery in 0-12
weeks, when stratifying by radiation for every stage at diagnosis (localized HR:0.92,
95%CI:0.76-1.11; regional HR:0.91, 95%CI:0.80-1.03; distant HR:0.50, 95%CI:0.390.63) (Table 5.5). Beyond 16 months of follow-up, localized stage patients receiving
surgery after 12 weeks had worse survival than localized patients receiving surgery in 012 weeks, stratifying by radiation (localized HR:1.20, 95%CI:1.06-1.33). The same
relationship was true for regional cases where after 16 months of follow-up, patients
receiving surgery after 12 weeks had worse survival than those initiation surgical
treatment in 0-12 weeks, stratifying by radiation (regional HR:1.18, 95%CI:1.06-1.32).
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Among distant stage cases beyond 16 months of follow-up, surgery after 12 weeks was
associated with improved survival when compared to distant cases who received surgery
in 0-12 weeks, stratifying by radiation (distant HR:0.61, 95%CI:0.46-0.82).

Rural residents who received surgery had worse adjusted survival than urban
residents, stratified by radiation at localized stages (localized HR:1.20, 95%CI:1.091.33). Among regional and distant stage cases who had surgery, there was no significant
difference in survival (regional HR:1.08, 95%CI:0.99-1.18; distant HR:0.96,
95%CI:0.79-1.18). Increasing comorbidities were associated with worse survival among
surgery patients at every stage, though not significant among distant cases, stratifying by
radiation (localized HR:1.36, 95%CI:1.23-1.51; regional HR:1.33, 95%CI:1.19-1.45;
distant HR:1.19, 95%CI:0.97-1.46).

Chemotherapy Patients Characteristics
We identified 59,623 patients who received chemotherapy with 39,724 (66.6%)
starting chemotherapy within 12 weeks following diagnosis and 19,927 (33.4%) in more
than 12 weeks after diagnosis (Table 5.1). All geographic, demographic, and clinical
factors differed significantly with p<0.01 by categories of time to treatment initiation. A
higher proportion of urban residents received treatment after 12 weeks (83.5%), while a
lower proportion of rural residents received treatment after 12 weeks (16.6%) (p<0.01). A
higher proportion of males received chemotherapy within 12 weeks of diagnosis (53.5%),
while a higher proportion of females received chemotherapy after 12 weeks (52.7%)
(p<0.01). Only 15.0% percent of patients that received chemotherapy within 12 weeks

88

had surgery, compared to 52.2% of those that received chemotherapy after 12 weeks
(p<0.01). Chemotherapy patient characteristics by stage at diagnosis are shown in Table
5.3.

Time to Chemotherapy and Survival
Our final model for time to chemotherapy initiation was a time dependent PH
model stratified by radiation, with a crossover in survival probability at 4 months of
follow up (Table 5.6). Region and race were not significant and dropped from the final
model. Those who initiated chemotherapy later than 12 weeks post diagnosis had better
survival when compared to those starting chemotherapy in 0-12 weeks at every stage at
diagnosis (localized HR:0.61, 95%CI: 0.57-0.65; regional HR:0.69, 95%CI:0.65-0.72,
distant HR:0.55, 95%CI:0.53-0.58). Rural residents had worse survival compared to
urban residents at every stage, though not significantly different among regional cases
(localized HR:1.12, 95%CI:1.04-1.20; regional HR:1.08, 95%CI:0.98-1.09, distant
HR:1.09, 95%CI:1.05-1.15). Survival worsened with increasing Charlson comorbidity
score at every stage of diagnosis (localized HR:1.10, 95%CI:1.02-1.19; regional HR:1.21,
95%CI:1.14-1.28; distant HR:1.13, 95%CI:1.09-1.18).

Radiation Patients Characteristics
A total of 34,621 patients were identified as having radiation treatment. Of all
patients who received radiation, 28,538 initiated radiation within 12 weeks of diagnosis
and 6,083 after 12 weeks. When comparing by time to radiation initiation, patients
differed by urban/rural residence (p<0.01), region (p<0.01), age (p<0.01), race (p<0.01),
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marital status (p<0.01), Medicaid enrollment (p<0.01), chemotherapy (p<0.01), surgery
(p<0.01), Charlson comorbidity score (p<0.01), and stage at diagnosis (p<0.01). A higher
proportion of the group starting radiation after 12 weeks also received surgery (21.3%)
and/or chemotherapy (84.5%), compared to 5.6% who received radiation within 12 weeks
also had surgery and 75.9% also had radiation (p<0.01). Time to radiation initiation was
not different by sex (p=0.05) and year of diagnosis (p=0.97). However, more than half of
those who received radiation were male (53.0% at 0-12 weeks; 51.6% at >12 weeks).
Radiation patient characteristics by stage at diagnosis are shown in Table 5.4.

Time to Radiation and Survival
Our final model for time to first radiation treatment was Cox PH model stratified
by region (Table 5.7). Urban/rural residence, race, marital status, and Charlson
comorbidity score were not significant and dropped from the final model. Those starting
radiation later than 12 weeks had better survival than those starting radiation within 12
weeks, stratified by region for every stage at diagnosis (localized HR:0.83, 95%CI:0.750.91; regional HR:0.73, 95%CI:0.69-0.77; HR:0.54, 95%CI:0.52-0.57). Increasing age
was associated with increasing hazards ratios, stratified by region at all stages. Females
had better survival than males (localized HR:0.79, 95%CI:0.73-0.86; regional HR:0.86,
95%CI:0.82-0.90; distant HR:0.92, 95%CI:0.89-0.95) and those on Medicaid had better
survival than those not on Medicaid (localized HR:0.92, 95%CI:0.82-1.04; regional
HR:0.91, 95%CI:0.84-0.98; distant HR:0.85, 95%CI:0.80-0.90), stratified by region at all
stages, though not significant among localized cases.
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5.4 Discussion
Developing treatment plans for lung cancer is a complex process, at times
involving multiple physicians, tumor boards, referral times, and diagnosis procedures.
Overall, we did not find an improvement in survival probability with treatment initiation
within 12 weeks of diagnosis except for localized and regional surgical cases after 16
months of follow up time. For surgical treatment, the relationship between time to
treatment initiation was not significant after 16 months of follow up. For chemotherapy
and radiation, our results showed that those with treatment initiation after 12 weeks
following diagnosis had better survival than those who received treatment by the 12-week
point among all stages. We demonstrated that a higher proportion of those who had
delayed chemotherapy treatment (>12 weeks) and a higher survival probability had also
received surgery (52.2%) while only 15% of the early chemotherapy group (0-12 weeks)
received surgery. The same trend held true for those receiving radiation after 12 weeks,
where 21.3% had surgery, compared with only 5.6% of those who started radiation in 012 weeks.

Studies examining the time to treatment initiation of lung cancer have reported
conflicting findings on the relationship with survival.9-17 We found that those who
received surgery within 12 weeks of diagnosis had worse survival in the first 16 months
following diagnosis. These findings are similar to those from Gould et al where a shorter
wait time was associated with worse survival.133 However, these findings contrast with
those showing shorter wait times and surgery before 8 weeks was associated with
improved survival.127,225,227 Among early-stage patients, Gomez et al showed better
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survival with early treatment but among all other stages there was no association between
time to surgery and survival.124 Using SEER-Medicare data from 2000-2002, Halpern et
al reported that late-stage patients were more likely to receive surgery quickly,136 but our
results showed that a higher proportion of cases treated after 12 weeks (7.5%) were
distant stage, compared to 5.5% treated within 12 weeks.

Among our chemotherapy and radiation cohorts, starting chemotherapy or
radiation within 12 weeks was associated with lower survival probability than those who
initiated chemotherapy or radiation after 12 weeks among all stages. However, this could
be attributed partially to the higher proportion of patients who started chemotherapy or
radiation after 12 weeks who also had received surgery, pointing back to surgery being an
effective treatment approach at improving survival for lung cancer. Also important to
consider is that radiation can be given as a palliative care option for patients not eligible
for surgery and/or chemotherapy due to comorbidities or advanced stage at
diagnosis.87,218 Our results are similar to those examining all treatment types together
where earlier treatment was associated with worse survival or there was no significant
difference in survival depending on the time to treatment initiation.126,128,133,134 It may be
informative to examine treatment types separately and sequences of treatment in future
analyses to better characterize the relationship of each the time to initiation of each
treatment type and survival.

Low income, black race, rural residence, and living in the South are associated
with poor lung cancer survival.4–7,28,42,187,190,228 In our results, rural residents had a higher
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proportion receiving treatment within 12 weeks for all three treatment categories.
However, rural residents had worse survival for surgery and chemotherapy. 4–6,10,11,13 Our
surgery sample was nearly 90% white, and black patients have been shown to be more
likely to decline surgery for cancer treatment than whites, even when diagnosed in early
stages. Urban/rural, regional, and racial difference in lung cancer survival may be driven
by disparities in access to surgical treatment as our data was restricted to only patients
who received treatment.

Our study is not without limitations. While SEER provides a large, diverse data
source, it is limited in the geographic coverage and underrepresents rural areas.222 This
may have underpowered our ability to detect differences between urban and rural
settings, a recurring issue for using national data to study urban and rural
differences.221,222,231,232 We did not examine Medicare Part D files in our analyses.
Chemotherapy only administered outpatient and billed through Part D claims were not be
captured. Medicare billing codes are not intended for use in research and it is possible
that some procedure codes are incorrect or missing. While we believe our list of codes
was thorough, it is possible that some procedure codes were missed. SEER-Medicare is
also limited to fee-for-service claims and does not include data on Medicare Advantage
beneficiaries.

Our study has many strengths, including the large sample size from SEERMedicare, a multi-site data source covering 26% of the US population.199 Our analyses
covered three treatment types (surgery, chemotherapy, radiation) providing a
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comprehensive examination of treatment options available from 2003-2011, assessing the
differing relationships of the treatment types and survival. Our results also provide
updated data for comparison to previous publications and future work. These results may
also provide meaningful insight to practicing clinicians as the time between diagnosis and
treatment initiation may not be an important factor when developing treatment protocols.

We did not find evidence of a survival benefit to receiving treatment within 12
weeks of diagnosis for chemotherapy and radiation. Time to treatment initiation may not
be as important as factors that influence the development of personalized treatment plans
such as confirmatory testing, surgical staging, and control of patient comorbidities. We
did, however, observe that the median survival of those who received surgery at any time
was higher than the overall median survival for lung cancer. We also found that surgery
within 12 weeks of diagnosis for localized and regional patients improved survival after
16 months of follow-up. Observed rural and racial disparities in lung cancer survival may
be primarily driven by lower surgical utilization among these populations rather than
differences in time to treatment initiation. Future work should focus on improving access
to surgical treatment for lung cancer through expansion of the availability of surgeons to
rural populations. Additional research is needed to better understand the complex
relationship of time to treatment initiation and its association with lung cancer survival.
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5.7 Tables
Table 5.1. Demographics of SEER-Medicare NSCLC Patients by Time from Diagnosis to Treatment, 2003-2011
Treatment Type*
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Total (N)
Rurality
Urban
Rural
Census Region
Midwest
Northeast
South
West
Demographic Factors
Age
66-69
70-74
75-79
80+
Sex
Male
Female
Race
White
Non-White
Marital Status
Married
Not married
Unknown/Missing
Medicaid Enrollment
No
Yes

Surgery
N=26,365
0-12 Weeks
>12 Weeks
22,021
4,344
p<0.01
85.7%
87.5%
14.3%
12.5%
p<0.01
11.7%
11.1%
22.0%
19.8%
26.1%
20.8%
40.2%
48.2%

Chemotherapy
N=59,623
0-12 Weeks
>12 Weeks
39,724
19,927
p<0.01
81.9%
83.5%
18.1%
16.6%
p<0.01
13.2%
13.1%
19.7%
20.9%
28.7%
26.6%
38.4%
39.4%

p<0.01
23.7%
30.4%
27.0%
19.0%

p<0.01
25.9%
31.0%
26.6%
16.5%

23.5%
29.6%
25.4%
21.5%

48.2%
51.8%

53.5%
46.5%

86.9%
13.1%

86.9%
13.1%

42.5%
55.0%
2.5%

40.3%
56.9%
2.9%

85.9%
14.1%

90.6%
9.4%

p=0.32
47.3%
52.7%

47.3%
52.7%

53.0%
47.1%

85.6%
14.4%

85.0%
15.0%

43.6%
53.6%
2.9%

54.6%
45.4%

88.0%
12.0%

91.0%
9.0%

24.7%
28.8%
25.0%
21.5%
p=0.05
51.6%
48.4%
p<0.01

p<0.01

p<0.01
89.2%
10.8%

21.5%
27.3%
24.9%
26.3%

p<0.01

p<0.01
37.8%
59.3%
2.9%

p<0.01
23.1%
28.4%
25.1%
23.4%

p<0.01

p<0.01
90.0%
10.0%

Radiation
N=34,621
0-12 Weeks
>12 Weeks
28,538
6,083
p<0.01
83.0%
84.8%
17.0%
15.2%
p<0.01
15.2%
14.9%
19.5%
20.9%
30.7%
24.7%
34.7%
39.5%

82.7%
17.3%
p<0.01

p<0.01

57.0%
43.0%
p<0.01
89.2%
10.8%

96

Clinical Factors
Radiation
p<0.01
Yes
8.9%
No
90.0%
Unknown/Missing
1.2%
Chemotherapy
p=0.24
Yes
65.7%
No
34.3%
Surgery
Yes
No
Charlson
p<0.01
Comorbidity Score
0-2
75.2%
3 or higher
11.4%
Missing/Unknown
13.5%
Year of diagnosis
p=0.03
2003-2005
29.9%
2006-2008
34.9%
2009-2011
35.2%
Stage at diagnosis
p<0.01
Localized
55.8%
Regional
38.7%
Distant
5.5%
*Treatment types are not mutually exclusive

p<0.01
21.7%
76.7%
1.6%

46.3%
52.0%
1.7%

30.5%
68.0%
1.6%

-

66.6%
33.4%

-

-

75.9%
24.1%

-

15.0%
85.0%

52.2%
47.8%

5.6%
94.4%

p<0.01

p<0.01

p<0.01

p<0.01
69.6%
9.5%
20.9%

81.1%
12.6%
6.3%

30.3%
36.5%
33.3%

34.8%
36.0%
29.1%

44.7%
47.8%
7.5%

12.0%
28.2%
59.8%

84.5%
15.5%
21.3%
78.7%
p<0.01

75.8%
13.2%
11.0%

78.7%
13.6%
7.7%

37.4%
34.7%
27.9%

34.7%
33.3%
32.0%

41.5%
33.0%
25.5%

12.2%
28.2%
59.6%

p<0.01

76.0%
12.7%
11.3%
p=0.97

p<0.01

34.6%
33.5%
32.0%
p<0.01
20.4%
39.3%
40.3%

Table 5.2 Demographics of NSCLC Surgery Patients by Time from Diagnosis to Treatment,
SEER-Medicare 2003-2011
Stage
Time to Surgery
Total
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Geographic Factors
Rurality
Urban
Rural
Census Region
Midwest
Northeast
South
West
Demographic Factors
Age
66-69
70-74
75-79
80+
Sex
Male
Female
Race
Caucasian
Non-Caucasian
Marital Status
Married
Not married
Medicaid Enrollment
Yes

Localized
N=14223
0-12 Weeks >12 Weeks
12280
1943

Regional
N=10607
0-12 Weeks >12 Weeks
8532
2075

Distant
N=1535
0-12 Weeks >12 Weeks
1209
326

N (%)

N (%)

N (%)

N (%)

N (%)

N (%)

10606 (86.2)
1674 (87.3)

1699 (13.8)
244 (12.7)

7220 (79.9)
1312 (83.5)

1815 (20.1)
260 (16.5)

1047 (78.5)
162 (80.2)

286 (21.5)
40 (19.8)

1451 (85.8)
2808 (88.8)
3208 (88.7)
4813 (83.7)

241 (14.1)
356 (11.3)
410 (11.3)
936 (16.3)

991 (82.9)
1774 (79.9)
2226 (84.0)
3541 (78.0)

205 (17.1)
447 (20.1)
425 (16.0)
998 (22.0)

142 (79.3)
255 (81.2)
311 (81.8)
501 (75.7)

37 (20.7)
59 (18.8)
69 (18.2)
161 (24.3)

2907 (86.7)
3792 (86.6)
331 (85.9)
2280 (86.0)

445 (13.3)
588 (13.4)
540 (14.1)
370 (14.0)

2045 (77.8)
2502 (79.4)
2345 (81.3)
1640 (84.5)

584 (22.2)
648 (20.6)
541 (18.8)
302 (15.6)

256 (72.5)
395 (78.2)
305 (80.3)
253 (85.20

97 (27.5)
110 (21.8)
75 (19.7)
44 (14.8)

5515 (85.8)
6765 (86.8)

910 (14.2)
1033 (13.3)

4292 (80.8)
4240 (80.1)

1020 (19.2)
1055 (19.9)

617 (79.2)
592 (78.3)

162 (20.8)
164 (21.7)

11115 (86.8)
1165 (81.8)

1684 (13.2)
259 (18.2)

7619 (81.0)
913 (76.4)

1793 (19.1)
282 (23.6)

1077 (78.4)
132 (81.5)

296 (21.6)
30 (18.5)

7218 (87.3)
4688 (84.7)

1049 (12.7)
849 (15.3)

5126 (81.7)
3176 (78.4)

1146 (18.3)
876 (21.6)

723 (78.8)
458 (79.4)

195 (21.2)
119 (20.6)

1367 (82.7)

287 (17.4)

906 (76.3)

282 (23.7)

114 (73.1)

42 (26.9)

No
Clinical Factors
Chemotherapy
Yes
No
Radiation
Yes
No
Charlson Comorbidity Score
0-2
3 or higher
Year of diagnosis
2003-2005
2006-2008
2009-2011

10309 (86.8)

1570 (13.2)

6866 (80.9)

1623 (19.1)

869 (77.5)

252 (22.5)

7734 (87.2)
4546 (84.9)

1135 (12.8)
808 (15.1)

5908 (79.7)
2624 (82.1)

1502 (20.3)
573 (17.9)

818 (76.2)
391 (84.8)

256 (23.8)
70 (15.2)

342 (71.25)
11838 (86.9)

138 (28.8)
1782 (13.1)

1276 (65.2)
7121 (84.0)

681 (34.8)
1357 (16.0)

340 (73.1)
848 (81.5)

125 (26.9)
193 (18.5)

9173 (87.6)
1516 (87.3)

1294 (12.4)
221 (12.7)

6483 (81.3)
841 (83.4)

1487 (18.7)
168 (16.7)

892 (78.6)
151 (86.30

243 (21.4)
24 (13.7)

3636 (86.4)
4359 (85.6)
4285 (87.1)

575 (13.7)
734 (14.4)
634 (12.9)

2574 (80.1)
2896 (79.8)
3062 (81.4)

641 (19.9)
733 (20.2)
701 (18.6)

382 (79.4)
421 (78.3)
406 (78.7)

99 (20.6)
117 (21.80
110 (21.3)
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Table 5.3 Demographics of NSCLC Chemotherapy Patients by Time from Diagnosis to
Treatment, SEER-Medicare 2003-2011
Stage
Time to Chemotherapy
Total
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Geographic Factors
Rurality
Urban
Rural
Census Region
Midwest
Northeast
South
West
Demographic Factors
Age
66-69
70-74
75-79
80+
Sex
Male
Female
Race
Caucasian
Non-Caucasian
Marital Status
Married
Not married
Medicaid Enrollment
Yes

Localized
N=13015
0-12 Weeks >12 Weeks
4763
8252

Regional
N=17763
0-12 Weeks >12 Weeks
11192
6571

Distant
N=28845
0-12 Weeks >12 Weeks
23769
5076

N (%)

N (%)

N (%)

N (%)

N (%)

N (%)

3774 (35.5)
989 (41.4)

6853 (64.5)
1399 (58.6)

9128 (62.4)
2064 (65.7)

5492 (37.6)
1079 (34.3)

19642 (82.2)
4127 (83.5)

4261 (17.8)
815 (16.5)

603 (35.3)
817 (32.6)
1582 (40.0)
1761 (36.7)

1104 (64.7)
1689 (67.4)
2417 (60.4)
3042 (63.3)

1379 (62.2)
2329 (61.6)
3509 (66.9)
3975 (61.0)

837 (37.8)
1453 (38.4)
1737 (33.1)
2544 (39.0)

3253 (83.1)
4666 (82.2)
6316 (84.7)
9534 (80.8)

663 (16.9)
1012 (17.8)
1142 (15.3)
2259 (19.2)

875 (33.3)
1305 (34.9)
1299 (37.8)
1284 (39.6)

1752 (66.7)
2434 (65.1)
2136 (62.2)
1930 (60.4)

2698 (63.2)
3453 (64.8)
2884 (62.6)
2157 (60.6)

1571 (36.8)
1874 (35.2)
1725 (37.4)
1401 (39.4)

5753 (81.9)
7005 (84.0)
5918 (83.8)
5093 (79.3)

1269 (18.1)
1339 (16.1)
1141 (16.2)
1327 (20.7)

2295 (38.5)
2468 (35.0)

3668 (61.5)
4584 (65.0)

6084 (65.5)
5108 (60.3)

3202 (34.5)
3369 (39.7)

12891 (83.5)
10878 (81.1)

2545 (16.5)
2531 (18.9)

4259 (36.8)
504 (34.9)

7313 (63.2)
939 (65.1)

9851 (63.5)
1341 (59.3)

5652 (36.5)
919 (40.7)

20417 (83.4)
3352 (76.8)

4064 (16.6)
1012 (23.2)

2543 (36.5)
2045 (36.3)

4428 (63.5)
3582 (63.7)

6423 (64.4)
4481 (61.2)

3556 (35.6)
2846 (38.8)

13624 (83.6)
9474 (80.9)

2674 (16.4)
2244 (19.2)

531 (35.1)

984 (65.0)

1070 (58.5)

760 (41.5)

2123 (76.8)

643 (23.3)

No
Clinical Factors
Surgery
Yes
No
Radiation
Yes
No
Charlson Comorbidity Score
0-2
3 or higher
Year of diagnosis
2003-2005
2006-2008
2009-2011

4232 (36.8)

7268 (63.2)

10122 (63.5)

5811 (36.5)

21646 (83.0)

4433 (17.0)

2096 (26.5)
2607 (51.9)

5801 (73.5)
2418 (48.1)

8014 (76.0)
3111 (43.6)

2527 (24.0)
4021 (56.4)

715 (57.8)
22929 (83.5)

523 (42.3)
4522 (16.5)

1433 (47.7)
3233 (33.0)

1572 (52.3)
6579 (67.1)

6338 (73.90
4637 (52.5)

2241 (26.1)
4204 (47.6)

12795 (82.4)
10617 (82.5)

2740 (17.6)
2247 (17.5)

3700 (36.7)
861 (40.7)

6388 (63.3)
1254 (59.3)

9152 (64.3)
1444 (65.6)

5081 (35.7)
759 (34.5)

19382 (84.3)
2703 (81.4)

3610 (15.7)
619 (18.6)

1648 (33.8)
1881 (39.1)
1234 (37.1)

3232 (66.2)
2931 (60.9)
2089 (62.9)

4040 (62.0)
3858 (63.7)
3294 (63.5)

2481 (38.1)
2198 (36.30
1892 (36.5)

8145 (82.6)
8579 (82.8)
7045 (81.8)

1721 (17.4)
1783 (17.2)
1572 (18.2)
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Table 5.4 Demographics of NSCLC Radiation Patients by Time from Diagnosis to Treatment,
SEER-Medicare 2003-2011
Stage
Time to Radiation
Total
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Geographic Factors
Rurality
Urban
Rural
Census Region
Midwest
Northeast
South
West
Demographic Factors
Age
66-69
70-74
75-79
80+
Sex
Male
Female
Race
Caucasian
Non-Caucasian
Marital Status
Married
Not married
Medicaid Enrollment
Yes

Localized
N=4725
0-12 Weeks >12 Weeks
3483
1242

Regional
N=10439
0-12 Weeks >12 Weeks
8048
2391

Distant
N=19457
0-12 Weeks >12 Weeks
17007
2450

N (%)

N (%)

N (%)

N (%)

N (%)

N (%)

2847 (73.5)
636 (74.5)

1024 (26.5)
218 (25.5)

6644 (76.5)
1404 (80.0)

2040 (23.5)
351 (20.0)

14191 (87.2)
2816 (88.8)

2093 (12.9)
357 (11.3)

570 (72.9)
539 (70.0)
1309 (79.3)
1065 (70.0)

212 (27.2)
231 (30.0)
342 (20.7)
457 (30.0)

1214 (79.7)
1645 (75.1)
2661 (81.4)
2528 (73.2)

309 (20.3)
546 (24.9)
609 (18.6)
927 (26.8)

2545 (86.9)
3366 (87.2)
4800 (89.7)
6296 (86.1)

384 (13.1)
493 (12.8)
554 (10.3)
1019 (13.9)

386 (66.4)
740 (69.9)
913 (73.4)
1444 (78.4)

195 (33.6)
319 (30.1)
331 (26.6)
397 (21.6)

1706 (72.9)
2280 (76.4)
2043 (76.7)
2019 (82.3)

633 (27.1)
703 (23.6)
621 (23.3)
434 (17.7)

4051 (85.8)
4782 (86.7)
4135 (87.9)
4039 (89.5)

673 (14.3)
732 (13.3)
571 (12.1)
474 (10.5)

1614 (74.5)
1869 (73.1)

533 (25.5)
689 (26.9)

4313 (77.8)
3735 (76.3)

1231 (22.2)
1160 (23.7)

9184 (87.2)
7823 (87.7)

1353 (12.8)
1097 (12.3)

3059 (74.3)
424 (69.6)

1057 (25.7)
185 (30.4)

6901 (77.7)
1147 (73.5)

1978 (22.3)
413 (26.5)

14306 (87.8)
2701 (85.6)

1995 (12.2)
455 (14.4)

1614 (73.9)
1733 (73.5)

571 (26.1)
626 (26.5)

4250 (75.60
3595 (78.6)

1371 (24.4)
979 (21.4)

9293 (86.6)
7275 (88.5)

1438 (13.4)
942 (11.5)

386 (68.4)

178 (31.6)

810 (76.2)

253 (23.8)

1384 (85.9)

228 (14.1)

No
Clinical Factors
Chemotherapy
Yes
No
Surgery
Yes
No
Charlson Comorbidity Score
0-2
3 or higher
Year of diagnosis
2003-2005
2006-2008
2009-2011

3097 (74.4)

1064 (25.6)

7238 (77.2)

2138 (22.8)

15623 (87.6)

2222 (12.5)

2678 (73.8)
805 (73.3)

949 (26.2)
293 (26.7)

6815 (76.4)
1233 (81.2)

2105 (23.6)
286 (18.8)

12171 (85.4)
4836 (93.0)

2083 (14.6)
367 (7.1)

227 (48.9)
3235 (76.4)

237 (51.1)
997 (23.6)

977 (52.8)
7043 (82.3)

875 (47.3)
1514 (17.7)

386 (68.1)
16575 (88.0)

181 (31.9)
2262 (12.0)

2540 (74.0)
826 (75.4)

891 (26.0)
269 (24.6)

6363 (77.2)
1169 (82.0)

1884 (22.8)
257 (18.0)

13541 (88.0)
1892 (88.5)

1847 (12.0)
246 (11.5)

1040 (73.3)
1097 (72.7)
1346 (74.9)

378 (26.7)
412 (27.3)
452 (25.1)

2985 (77.9)
2577 (76.4)
2486 (76.9)

845 (22.1)
798 (23.6)
748 (23.1)

5879 (87.0)
5826 (87.6)
5303 (87.7)

881 (13.0)
825 (12.4)
744 (12.3)

102

Table 5.5 Time-Dependent Cox PH Model of Time to Surgery and Lung Cancer-Specific Survival, Stratified by
Radiation, SEER-Medicare 2003-2011
Surgery
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Localized Stage
Adjusted
HR (95%CI)
Time to Surgery at time <16 months
0-12 weeks
1.00 (Reference)
>12 weeks
0.92 (0.76-1.11)
Time to Surgery at time ≥ 16 months
0-12 weeks
1.00 (Reference)
>12 weeks
1.20 (1.06-1.33)*
Rurality
Urban
1.00 (Reference)
Rural
1.20 (1.09-1.33)*
Age
66-69
1.00 (Reference)
70-74
1.23 (1.10-1.37)*
75-79
1.43 (1.28-1.59)*
80+
1.76 (1.57-1.98)*
Sex
Male
1.00 (Reference)
Female
0.67 (0.62-0.73)*
Marital Status
Married
1.00 (Reference)
Not married
1.17 (1.08-1.27)*
Charlson Comorbidity Score
0-2
1.00 (Reference)
3 or higher
1.36 (1.23-1.51)*
Year of diagnosis
2003-2005
1.29 (1.15-1.44)*
2006-2008
1.16 (1.04-1.30)*
2009-2011
1.00 (Reference)
*significant at =0.05

Regional Stage
Adjusted
HR (95%CI)

Distant Stage
Adjusted
HR (95%CI)

1.00 (Reference)
0.91 (0.80-1.03)

1.00 (Reference)
0.50 (0.39-0.63)*

1.00 (Reference)
1.18 (1.06-1.32)*

1.00 (Reference)
0.61 (0.46-0.82)*

1.00 (Reference)
1.08 (0.99-1.18)

1.00 (Reference)
0.96 (0.79-1.18)

1.00 (Reference)
1.14 (1.04-1.25)*
1.30 (1.18-1.42)*
1.53 (1.38-1.69)*

1.00 (Reference)
1.01 (0.83-1.22)
1.01 (0.83-1.24)
1.27 (1.03-1.57)*

1.00 (Reference)
0.77 (0.72-0.83)*

1.00 (Reference)
0.72 (0.62-0.83)*

1.00 (Reference)
1.13 (1.05-1.21)*

1.00 (Reference)
1.26 (1.09-1.46)*

1.00 (Reference)
1.33 (1.19-1.45)*

1.00 (Reference)
1.19 (0.97-1.46)

1.25 (1.14-1.36)*
1.22 (1.11-1.33)*
1.00 (Reference)

1.27 (1.06-1.51)*
1.03 (0.86-1.23)
1.00 (Reference)

Table 5.6 Time-Dependent Cox PH Model of Time to Chemotherapy and Lung Cancer-Specific Survival,
SEER-Medicare 2003-2011
Chemotherapy

104

Time to Chemotherapy
0-12 weeks
>12 weeks
Rurality
Urban
Rural
Age
66-69
70-74
75-79
80+
Sex
Male
Female
Marital Status
Married
Not married
Medicaid Enrollment
Yes
No
Charlson Comorbidity Score
0-2
3 or higher
Radiation, time<4 months
Yes
No
Radiation, time≥4 months
Yes
No

Localized Stage
Adjusted
HR (95%CI)

Regional Stage
Adjusted
HR (95%CI)

Distant Stage
Adjusted
HR (95%CI)

1.00 (Reference)
0.61 (0.57-0.65)*

1.00 (Reference)
0.69 (0.65-0.72)*

1.00 (Reference)
0.55 (0.53-0.57)*

1.00 (Reference)
1.12 (1.04-1.20)*

1.00 (Reference)
1.03 (0.98-1.09)

1.00 (Reference)
1.09 (1.05-1.13)*

1.00 (Reference)
1.19 (1.08-1.30)*
1.23 (1.12-1.35)*
1.25 (1.14-1.38)*

1.00 (Reference)
1.10 (1.04-1.17)*
1.19 (1.13-1.26)*
1.28 (1.20-1.36)*

1.00 (Reference)
1.04 (1.00-1.08)
1.09 (1.05-1.14)*
1.24 (1.19-1.29)*

1.00 (Reference)
0.69 (0.65-0.74)*

1.00 (Reference)
0.82 (0.78-0.85)*

1.00 (Reference)
0.85 (0.82-0.87)*

1.00 (Reference)
1.10 (1.04-1.18)*

1.00 (Reference)
1.08 (1.04-1.13)*

1.00 (Reference)
1.12 (1.08-1.15)*

0.87 (0.80-0.96)*
1.00 (Reference)

0.85 (0.80-0.91)*
1.00 (Reference)

0.82 (0.78-0.85)*
1.00 (Reference)

1.00 (Reference)
1.10 (1.02-1.19)*

1.00 (Reference)
1.21 (1.14-1.28)*

1.00 (Reference)
1.13 (1.09-1.18)*

1.00 (Reference)
1.92 (1.51-2.44)*

1.00 (Reference)
1.81 (1.61-2.04)*

1.00 (Reference)
1.20 (1.14-1.25)*

1.00 (Reference)
1.15 (1.07-1.24)*

1.00 (Reference)
1.08 (1.03-1.14)*

1.00 (Reference)
0.90 (0.87-0.93)*

Surgery
Yes
No
Year of diagnosis
2003-2005
2006-2008
2009-2011
*significant at =0.05

1.00 (Reference)
4.16 (3.86-4.48)*

1.00 (Reference)
2.81 (2.67-2.96)*

1.00 (Reference)
1.84 (1.71-1.98)*

1.23 (1.13-1.34)*
1.06 (0.97-1.16)
1.00 (Reference)

1.26 (1.19-1.33)*
1.13 (1.07-1.19)*
1.00 (Reference)

1.17 (1.13-1.21)*
1.09 (1.05-1.13)*
1.00 (Reference)
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Table 5.7 Cox PH Model of Time to Radiation and Lung Cancer-Specific Survival, Stratified by Region,
SEER-Medicare 2003-2011
Radiation
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Time to Radiation
0-12 weeks
>12 weeks
Age
66-69
70-74
75-79
80+
Sex
Male
Female
Medicaid Enrollment
Yes
No
Chemotherapy
Yes
No
Surgery
Yes
No
Year of diagnosis
2003-2005
2006-2008
2009-2011
*significant at =0.05

Localized Stage
Adjusted
HR (95%CI)

Regional Stage
Adjusted
HR (95%CI)

Distant Stage
Adjusted
HR (95%CI)

1.00 (Reference)
0.83 (0.75-0.91)*

1.00 (Reference)
0.73 (0.69-0.77)*

1.00 (Reference)
0.54 (0.52-0.57)*

1.00 (Reference)
1.15 (1.00-1.33)
1.08 (0.94-1.24)
1.17 (1.03-1.34)*

1.00 (Reference)
1.11 (1.04-1.19)*
1.22 (1.15-1.31)*
1.25 (1.16-1.34)*

1.00 (Reference)
1.05 (1.01-1.10)*
1.10 (1.05-1.15)*
1.14 (1.09-1.19)*

1.00 (Reference)
0.79 (0.73-0.86)*

1.00 (Reference)
0.86 (0.82-0.90)*

1.00 (Reference)
0.92 (0.89-0.95)*

0.92 (0.82-1.04)
1.00 (Reference)

0.91 (0.84-0.98)*
1.00 (Reference)

0.85 (0.80-0.90)*
1.00 (Reference)

1.00 (Reference)
1.11 (1.01-1.22)*

1.00 (Reference)
1.73 (1.62-1.84)*

1.00 (Reference)
2.15 (2.08-2.23)*

1.00 (Reference)
1.46 (1.26-1.68)*

1.00 (Reference)
1.77 (1.65-1.89)*

1.00 (Reference)
1.61 (1.46-1.76)*

1.75 (1.58-1.95)*
1.40 (1.26-1.55)*
1.00 (Reference)

1.25 (1.18-1.32)*
1.11 (1.04-1.18)*
1.00 (Reference)

1.07 (1.03-1.11)*
1.05 (1.01-1.09)*
1.00 (Reference)

5.8 Figures
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Figure 5.1 Kaplan Meier Curve of Lung Cancer-Specific Survival by Time to Surgical Treatment
Initiation, SEER-Medicare NSCLC Cases 2003-2011
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Figure 5.2 Kaplan Meier Curve of Lung Cancer-Specific Survival by Time to Chemotherapy Treatment
Initiation, SEER-Medicare NSCLC Cases 2003-2011
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Figure 5.3 Kaplan Meier Curve of Lung Cancer-Specific Survival by Time to Radiation Treatment
Initiation, SEER-Medicare NSCLC Cases 2003-2011

CHAPTER 6
PATIENT AND COUNTY LEVEL DETERMINANTS OF SURGICAL
TREATMENT FOR NON-SMALL CELL LUNG CANCER: A
MULTILEVEL SEER-MEDICARE ANALYSIS3

3

Odahowski CL, Alberg A, Schootman M, Zhang J, Eberth JM. To be submitted to Cancer Epidemiology,
Biomarkers & Prevention
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6.1 Abstract
Introduction
Rural residents face a higher incidence of lung cancer, longer drive times to
access care, and worse survival than urban lung cancer patients. Surgical resection is the
recommended treatment approach for healthy adults diagnosed with early stages of lung
cancer by the National Comprehensive Cancer Network and is considered the most
effective treatment approach for improving survival among localized cases. Despite this,
inequities in the utilization of surgical treatment exist for some minority groups,
particularly black versus white patients. We hypothesized that observed rural survival
disparities in early stage rural lung cancer patient may be due lower utilization of surgical
treatment when compared to their urban counterparts, in addition to racial disparities in
surgical utilization. To assess this, we examined patient- and county-level determinants
of receipt of surgical treatment for non-small cell lung cancer (NSCLC), focusing on
rural vs. urban disparities.
Methods
We examined patients nested within counties in a multilevel logistic regression
model stratified by stage at diagnosis, predicting receipt of surgical treatment. Our
sample included 63,767 localized and regional NSCLC cases diagnosed between 20032011 using SEER-Medicare data across the United States. Predictors examined included
patient demographics, clinical characteristics and county-level factors, including urban
versus rural designation, percent of the 65 and older population in poverty, and Medically
Underserved Areas.
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Results
Less than one-half (46.1%) of patients with early stage lung cancer received
surgical treatment. Of patients diagnosed at localized stage, 56.7% received surgery
compared to 42.6% of patients diagnosed at regional stage. Fewer rural residents received
surgery when compared with urban residents (42.0% vs. 46.8%), and fewer black patients
received surgery (32.9%) than white patients (47.1%) and those of other races (48.0%).
Rural residence was not a significant predictor of surgery at the county level for local
stage cases (OR=0.87, 95% CI:0.74-1.03) nor regional stage cases (OR-1.09, 95%
CI:0.95-1.26). However, the odds of surgical treatment decreased per 5% increase in
county-level poverty for both local and regional stages (local OR=0.83, 95% CI:0.770.91; regional OR=0.84, 95%CI: 0.79-0.90). Patient factors associated with lower
likelihood of surgical treatment included increasing age, male sex, black race, those not
married, dual Medicare/Medicaid enrollment, increasing number of comorbidities, and
bilateral or midline location for both stages. In comparison to well-differentiated grade,
cases with moderately differentiated grade did not have a significantly different odds of
surgical treatment. All other grade categories (poorly differentiated, undifferentiated, and
undetermined grade) were associated with lower odds of surgical treatment as compared
to well differentiated grade.
Conclusions
While rural residence itself was not a significant predictor of surgical treatment,
the association between county rurality and surgery was attenuated by area poverty,
which is observed at higher rates among rural populations. Medicaid enrollment, a proxy
measure of patient-level poverty, was also associated with a reduced likelihood of
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receiving surgery at both stages. While the significant predictors of surgical treatment
were similar for local and regional stage cases, the magnitudes of the odds ratios were
stronger among local cases for increasing age, black race, and increasing comorbidities.
Cancer treatment decisions are complex, and this could be an indicator that patient
demographics and comorbidities play a greater role in surgical decisions among local
stage cases than regional cases. Future research is needed to improve our understanding
of treatment decisions among low-income and black lung cancer patients to inform the
development of future interventions aimed at eliminating these disparities in lung cancer
treatment.

Keywords: Non-Small Cell Lung Cancer, Healthcare Disparities, Social Determinants of
Health

6.2 Introduction
Most rural areas in the United States have a cigarette smoking prevalence twice
that of large urban areas, contributing to higher lung cancer incidence and mortality rates
in rural areas.26,78,211,233 Additionally, rural residents face higher rates of late-stage lung
cancer diagnoses than urban residents.185 The increased likelihood of late-stage diagnosis
and limited treatment options for late-stage disease contributes to higher observed
mortality rates for rural Americans with lung cancer 25,184,234 However, even among stage
I patients diagnosed between 2000 and 2006, rural residents were less likely than their
urban counterparts to receive curative surgery.48 Combined with the sheer disease burden,
rural residents also face socioeconomic disadvantages including higher poverty rates,
lower education, and a higher proportion of uninsured and elderly adults than urban
113

residents.48,78,183 These factors may make accessing care more difficult for rural lung
cancer patients, particularly accessing specialist physicians who are sparse in rural
areas.235

Treatment approaches for lung cancer are highly variable depending on many
clinical factors such as histologic type, stage at diagnosis, and patients’ health
status.100,102 In healthy adults with earlier stage cancer that has not metastasized, surgery
is the most favorable treatment approach in terms of improved survival.100 Staging, tumor
characteristics, and patient comorbidities (i.e., medical operability) are collectively
considered when determining if surgical resection is appropriate and is performed
primarily for patients diagnosed in early stages in good health.100,102

Challenges in accessing care may also be impacting treatment utilization among
rural cancer patients. The U.S. rural population is dispersed over 97% of the nation’s
land area, making travel time to cancer treatment centers a barrier many rural patients
must overcome.186,187 A geographic analysis of drive times to cancer treatment centers
found that Native Americans, rural residents, and those living in the South had the
longest drive times to reach any cancer treatment centers.187 A separate study of treatment
access in Nevada found that rural residents in the state were less likely to get surgery and
have worse survival.236

Socioeconomic status (SES) also plays a role in lung cancer disparities, as lower
SES is related to higher smoking rates and higher cancer incidence.78 Among lung cancer
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patients, low SES is linked to lower likelihood of surgical resection, guideline-concordant
treatment, and lower survival.6,51,195,197 Even after adjusting for comorbidities, patients
with the lowest SES continue to have worse survival outcomes compared to those of
higher SES.6 For example, among lung cancer patients in Georgia, those in segregated
and poor neighborhoods were less likely to receive treatment for lung cancer.237
Differences in SES may be contributing to observed cancer disparities among rural and
black populations. While some have shown that adjusting for SES eliminates rural and
racial disparities,53,195 others have demonstrated that these disparities are reduced, but not
eliminated, after adjusting for SES.146,238,239

Patient residence (urban vs. rural), race, and SES impact receipt of cancer
treatment and thus survival. Improved understanding of disparities in utilization of
surgical treatment for lung cancer is a crucial step in reducing disease mortality. Our
objective was to examine disparities in receipt of surgical treatment for non-small cell
lung cancer by rural residence while controlling for independent patient- and county-level
determinants of surgical treatment.

6.3 Methods
Data
We examined a cohort of non-small cell lung cancer (NSCLC) patients from the
Surveillance, Epidemiology, and End Results (SEER) program cancer registry linked
with Medicare billing data (SEER-Medicare).200,240 Our cohort included patients
diagnosed from 2003-2011, aged 66 and older to ensure a minimum of 12 months of
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Medicare claims prior to lung cancer diagnosis. We excluded distant stage cases, as our
interest was to assess surgical treatment with curative intent, and surgical treatment is
primarily performed in early-stage cases. We also excluded patients with End Stage
Renal Disease, as the prognosis and treatment recommendations for these patients greatly
differ from cancer patients without ESRD. Our outcome, utilization of lung cancerrelated surgical treatment (yes/no) was defined from SEER records and Medicare billing
codes.201 A full list of the billing codes used are included in the appendix, Table A.1.
Patient demographics and clinical characteristics were also pulled from SEER data
including age at diagnosis, race, sex, marital status, Medicaid enrollment, stage at
diagnosis, tumor grade, and laterality. The Charlson comorbidity score was determined
from Medicare claims from 12 months to 1 month before lung cancer diagnosis using a
validated SAS macro from the National Institutes of Health.230

We examined geographic impacts at the county level. Patients were clustered by
county of residence at the time of diagnosis as reported by SEER. We used the 2003
Rural Urban Continuum Codes (RUCC) from the U.S. Department of Agriculture to
create a binary definition for rurality by collapsing county-level RUCC codes into
Metro/urban versus Nonmetro/rural categories.203 In addition to rurality, we examined
county fixed effects for the percent of the population over 65 in poverty (as a measure of
socioeconomic status of the county), and county Medically Underserved Area
designation (MUA).208 County MUAs are assigned by the Health Resources and Services
Administration through an index score including the ratio of healthcare providers per
1,000 population.208
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Analyses
We examined differences in the receipt of lung cancer-related surgical treatment
by patient demographic and clinical characteristics as well as county factors using chisquare tests for categorical variables and t-tests for continuous variables. We calculated
the unadjusted odds ratios (OR) with 95% confidence intervals (CI) of all patient-level
covariates with surgical treatment. All tests were assessed at the significance level
=0.05.

For the adjusted analysis, we employed a multilevel logistic regression,
specifically a random intercept is applied to county level, which allows the intercept to
vary randomly across counties, thus jointly estimating the county and patient effect in
receipt of surgical treatment.209 We first estimated the null model predicting surgery
utilization from only county-level random effects to measure the between-county
variance in receipt of surgical treatment. Using this intercept-only model we then
calculated the median odds ratio (MOR) to examine the median magnitude of the odds
ratio between two randomly chosen counties and the intraclass correlation coefficient
(ICC). MOR expresses the amount of individual probability of surgical utilization
attributed to county characteristics, where a MOR not equal to (or close to) 1.0 indicates
that the multilevel model is an appropriate statistical approach for the data.209 The ICC
measures the proportion of the total variance in surgical treatment that can be attributed
to the county level.210 Next, we built our level-one model with patient characteristics
predicting surgical utilization. We stratified by the patient stage at diagnosis, as treatment
decision differ from one stage to another. Patient variables deemed to be significant based
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on the literature related to our research question stayed in the models, and other patient
characteristics were selected by backward selection based on coefficients with a p-value
less than or equal to 0.05.

We tested for the need of random slopes for race, Medicaid enrollment, and
Charlson comorbidity score to allow for variation of these patient factors across counties.
We assessed the fit of each model by calculating the pseudo R-squared. Using the final
two-level model, we produced the estimated variance of the distribution of random
effects and ORs with 95% CIs for variables associated with utilizing surgical treatment
among early stage lung cancer patients. We also performed a post-hoc comparison of
county-level MUAs and the percent of poverty by urban and rural designations to assess
the representativeness of these factors in our sample covered by SEER registries in
comparison to the overall U.S.

6.4 Results
Patient Characteristics and Surgical Treatment
Our final cohort consisted of 63,767 NSCLC patients nested within 365 counties
(Table 6.1). The average age was 75.9 years (std=6.4) and the majority of the sample was
white (85.2%) and not enrolled in Medicaid (72.5%) (Table 6.1). Slightly more than half
were female (50.7%) and married (51.6%). Over half were diagnosed at a regional stage
(53.4%) and 46.6% at a localized stage. The majority of patients had right side laterality
(58.2%). Undetermined tumor grade was present in 35.6% of patients and 47.8% had no
comorbidities. Less than half of the total sample received surgery (46.1%).
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When examining differences in surgical treatment by stage, a higher proportion of
localized cases received surgery than regional cases (56.7% vs. 36.8%, Table 6.1).
Among localized cases, factors associated with higher likelihood of surgery were who
white race (57.8%) and not being married (64.2%, Table 6.2). Among regional cases,
factors associated with a greater probability of surgery were being categorized as other
races (41.2%) and married (42.0%) (Table 6.3). For both stages, factors associated with
greater likelihood of surgery were urban residence, not being on Medicaid, younger age
and having few comorbidities.

County Characteristics and Surgical Treatment
The majority of counties in which patients resided were urban (85.3%) and not
designated MUAs (62.5%). The mean county-level percent poverty for the 65 and older
population was 9.0%. (Table 6.1). When comparing receipt of surgical treatment, fewer
local stage rural residents received surgery than urban residents (57.7% vs. 50.5%,
p<0.01, Table 6.2). The same was true for comparing regional stage cases with 37.2% of
urban cases receiving surgery and 34.7% of rural residents receiving surgery (p=0.01,
Table 6.3). The mean county poverty for those 65 and older was similar for those who did
not receive surgery than for other who did (9.2% vs. 8.8%). When examined by MUA
designation, a significantly higher proportion of geographic MUA residents received
surgery than those not living in MUAs (48.9% vs, 44.4%). The same was true when
examined by stage at diagnosis.
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Model Selection
The intercept-only model indicated significant variation in receipt of surgical
treatment at the county level (p<0.01) with MOR=1.34 (Table 6.4). However, a low ICC
of 0.028 indicated that only 2.8% of the variation in surgical treatment was attributed to
the county level. Rurality was a borderline significant county-level fixed effect (p=0.05).
With the addition of MUA and percent of population in poverty over 65, the fixed effect
for rurality was no longer marginally significant (p=0.77). The fixed effect for MUA was
not significant (p=0.18) while the percent poverty fixed effect was highly significant at
p<0.01. We considered removing rurality and MUA from the model given the nonsignificant p-values (greater than 0.05) but based on significant likelihood ratio tests for
the model including both rurality and including MUA, we retained both variables in the
model. All patient-level demographic and clinical characteristics were significant at
p<0.01 and kept in the model. We tested random slopes for race, comorbidities, and
Medicaid enrollment, all of which were not significant and therefore not retained in the
model. The final model’s MOR for the random effect at the county-level was 1.38 and
the ICC increased slightly to 0.033. The pseudo R-squared improved from 0.01 in the
model with only county-level rurality to 0.51 in the final model for localized cases and
0.44 for regional cases.
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Multilevel Logistic Regression Results
In our final multilevel model stratified by stage, the county-level fixed effect for
the percent of poverty in the over 65 population was significant where the odds of
receiving surgical treatment decreased by 17% with each 5% increase in poverty among
localized stage cases (OR=0.83, 95% CI: 0.77-0.91) and by 16% for regional cases
(OR=0.84, 95%CI: 0.79-0.90) (Table 6.4). At the patient-level, a 5-year increase in age
also resulted in lower odds of surgical treatment for localized cases (OR=0.58, 95% CI:
0.56-0.59) and for regional cases (OR=0.74, 95%CI: 0.72-0.75). Men had lower odds of
receiving surgery when compared to women at both localized and regional stages. Black
patients had 43% lower odds of receiving surgery than white patients for localized stage
(OR=0.60, 95% CI: 0.56-0.66) and 37% lower odds for regional cases (OR=0.63, 95%CI:
0.56-0.70). For localized cases, those of other races also had lower odds of surgical
treatment than whites (OR=0.83, 95%CI: 0.73-0.95) while there was no significant
difference for regional stage patients categorized as other races compared with whites
(OR=1.04, 95% CI: 0.93-1.16). For both stages, non-married patients had lower odds of
surgery than married patients (localized OR=0.65, 95% CI:0.61-0.69; regional OR=0.70
95% CI:0.66-0.75), and those enrolled in Medicaid had lower odds of surgery compared
to those on Medicare alone (localized OR=0.83, 95% CI:0.73-0.95; regional OR=0.85,
95%CI:). An increasing number of comorbid conditions was associated with decreasing
odds of surgical treatment for both localized and regional cases. In terms of laterality,
when compared with right primary location the left location of tumors in localized cases
had slightly lower odds of surgery (OR=0.93, 95% CI:0.88-0.99), but regional cases had
higher odds of surgical treatment with left laterality vs. right (OR=1.19, 95% CI:1.13-
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1.26). Bilateral or midline locations had much lower odds of surgery for both stages
(localized OR=0.11, 95% CI:0.03-0.43; regional OR=0.09, 95% CI:0.04-0.17). Over onethird of the sample had undetermined tumor grade, which was associated with the lowest
odds of receiving surgery compared to well-differentiated grade for both stages (localized
OR=0.07, 95% CI:0.06-0.07; regional OR=0.05, 95%CI:0.05-0.06). Moderately
differentiated grade was not significantly different from well differentiated for either
stage. Poorly differentiated (localized OR=0.50, 95% CI:0.45-0.55; regional OR=0.54,
95%CI: 0.48-0.61) and undifferentiated (localized OR=0.54, 95% CI:0.43-0.67; regional
OR=0.56, 95%CI: 0.46-0.68) grades had similarly low odds of surgery in comparison to
well differentiated grade.

6.5 Discussion
In our examination of a large, national sample of local and regional stage NSCLC
patients, only 46.1% (n=29,381) received surgical treatment, with 57.4% of those
diagnosed at localized stage and 42.6% diagnosed at regional stage. In unadjusted
examination of surgical utilization, a lower proportion of rural residents received surgery
when compared to urban residents. When rurality was examined as a county-level fixed
effect, it was a borderline significant predictor of surgical treatment utilization (p=0.05),
where rural residents had decreased odds of surgical treatment. However, the relationship
of rurality and surgical treatment was attenuated with the addition of fixed effects for
county-level MUAs and percent poverty in the 65 and older population. The unadjusted
association of patient race and surgical treatment showed that black patients had lower
odds of receiving surgical treatment than white patients at both localized and regional
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stages. This relationship held true for black race in the adjusted multilevel model
controlling for patient demographic and clinical characteristics as well as county-level
effects. While both had lower odds of surgical treatment, the magnitude of the odds ratios
for black race and comorbidities were stronger among those diagnosed at localized stages
when compared with regional stage.

A higher percentage of rural residents living in poverty may be driving disparities
in treatment and furthermore a primary factor contributing to observed lower survival
among rural patients.233,241 When examining county-level fixed effects for surgical
treatment, poverty in the 65 and older population was highly significant (p<0.01) with
increasing poverty associated with lower odds of receiving surgical treatment. In our
sample, only 14.7% the of counties were rural, compared to 19.3% of the U.S.242
Furthermore, our data does not provide a representative sample of rural MUAs, as 54.6%
of the total MUAs in the U.S. are rural and another 9.3% are partially rural.208 In a posthoc comparison of county-level MUAs and poverty by urban/rural designation, rural
counties had a significantly higher percent of the 65 and older population living in
poverty at 11.3% compared to 8.7% for urban counties (p<0.01). Conversely, only 6.9%
of the rural counties in our sample were MUAs. In our multilevel model, MUA had a
positive but non-significant association with surgical utilization (OR=1.10, 95% CI: 0.971.25). Like rurality, the association between MUA and surgical utilization may be driven
by poverty levels, because MUA counties in our sample had a significantly lower mean
percent of the population over 65 living in poverty at 8.7% compared to 9.2% in nonMUA counties (p<0.01). 42
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Our analysis revealed that adjusting for county-level poverty eliminated the
significance of rurality and MUA. On the contrary, race remained a significant factor in
our adjusted analysis, with black patients having lower odds of surgical treatment when
compared to whites. Black cases of other cancer types are less likely to receive surgery as
well, citing fatalism and distrust in the medical community.243,244 Our results were similar
to those previously showing that black cancer patients diagnosed at early stages are less
likely to receive surgery than any other racial or ethnic group.5,6,10–12,245 Also like other
studies, 146,238,246 our results showed a reduction in racial disparities in surgical treatment
after adjusting for demographics including SES via county-level poverty, though the
reduction in the association was minimal when comparing black vs white cases (localized
unadjusted OR=0.55 vs. localized adjusted OR=0.57; regional unadjusted OR=0.58 vs.
regional adjusted OR=0.63).

While individual income is not available in SEER-Medicare data, we were able to
include Medicaid enrollment as a covariate. With Medicaid enrollment functioning as a
measure of individual income in our multilevel model, were able to conclude that those
enrolled in Medicaid (those with low incomes) had lower odds of receiving surgical
treatment than those not enrolled in Medicaid. This relationship should be reevaluated
with future data to examine the potential association of Medicaid expansion under the
Affordable Care Act on surgical receipt among Medicaid enrollees.

All patient-level demographic and clinical characteristics in our adjusted analysis
were significantly associated with receipt of surgical treatment for local and regional
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stage NSCLC. Increasing age and number of comorbidities were both associated with
decreasing odds of surgical treatment. Older age and comorbidities can create challenges
when deciding treatment plans for cancer patients as both are also related to worse
survival among lung cancer patients.247 Risk of surgery, recovery and quality of life
following surgery must be considered when treatment recommendations are made to
patients.247 We did not assess the physician’s recommendation of surgery; therefore, it is
possible that older patients and those with multiple comorbidities were not considered
eligible for surgical treatment.

Our results are limited by some aspects of the data source. SEER-Medicare data is
restricted to Fee-for-Service beneficiaries only and does not include those enrolled in
Medicare Advantage plans (approximately 25% of total Medicare beneficiaries in
2011).248 Individual smoking history is also not available, preventing us from controlling
for the potential effect of smoking on surgical treatment. Smoking has been cited as
reason for delay in treatment initiation,125 although not all current smoker patients who
attempt to quit are successful. This could potentially be an additional contributor for
some patients not receiving surgery. We also measured rurality at the county-level.
Counties vary greatly in both population sizes and geographic area across the U.S. Using
a county-level measure may have contributed to our null results. Granularity in rurality
measures may be more accurate when assessed at a smaller geographic region, such as
census tracts.
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Our study is strengthened by the large sample size, that although limited in rural
representation, still covers approximately 26% of cancer cases in the U.S. Our results
provide an updated analysis the urban vs. rural comparison of lung cancer treatment since
the 2017 publication of Atkins et al. based on patients diagnosed between 2000-2006.211
We also accounted for rurality in a multilevel model as a contextual effect rather than a
patient-level variable, portraying a more accurate depiction of geographic impacts on
health care utilization.249

6.6 Conclusions
While rural residence itself was not a significant predictor of surgical treatment,
the association of rurality was attenuated by area poverty, which is observed at higher
rates among rural populations. Area deprivation, measured by the percent of the
population age 65 and over living in poverty, appears to be a stronger driving factor in
surgical treatment utilization than rurality itself. Medicaid enrollment, a measure of
patient-level poverty, and black race were also associated with a reduced likelihood of
receiving surgery. We have documented lower utilization of surgical care for local and
regional lung cancer among lower socioeconomic status and black populations. The
reasons for these inequities are likely complex and multifaceted. Future research is
needed to understand the causes of these disparities in surgical treatment of lung cancer
so strategies to eliminate them may be developed.
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6.8 Tables
Table 6.1 Patient and County Level Characteristics by Receipt of Surgical
Treatment, NSCLC, SEER-Medicare 2003-2011
Total
N
Level 1 Patient Demographics
Total
63,767
Age
Mean (std)
75.9 (6.4)
Sex
Male
31,411
Female
32,356
Race
White
54,313
Black
4,979
Other
4,475
Marital Status
Married
32,870
Not Married
28,850
Unknown/Missing
2,047
Medicaid Enrollment
Yes
6,456
No
57,311
Level 1 Patient Clinical Characteristics
Stage at Diagnosis
Localized
29,743
Regional
34,024
Comorbidities
0
30,465
1
15,951
2
3,535
3 or higher
2,980
Laterality
Right: origin of
37,106
primary
Left: origin of primary 26,203
Bilateral, Midline, or
458
Unspecified
Grade
I, well differentiated
5,220
II, moderately
11,621
differentiated
III, poorly
10,175
differentiated
IV, undifferentiated
740
Undetermined
2,953
Level 2 County Characteristics

No Surgery
N (%)
34386 (53.9)

Surgery
N (%)

p-value

29381 (46.1)
<.01

77.4 (6.8)

74.2 (5.5)

17,141 (54.6)
17,245 (53.3)

14,270 (45.4)
15,111 (46.7)

<.01

28,718 (52.9)
3,341 (67.1)
2,327 (52.0)

25,595 (47.1)
1,638 (32.9)
2,148 (48.0)

<.01

15,685 (47.7)
17,475 (60.6)
1,226 (59.9)

17,185 (52.3)
11,375 (39.4)
821 (40.1)

<.01

4,124 (63.9)
30,262 (52.8)

2,332 (36.1)
27,049 (47.2)

<.01

<.01
12,888 (43.3)
21,498 (63.2)

16,855 (56.7)
12,526 (36.8)

14,928 (49.0)
8,622 (54.0)
5,022 (58.7)
5,814 (66.1)

15,537 (51.0)
7,329 (46.0)
3,535 (41.3)
2,980 (33.9)

20,061 (54.1)

17,045 (45.9)

13,884 (53.0)
441 (96.3)

12,319 (47.1)
17 (3.7)

1,328 (25.4)
4,521 (28.0)

3,892 (74.6)
11,621 (72.0)

8,203 (44.6)

10,175 (55.4)

562 (43.2)
19,772 (87.0)

740 (13.0)
2,953 (13.0)

<.01

<.01

<.01
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Rurality
Urban
Rural
Percent Poverty in
over 65 Population
Mean (std)
Medically
Underserved Areas
Yes
No

<.01
54,393
9,374

28,946 (53.2)
5,440 (58.0)

25,447 (46.8)
3,934 (42.0)
<.01

9.0 (3.2)

9.2 (3.3)

8.8 (3.0)
<.01

23,927
39,840

12,224 (51.1)
22,162 (55.6)
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11,703 (48.9)
17,678 (44.4)

Table 6.2 Patient and County Level Characteristics by Receipt of Surgical
Treatment among NSCLC Localized Stage Cases, SEER-Medicare 2003-2011
Total
N
Level 1 Patient Demographics
Total
29,743
Age
Mean (std)
76.1 (6.5)
Sex
Male
13,789
Female
15,954
Race
White
25,659
Black
2,067
Other
2,017
Marital Status
Married
13,489
Not Married
15,212
Unknown/Missing
1,042
Medicaid
Enrollment
No
26,682
Yes
3,061
Level 1 Patient Clinical Characteristics
Comorbidities
0
13,508
1
7,577
2
4,158
3 or higher
4,473
Laterality
Right: origin of
17,346
primary
Left: origin of
12,329
primary
Bilateral, Midline, or 68
Unspecified
Grade
I, well differentiated
3,730
II, moderately
8,338
differentiated
III, poorly
7,513
differentiated
IV, undifferentiated
534
Undetermined
9628
Level 2 County Characteristics
Rurality
Urban
25,448

Localized Stage
No Surgery
N (%)

Localized Stage
Surgery
N (%)

12,888 (43.3)

16,855 (56.7)

78.6 (6.8)

74.3 (5.5)

p-value

<0.01
0.47
5,944 (43.1)
6,944 (43.5)

7,845 (56.9)
9,010 (56.5)
<0.01

10,829 (42.2)
1,177 (56.9)
882 (43.7)

14,830 (57.8)
890 (43.0)
1,135 (56.3)
<0.01

6,899 (51.2)
5,443 (35.8)
546 (52.4)

6,590 (48.9)
9,769 (64.2)
496 (47.6)

11,164 (41.8)
1,724 (56.3)

15,518 (58.2)
1,337 (43.7)

4,862 (36.0)
3,335 (44.0)
2,086 (49.8)
2,605 (58.2)

8,646 (64.0)
4,242 (56.0)
2,099 (50.2)
1,868 (41.8)

<0.01

<0.01

<0.01
7,339 (42.3)

10,007 (57.7)

5,487 (44.5)

6,842 (55.5)

62 (91.2)

6 (8.8)

764 (20.5)
1,686 (20.2)

2,966 (79.5)
6,652 (79.8)

2,543 (33.9)

4,970 (67.8)

172 (32.2)
7723 (80.2)

362 (67.8)
1905 (19.8)

<0.01

<0.01
10,763 (42.3)
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14,685 (57.7)

Rural
Percent Poverty in
over 65 Population
Mean (std)
Medically
Underserved Areas
No
Yes

4,295

2,125 (49.5)

2,170 (50.5)

9.0 (3.2)

9.3 (3.3)

8.8 (3.0)

<0.01

<0.01
18,614
11,129

8379 (45.0)
4,509 (40.5)
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10,235 (55.0)
6,620 (59.5)

Table 6.3 Patient and County Level Characteristics by Receipt of Surgical
Treatment among NSCLC Regional Stage Cases, SEER-Medicare 2003-2011
Total
N
Level 1 Patient Demographics
Total
34,024
Age
Mean (std)
75.7 (6.4)
Sex
Male
17,622
Female
16,402
Race
White
28,654
Black
2,912
Other
2,458
Marital Status
Married
15,361
Not Married
17,658
Unknown/Missing
1,005
Medicaid
Enrollment
No
30,629
Yes
3,395
Level 1 Patient Clinical Characteristics
Comorbidities
0
16,957
1
8,374
2
4,372
3 or higher
4,321
Laterality
Right: origin of
19,760
primary
Left: origin of
13,874
primary
Bilateral, Midline, or 390
Unspecified
Grade
I, well differentiated
1,490
II, moderately
7,804
differentiated
III, poorly
10,865
differentiated
IV, undifferentiated
768
Undetermined
13,097
Level 2 County Characteristics
Rurality
Urban
28,945

Regional Stage
No Surgery
N (%)

Regional Stage
Surgery
N (%)

21,498 (63.2)

12,526 (36.8)

76.7 (6.6)

74.1 (5.5)

p-value

<0.01
0.16
11,197 (63.5)
10,301 (62.8)

6,425 (36.5)
6,101 (37.2)
<0.01

17,889 (62.4)
2,164 (74.3)
1,445 (58.8)

10,765 (37.6)
748 (25.7)
1,013 (41.2)
<0.01

10,242 (58.0)
10,576 (68.9)
680 (67.7)

7,416 (42.0)
4,785 (31.2)
325 (32.3)

19,098 (62.4)
2,400 (70.7)

11,531 (37.7)
995 (29.3)

10,066 (59.4)
5,287 (63.1)
2,936 (67.2)
3,209 (74.3)

6,891 (40.6)
3,087 (36.9)
1,436 (32.9)
1,112 (25.7)

<0.01

<0.01

<0.01
12,722 (64.4)

7,0.8 (35.6)

8,397 (60.5)

5,477 (39.5)

379 (97.2)

11 (2.8)

564 (37.9)
2,835 (36.3)

926 (62.2)
4,969 (63.7)

5,660 (52.1)

5,205 (47.9)

390 (50.8)
12,049 (92.0)

378 (49.2)
1,048 (8.00)

<0.01

0.01
18,183 (62.8)
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10,762 (37.2)

Rural
Percent Poverty in
over 65 Population
Mean (std)
Medically
Underserved Areas
No
Yes

5,079

3,315 (65.3)

1,764 (34.7)

9.0 (3.2)

9.2 (3.3)

8.9 (3.1)

<0.01
<0.01

21,226
12,798

13,783 (64.9)
7,715 (60.3)
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7,443 (35.1)
5,083 (39.7)

Table 6.4 Unadjusted Associations between Patient Characteristics and Surgical
Treatment of NSCLC, SEER-Medicare 2003-2011

Patient Fixed Effects
Age
5-year increase
Sex
Male
Female
Race
White
Black
Other
Marital Status
Married
Not Married
Medicaid Enrollment
No
Yes
Comorbidities
0
1
2
3 or more
Laterality
Right
Left
Bilateral, Midline, or Unspecified
Grade
I, well differentiated
II, moderately differentiated
III, poorly differentiated
IV, undifferentiated
Undetermined

Local Stage
OR (95% CI)

Regional Stage
OR (95% CI)

0.89 (0.89-0.90)

0.93 (0.93-0.94)

1.00 (Reference)
0.98 (0.94-1.03)

1.00 (Reference)
1.03 (0.99-1.08)

1.00 (Reference)
0.55 (0.50-0.60)
0.94 (0.86-1.03)

1.00 (Reference)
0.58 (0.53-0.63)
1.17 (1.07-1.27)

1.00 (Reference)
0.98 (0.94-1.03)

1.00 (Reference)
1.03 (0.99-1.08)

1.00 (Reference)
0.56 (0.52-0.60)

1.00 (Reference)
0.69 (0.64-0.74)

1.00 (Reference)
0.72 (0.68-0.76)
0.57 (0.53-0.61)
0.40 (0.38-0.43)

1.00 (Reference)
0.85 (0.81-0.90)
0.71 (0.67-0.77)
0.51 (0.47-0.55)

1.00 (Reference)
0.91 (0.87-0.96)
0.07 (0.03-0.16)

1.00 (Reference)
1.18 (1.13-1.23)
0.05 (0.02-0.10)

1.00 (Reference)
1.02 (0.92-1.12)
0.50 (0.46-0.55)
0.54 (0.45-0.66)
0.06 (0.06-0.07)

1.00 (Reference)
1.07 (0.95-1.30)
0.56 (0.50-0.63)
0.59 (0.50-0.70)
0.05 (0.05-0.06)
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Table 6.5 Results Summary of Multilevel Logistic Mixed Models for Surgical Treatment of NSCLC,
SEER-Medicare 2003-2011
Model 1
County
Random
Intercept
Only
Pseudo R2
County Random Effect
MOR
1.49
County Fixed Effects
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Rurality
Urban
Rural
Medically
Underserved
Areas
No
Yes
Percent
Poverty in over
age 65
5% increase
Patient Fixed Effects
Age
5-year increase

Model 2
County Random
Intercept and
Rurality Fixed
Effect

Model 3
County Random
Intercept, Rurality
and MUA Fixed
Effects
0.05

Model 4
Final Adjusted
County and
Patient Fixed
Effects,
Local Stage
0.51

Model 4
Final Adjusted
County and
Patient Fixed
Effects,
Regional Stage
0.44

0.00
1.34

1.33

1.38

1.38

OR (95% CI)

OR (95% CI)

OR (95% CI)

OR (95% CI)

1.00 (Reference)
0.95 (0.86-1.00)

1.00 (Reference)
0.95 (0.87-1.02)

1.00 (Reference)
0.87 (0.74-1.03)

1.00 (Reference)
1.09 (0.95-1.26)

1.00 (Reference)
1.14 (1.02-1.26)

1.00 (Reference)
1.05 (0.88-1.25)

1.00 (Reference)
1.14 (1.01-1.29)

0.85 (0.81-0.89)

0.83 (0.77-0.91)

0.84 (0.79-0.90)

OR (95% CI)

OR (95% CI)

0.58 (0.56-0.59)

0.74 (0.72-0.75)
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Sex
Male
Female
Race
White
Black
Other
Marital Status
Married
Not Married
Medicaid
Enrollment
No
Yes
Comorbidities
0
1
2
3 or more
Laterality
Right
Left
Bilateral,
Midline, or
Unspecified
Grade
I, well
differentiated
II, moderately
differentiated

1.00 (Reference)
0.85 (0.80-0.91)

1.00 (Reference)
0.82 (0.78-0.87)

1.00 (Reference)
0.57 (0.51-0.65)
0.83 (0.73-0.95)

1.00 (Reference)
0.63 (0.56-0.70)
1.04 (0.93-1.16)

1.00 (Reference)
0.65 (0.61-0.69)

1.00 (Reference)
0.70 (0.66-0.75)

1.00 (Reference)

1.00 (Reference)
0.85 (0.76-0.94)

1.00 (Reference)
0.75 (0.69-0.80)
0.64 (0.58-0.70)
0.46 (0.42-0.51)

1.00 (Reference)
0.91 (0.85-0.97)
0.86 (0.79-0.94)
0.67 (0.61-0.73)

1.00 (Reference)
0.93 (0.88-0.99)
0.11 (0.03-0.43)

1.00 (Reference)
1.19 (1.13-1.26)
0.09 (0.04-0.17)

1.00 (Reference)

1.00 (Reference)

1.07 (0.96-1.19)

1.07 (0.95-1.21)

III, poorly
differentiated
IV,
undifferentiated
Undetermined

0.50 (0.45-0.55)

0.54 (0.48-0.61)

0.54 (0.43-0.67)

0.56 (0.46-0.68)

0.07 (0.06-0.07)

0.05 (0.05-0.06)
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CHAPTER 7
CONCLUSIONS
The goals for this dissertation were to investigate rural and racial disparities in
lung cancer survival and treatment. The results provided updated U.S. estimates of
survival by rurality and region, examined the potential association between time to
treatment initiation and lung cancer survival, and identified inequities in surgical
treatment for lung cancer. These results enhance the understanding of lung cancer
survival disparities and identified lines of inquiry for future research.

The lung cancer landscape has evolved in many ways in recent years, with the
National Lung Screening Trial results and subsequent recommendations from the
USPSTF in 2013 to screen high risk patients annually. The Affordable Care Act has also
changed the national healthcare environment of the country since its inception. Our
results include patients diagnosed between 2003-2011, providing a useful baseline of
lung cancer survival differences by rurality that can be compared to future data
examining the impact of annual LDCT screening and ACA coverage.

The findings of our three papers provide additional insight into disparities in lung
cancer survival. Our first paper showed that both all cause and lung cancer specific
survival was lower among lung cancer patient residing in rural versus urban counties at
the time of their diagnosis, particularly in the South and West regions. Comorbidities and
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surgical treatment were strongly associated with the observed survival differences. These
results motivated the second research topic, examining if urban vs. rural differences in
time to treatment initiation could be a factor impacting the observed differences in
survival. In the second paper, having lung cancer surgery within 12 weeks of being
diagnosed was associated with greater survival benefit among localized and regional
stage lung cancer cases compared with distant cases when examined beyond 16 months
of follow-up. Conversely, in the first 16 months post-diagnosis, surgery initiation after 12
weeks was associated with better survival among all stages. Similarly, chemotherapy and
radiation initiation after 12 weeks post diagnosis was associated with lower risk of death
at all stages. Combinations of treatment types and differing sequences of treatments may
be contributing to our results. Delays in chemotherapy may be due to surgery or
procedures to confirm diagnosis, leading to a survival advantage. Further investigation
accounting in a more refined fashion for patterns of care within stage of diagnosis is
needed to better understand these observed differences.

The third paper, investigating racial and rural differences in the utilization of
surgical treatment of lung cancer, also identified potential factors contributing to
disparities in lung cancer survival. Among early stage cases, county-level poverty in the
aged 65 and older population was more strongly associated than rurality with the
likelihood of surgical treatment for lung cancer. Individual poverty (measured by
Medicaid enrollment) and black race were also associated with a lower likelihood of
surgery. Additional work is needed to better understand the complex causes of these
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disparities in surgical treatment of lung cancer so strategies to eliminate them may be
developed.

Overall, these findings advance understanding of the existing disparities in lung
cancer treatment and survival, especially for the urban versus rural comparisons that had
not previously been so thoroughly investigated. This includes the refined examination of
rural vs. urban residence across regions of the United States; to our knowledge, our
results are the first to also make urban vs. rural lung cancer survival comparisons by
region and they revealed that the association varied by region. As expected, a greater
comorbidity burden and not receiving surgical treatment were associated with worse
survival. Future research that examinations the potential benefits of effective
management of preexisting conditions during lung cancer treatment is warranted. For
example, uncontrolled diabetes could lessen survival independently and via worsening
response to lung cancer treatments. The evidence generated on time to treatment
initiation and survival needs to be further refined, but in the long run this evidence could
inform recommendations for timely surgical treatment in early stage cases. Consistent
with prior evidence, we observed that black race continues to have a lower likelihood of
surgery for lung cancer, indicating that black lung cancer patients may benefit from
targeted interventions addressing patient and provider education aimed at improving
utilization of surgery, when appropriate, in this population. The body of evidence
presented in this document contributes an advance in understanding disparities in lung
cancer survival, but this research area needs continued focus to further improve
understanding of the causal factors driving disparities in lung cancer survival.
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APPENDIX A
CPT, HCPCS, ICD CODES FOR LUNG CANCER TREATMENT
Table A.1 CPT, HCPCS, ICD Codes for Lung Cancer Treatment
Code Type

Code

Treatment Type

Description

HCPCS

C9216

Chemotherapy

ABARELIX

HCPCS

J9216

Chemotherapy

ABARELIX

HCPCS

J0128

Chemotherapy

ABARELIX

HCPCS

S0165

Chemotherapy

ABARELIX

HCPCS

J3490

Chemotherapy

ABATACEPT

HCPCS

C9230

Chemotherapy

ABATACEPT

HCPCS

J0129

Chemotherapy

ABATACEPT

HCPCS

J9354

Chemotherapy

ADO-TRASTUZUMAB EMTANSINE

HCPCS

C9131

Chemotherapy

ADO-TRASTUZUMAB EMTANSINE

HCPCS

J0178

Chemotherapy

AFLIBERCEPT

HCPCS

Q2046

Chemotherapy

AFLIBERCEPT

HCPCS

J9400

Chemotherapy

AFLIBERCEPT

HCPCS

J9015

Chemotherapy

ALDESLEUKIN

HCPCS

S0087

Chemotherapy

ALEMTUZUMAB

HCPCS

J9010

Chemotherapy

ALEMTUZUMAB

HCPCS

J0202

Chemotherapy

ALEMTUZUMAB

HCPCS

C9110

Chemotherapy

ALEMTUZUMAB

HCPCS

J9215

Chemotherapy

ALFERON

HCPCS

J0207

Chemotherapy

AMIFOSTINE

161

HCPCS

S0170

Chemotherapy

ANASTROZOLE

HCPCS

J9017

Chemotherapy

ARSENIC

HCPCS

C9012

Chemotherapy

ARSENIC

HCPCS

J9019

Chemotherapy

ASPARAGINASE

HCPCS

J9020

Chemotherapy

ASPARAGINASE

HCPCS

J9025

Chemotherapy

AZACITIDINE

HCPCS

C9416

Chemotherapy

BCG LIVE

HCPCS

J9031

Chemotherapy

BCG LIVE

HCPCS

Q2044

Chemotherapy

BELIMUMAB

HCPCS

J0490

Chemotherapy

BELIMUMAB

HCPCS

J9034

Chemotherapy

BENDAMUSTINE

HCPCS

J9033

Chemotherapy

BENDAMUSTINE

HCPCS

S0116

Chemotherapy

BEVACIZUMAB

HCPCS

C9257

Chemotherapy

BEVACIZUMAB

HCPCS

Q2024

Chemotherapy

BEVACIZUMAB

HCPCS

J9035

Chemotherapy

BEVACIZUMAB

HCPCS

C9214

Chemotherapy

BEVACIZUMAB

HCPCS

J9040

Chemotherapy

BLEOMYCIN

HCPCS

C9417

Chemotherapy

BLEOMYCIN

HCPCS

S0115

Chemotherapy

BORTEZOMIB

HCPCS

J9041

Chemotherapy

BORTEZOMIB

HCPCS

C9207

Chemotherapy

BORTEZOMIB

HCPCS

J9042

Chemotherapy

BRENTUXIMAB

HCPCS

J8510

Chemotherapy

BUSULFAN

HCPCS

C1178

Chemotherapy

BUSULFAN

HCPCS

J0594

Chemotherapy

BUSULFAN

HCPCS

J8520

Chemotherapy

CAPECITABINE

162

HCPCS

J8521

Chemotherapy

CAPECITABINE

HCPCS

J9045

Chemotherapy

CARBOPLATIN

HCPCS

J9047

Chemotherapy

CARFILZOMIB

HCPCS

J9050

Chemotherapy

CARMUSTINE

HCPCS

C9437

Chemotherapy

CARMUSTINE

HCPCS

J9055

Chemotherapy

CETUXIMAB

HCPCS

C9215

Chemotherapy

CETUXIMAB

HCPCS

G0360

Chemotherapy

CHEMOTHERAPY

HCPCS

C8954

Chemotherapy

CHEMOTHERAPY

HCPCS

C8955

Chemotherapy

CHEMOTHERAPY

HCPCS

G9029

Chemotherapy

CHEMOTHERAPY

HCPCS

G9031

Chemotherapy

CHEMOTHERAPY

HCPCS

G9030

Chemotherapy

CHEMOTHERAPY

HCPCS

G9032

Chemotherapy

CHEMOTHERAPY

HCPCS

G9021

Chemotherapy

CHEMOTHERAPY

HCPCS

G9022

Chemotherapy

CHEMOTHERAPY

HCPCS

G9023

Chemotherapy

CHEMOTHERAPY

HCPCS

G9024

Chemotherapy

CHEMOTHERAPY

HCPCS

G9025

Chemotherapy

CHEMOTHERAPY

HCPCS

G9026

Chemotherapy

CHEMOTHERAPY

HCPCS

G9027

Chemotherapy

CHEMOTHERAPY

HCPCS

G9028

Chemotherapy

CHEMOTHERAPY

HCPCS

G8372

Chemotherapy

CHEMOTHERAPY

HCPCS

G0359

Chemotherapy

CHEMOTHERAPY

HCPCS

G8373

Chemotherapy

CHEMOTHERAPY

HCPCS

G8374

Chemotherapy

CHEMOTHERAPY

HCPCS

G0355

Chemotherapy

CHEMOTHERAPY

163

HCPCS

C8953

Chemotherapy

CHEMOTHERAPY

HCPCS

S5019

Chemotherapy

CHEMOTHERAPY

HCPCS

S5020

Chemotherapy

CHEMOTHERAPY

HCPCS

Q0085

Chemotherapy

CHEMOTHERAPY

HCPCS

Q0084

Chemotherapy

CHEMOTHERAPY

HCPCS

Q0083

Chemotherapy

CHEMOTHERAPY

HCPCS

G0358

Chemotherapy

CHEMOTHERAPY

HCPCS

G0362

Chemotherapy

CHEMOTHERAPY

HCPCS

G0357

Chemotherapy

CHEMOTHERAPY

HCPCS

S9329

Chemotherapy

CHEMOTHERAPY

HCPCS

S9330

Chemotherapy

CHEMOTHERAPY

HCPCS

S9331

Chemotherapy

CHEMOTHERAPY

HCPCS

G0361

Chemotherapy

CHEMOTHERAPY

HCPCS

J9999

Chemotherapy

CHEMOTHERAPY

HCPCS

J8999

Chemotherapy

CHEMOTHERAPY

HCPCS

J7150

Chemotherapy

CHEMOTHERAPY

HCPCS

J3590

Chemotherapy

CHEMOTHERAPY

HCPCS

S0172

Chemotherapy

CHLORAMBUCIL

HCPCS

J9062

Chemotherapy

CISPLATIN

HCPCS

C9418

Chemotherapy

CISPLATIN

HCPCS

J9060

Chemotherapy

CISPLATIN

HCPCS

209622

Chemotherapy

CISPLATIN

HCPCS

C9419

Chemotherapy

CLADRIBINE

HCPCS

J9065

Chemotherapy

CLADRIBINE

HCPCS

J9027

Chemotherapy

CLOFARABINE

HCPCS

J9091

Chemotherapy

CYCLOPHOSPHAMIDE

HCPCS

J9070

Chemotherapy

CYCLOPHOSPHAMIDE

164

HCPCS

J9092

Chemotherapy

CYCLOPHOSPHAMIDE

HCPCS

J9080

Chemotherapy

CYCLOPHOSPHAMIDE

HCPCS

J9090

Chemotherapy

CYCLOPHOSPHAMIDE

HCPCS

C9420

Chemotherapy

CYCLOPHOSPHAMIDE

HCPCS

J9096

Chemotherapy

CYCLOPHOSPHAMIDE

HCPCS

J9093

Chemotherapy

CYCLOPHOSPHAMIDE

HCPCS

J9097

Chemotherapy

CYCLOPHOSPHAMIDE

HCPCS

J9094

Chemotherapy

CYCLOPHOSPHAMIDE

HCPCS

J9095

Chemotherapy

CYCLOPHOSPHAMIDE

HCPCS

C9421

Chemotherapy

CYCLOPHOSPHAMIDE

HCPCS

J8530

Chemotherapy

CYCLOPHOSPHAMIDE

HCPCS

C9438

Chemotherapy

CYCLOSPORINE

HCPCS

J9098

Chemotherapy

CYTARABINE

HCPCS

J9100

Chemotherapy

CYTARABINE

HCPCS

J9110

Chemotherapy

CYTARABINE

HCPCS

C9422

Chemotherapy

CYTARABINE

HCPCS

C1166

Chemotherapy

CYTARABINE

HCPCS

J9130

Chemotherapy

DACARBAZINE

HCPCS

J9140

Chemotherapy

DACARBAZINE

HCPCS

C9423

Chemotherapy

DACARBAZINE

HCPCS

J9120

Chemotherapy

DACTINOMYCIN

HCPCS

J9145

Chemotherapy

DARATUMUMAB

HCPCS

J9151

Chemotherapy

DAUNORUBICIN

HCPCS

J9150

Chemotherapy

DAUNORUBICIN

HCPCS

C9424

Chemotherapy

DAUNORUBICIN

HCPCS

J0894

Chemotherapy

DECITABINE

HCPCS

J9155

Chemotherapy

DEGARELIX

165

HCPCS

C1084

Chemotherapy

DENILEUKIN

HCPCS

J9160

Chemotherapy

DENILEUKIN

HCPCS

C9272

Chemotherapy

DENOSUMAB

HCPCS

J0897

Chemotherapy

DENOSUMAB

HCPCS

J8540

Chemotherapy

DEXAMETHASONE

HCPCS

J1094

Chemotherapy

DEXAMETHASONE

HCPCS

J1100

Chemotherapy

DEXAMETHASONE

HCPCS

J1190

Chemotherapy

DEXRAZOXANE

HCPCS

J9165

Chemotherapy

DIETHYLSTILBESTROL

HCPCS

J9170

Chemotherapy

DOCETAXEL

HCPCS

J9171

Chemotherapy

DOCETAXEL

HCPCS

J9000

Chemotherapy

DOXORUBICIN

HCPCS

J9001

Chemotherapy

DOXORUBICIN

HCPCS

C9415

Chemotherapy

DOXORUBICIN

HCPCS

J9002

Chemotherapy

DOXORUBICIN

HCPCS

Q2049

Chemotherapy

DOXORUBICIN

HCPCS

Q2048

Chemotherapy

DOXORUBICIN

HCPCS

Q2050

Chemotherapy

DOXORUBICIN

HCPCS

J9180

Chemotherapy

EPIRUBICIN

HCPCS

J9178

Chemotherapy

EPIRUBICIN

HCPCS

C1167

Chemotherapy

EPIRUBICIN

HCPCS

J9181

Chemotherapy

ETOPOSIDE

HCPCS

J9182

Chemotherapy

ETOPOSIDE

HCPCS

C9425

Chemotherapy

ETOPOSIDE

HCPCS

C9414

Chemotherapy

ETOPOSIDE

HCPCS

J8560

Chemotherapy

ETOPOSIDE

HCPCS

J7527

Chemotherapy

EVEROLIMUS

166

HCPCS

J8561

Chemotherapy

EVEROLIMUS

HCPCS

S0156

Chemotherapy

EXEMESTANE

HCPCS

J9200

Chemotherapy

FLOXURIDINE

HCPCS

C9426

Chemotherapy

FLOXURIDINE

HCPCS

J9185

Chemotherapy

FLUDARABINE

HCPCS

C9262

Chemotherapy

FLUDARABINE

HCPCS

J8562

Chemotherapy

FLUDARABINE

HCPCS

J9190

Chemotherapy

FLUOROURACIL

HCPCS

S0175

Chemotherapy

FLUTAMIDE

HCPCS

J9395

Chemotherapy

FULVESTRANT

HCPCS

C9434

Chemotherapy

GALLIUM

HCPCS

J1457

Chemotherapy

GALLIUM

HCPCS

J8565

Chemotherapy

GEFITINIB

HCPCS

J9201

Chemotherapy

GEMCITABINE

HCPCS

C9004

Chemotherapy

GEMTUZUMAB

HCPCS

J9300

Chemotherapy

GEMTUZUMAB

HCPCS

J1620

Chemotherapy

GONADORELIN

HCPCS

J9202

Chemotherapy

GOSERELIN

HCPCS

J9226

Chemotherapy

HISTRELIN

HCPCS

J9225

Chemotherapy

HISTRELIN

HCPCS

J1675

Chemotherapy

HISTRELIN

HCPCS

Q2020

Chemotherapy

HISTRELIN

HCPCS

G0356

Chemotherapy

HORMONE

HCPCS

S0176

Chemotherapy

HYDROXYUREA

HCPCS

A9522

Chemotherapy

IBRITUMOMAB

HCPCS

J9211

Chemotherapy

IDARUBICIN

HCPCS

C9429

Chemotherapy

IDARUBICIN

167

HCPCS

C9427

Chemotherapy

IFOSFAMIDE

HCPCS

J9208

Chemotherapy

IFOSFAMIDE

HCPCS

S0088

Chemotherapy

IMATINIB

HCPCS

S2107

Chemotherapy

IMMUNOTHERAPY

HCPCS

J9213

Chemotherapy

INTERFERON ALFA-2A

HCPCS

S0146

Chemotherapy

INTERFERON ALFA-2B

HCPCS

J9214

Chemotherapy

INTERFERON ALFA-2B

HCPCS

J9212

Chemotherapy

INTERFERON ALFACON

HCPCS

J1826

Chemotherapy

INTERFERON BETA-1A

HCPCS

J9228

Chemotherapy

IPILIMUMAB

HCPCS

J9206

Chemotherapy

IRINOTECAN

HCPCS

J9207

Chemotherapy

IXABEPILONE

HCPCS

J1930

Chemotherapy

LANREOTIDE

HCPCS

C9237

Chemotherapy

LANREOTIDE

HCPCS

J0640

Chemotherapy

LEUCOVORIN

HCPCS

J1950

Chemotherapy

LEUPROLIDE

HCPCS

J9217

Chemotherapy

LEUPROLIDE

HCPCS

J9219

Chemotherapy

LEUPROLIDE

HCPCS

J9218

Chemotherapy

LEUPROLIDE

HCPCS

S0177

Chemotherapy

LEVAMISOLE

HCPCS

J0641

Chemotherapy

LEVOLEUCOVORIN

HCPCS

S0178

Chemotherapy

LOMUSTINE

HCPCS

J9230

Chemotherapy

MECHLORETHAMINE

HCPCS

J1050

Chemotherapy

MEDROXYPROGESTERONE

HCPCS

J1051

Chemotherapy

MEDROXYPROGESTERONE

HCPCS

S0179

Chemotherapy

MEGESTROL

HCPCS

J9245

Chemotherapy

MELPHALAN
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HCPCS

J8600

Chemotherapy

MELPHALAN

HCPCS

S0108

Chemotherapy

MERCAPTOPURINE

HCPCS

J9209

Chemotherapy

MESNA

HCPCS

J9250

Chemotherapy

METHOTREXATE

HCPCS

J9260

Chemotherapy

METHOTREXATE

HCPCS

J8610

Chemotherapy

METHOTREXATE

HCPCS

J9290

Chemotherapy

MITOMYCIN

HCPCS

J9291

Chemotherapy

MITOMYCIN

HCPCS

J9280

Chemotherapy

MITOMYCIN

HCPCS

C9432

Chemotherapy

MITOMYCIN

HCPCS

J9293

Chemotherapy

MITOXANTRONE

HCPCS

J0340

Chemotherapy

NANDROLONE

HCPCS

J2320

Chemotherapy

NANDROLONE

HCPCS

J2321

Chemotherapy

NANDROLONE

HCPCS

J2322

Chemotherapy

NANDROLONE

HCPCS

J2323

Chemotherapy

NATALIZUMAB

HCPCS

Q4079

Chemotherapy

NATALIZUMAB

HCPCS

J9261

Chemotherapy

NELARABINE

HCPCS

J9299

Chemotherapy

NIVOLUMAB

HCPCS

J9301

Chemotherapy

OBINUTUZUMAB

HCPCS

J2352

Chemotherapy

OCTREOTIDE

HCPCS

J2353

Chemotherapy

OCTREOTIDE

HCPCS

J2354

Chemotherapy

OCTREOTIDE

HCPCS

J9302

Chemotherapy

OFATUMUMAB

HCPCS

C9297

Chemotherapy

OMACETAXINE

HCPCS

J9262

Chemotherapy

OMACETAXINE

HCPCS

J9263

Chemotherapy

OXALIPLATIN

169

HCPCS

C9205

Chemotherapy

OXALIPLATIN

HCPCS

J9264

Chemotherapy

PACLITAXEL

HCPCS

J9267

Chemotherapy

PACLITAXEL

HCPCS

J9265

Chemotherapy

PACLITAXEL

HCPCS

C9431

Chemotherapy

PACLITAXEL

HCPCS

J2430

Chemotherapy

PAMIDRONATE

HCPCS

C9235

Chemotherapy

PANITUMUMAB

HCPCS

J9303

Chemotherapy

PANITUMUMAB

HCPCS

J9266

Chemotherapy

PEGASPARGASE

HCPCS

C9027

Chemotherapy

PEMBROLIZUMAB

HCPCS

J9271

Chemotherapy

PEMBROLIZUMAB

HCPCS

J9305

Chemotherapy

PEMETREXED

HCPCS

C9213

Chemotherapy

PEMETREXED

HCPCS

J9268

Chemotherapy

PENTOSTATIN

HCPCS

J9306

Chemotherapy

PERTUZUMAB

HCPCS

J9270

Chemotherapy

PLICAMYCIN

HCPCS

J9600

Chemotherapy

PORFIMER

HCPCS

J9307

Chemotherapy

PRALATREXATE

HCPCS

S0182

Chemotherapy

PROCARBAZINE

HCPCS

J2675

Chemotherapy

PROGESTERONE

HCPCS

J9308

Chemotherapy

RAMUCIRUMAB

HCPCS

214693

Chemotherapy

RITUXIMAB

HCPCS

J9310

Chemotherapy

RITUXIMAB

HCPCS

J9315

Chemotherapy

ROMIDEPSIN

HCPCS

C9265

Chemotherapy

ROMIDEPSIN

HCPCS

A9604

Chemotherapy

SAMARIUM

HCPCS

A9605

Chemotherapy

SAMARIUM
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HCPCS

Q2043

Chemotherapy

SIPULEUCEL

HCPCS

J9320

Chemotherapy

STREPTOZOCIN

HCPCS

A9600

Chemotherapy

STRONTIUM-89

HCPCS

S0187

Chemotherapy

TAMOXIFEN

HCPCS

J9328

Chemotherapy

TEMOZOLOMIDE

HCPCS

C1086

Chemotherapy

TEMOZOLOMIDE

HCPCS

J8700

Chemotherapy

TEMOZOLOMIDE

HCPCS

J9330

Chemotherapy

TEMSIROLIMUS

HCPCS

Q2017

Chemotherapy

TENIPOSIDE

HCPCS

J1070

Chemotherapy

TESTOSTERONE

HCPCS

J1080

Chemotherapy

TESTOSTERONE

HCPCS

J1090

Chemotherapy

TESTOSTERONE

HCPCS

J1060

Chemotherapy

TESTOSTERONE

HCPCS

J3120

Chemotherapy

TESTOSTERONE

HCPCS

J3130

Chemotherapy

TESTOSTERONE

HCPCS

J0900

Chemotherapy

TESTOSTERONE

HCPCS

J3150

Chemotherapy

TESTOSTERONE

HCPCS

J3140

Chemotherapy

TESTOSTERONE

HCPCS

J9340

Chemotherapy

THIOTEPA

HCPCS

C9433

Chemotherapy

THIOTEPA

HCPCS

J3262

Chemotherapy

TOCILIZUMAB

HCPCS

J9351

Chemotherapy

TOPOTECAN

HCPCS

J9350

Chemotherapy

TOPOTECAN

HCPCS

J8705

Chemotherapy

TOPOTECAN

HCPCS

C9480

Chemotherapy

TRABECTEDIN

HCPCS

J9355

Chemotherapy

TRASTUZUMAB

HCPCS

J3315

Chemotherapy

TRIPTORELIN
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HCPCS

J9357

Chemotherapy

VALRUBICIN

HCPCS

J9360

Chemotherapy

VINBLASTINE

HCPCS

J9370

Chemotherapy

VINCRISTINE

HCPCS

J9375

Chemotherapy

VINCRISTINE

HCPCS

J9380

Chemotherapy

VINCRISTINE

HCPCS

J9371

Chemotherapy

VINCRISTINE

HCPCS

C9440

Chemotherapy

VINORELBINE

HCPCS

J9390

Chemotherapy

VINORELBINE

ICD-9

9928

Chemotherapy

CHEMOTHERAPY

ICD-9

9925

Chemotherapy

CHEMOTHERAPY

ICD-9

9929

Chemotherapy

CHEMOTHERAPY

ICD-9

177

Chemotherapy

CLOFARABINE

CPT

C9287

Chemotherapy

BRENTUXIMAB

CPT

J9043

Chemotherapy

CABAZITAXEL

CPT

4180F

Chemotherapy

CHEMOTHERAPY

CPT

36640

Chemotherapy

CHEMOTHERAPY

CPT

96446

Chemotherapy

CHEMOTHERAPY

CPT

96445

Chemotherapy

CHEMOTHERAPY

CPT

96440

Chemotherapy

CHEMOTHERAPY

CPT

96450

Chemotherapy

CHEMOTHERAPY

CPT

96423

Chemotherapy

CHEMOTHERAPY

CPT

96425

Chemotherapy

CHEMOTHERAPY

CPT

96422

Chemotherapy

CHEMOTHERAPY

CPT

96420

Chemotherapy

CHEMOTHERAPY

CPT

96415

Chemotherapy

CHEMOTHERAPY

CPT

96417

Chemotherapy

CHEMOTHERAPY

CPT

96416

Chemotherapy

CHEMOTHERAPY
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CPT

96413

Chemotherapy

CHEMOTHERAPY

CPT

96410

Chemotherapy

CHEMOTHERAPY

CPT

96408

Chemotherapy

CHEMOTHERAPY

CPT

96402

Chemotherapy

CHEMOTHERAPY

CPT

96401

Chemotherapy

CHEMOTHERAPY

CPT

96400

Chemotherapy

CHEMOTHERAPY

CPT

96406

Chemotherapy

CHEMOTHERAPY

CPT

96405

Chemotherapy

CHEMOTHERAPY

CPT

96411

Chemotherapy

CHEMOTHERAPY

CPT

96409

Chemotherapy

CHEMOTHERAPY

CPT

219583

Chemotherapy

CHEMOTHERAPY

CPT

96542

Chemotherapy

CHEMOTHERAPY

CPT

203682

Chemotherapy

CHEMOTHERAPY

CPT

96414

Chemotherapy

CHEMOTHERAPY

CPT

96412

Chemotherapy

CHEMOTHERAPY

CPT

242226

Chemotherapy

CHEMOTHERAPY

CPT

61517

Chemotherapy

CHEMOTHERAPY

CPT

219687

Chemotherapy

CHEMOTHERAPY

CPT

0519F

Chemotherapy

CHEMOTHERAPY

CPT

96545

Chemotherapy

CHEMOTHERAPY

CPT

206820

Chemotherapy

CHEMOTHERAPY

CPT

206929

Chemotherapy

CHEMOTHERAPY

CPT

96549

Chemotherapy

CHEMOTHERAPY

CPT

J9179

Chemotherapy

ERIBULIN

CPT

81350

Chemotherapy

IRINOTECAN

CPT

83520

Chemotherapy

METHOTREXATE

ICD-9

922

Radiation

Brachytherapy
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ICD-9

9221

Radiation

Beam

ICD-9

9222

Radiation

Beam

ICD-9

9223

Radiation

Beam

ICD-9

9224

Radiation

Beam

ICD-9

9225

Radiation

Beam

ICD-9

9226

Radiation

Beam

ICD-9

9227

Radiation

Brachytherapy

ICD-9

9228

Radiation

Isotopes

ICD-9

9229

Radiation

General

ICD-9

923

Radiation

Beam

ICD-9

9231

Radiation

Beam

ICD-9

9232

Radiation

Beam

ICD-9

9233

Radiation

Beam

ICD-9

9239

Radiation

Beam

ICD-9

9241

Radiation

Beam

ICD-9

9220

Radiation

Brachytherapy

ICD-9

9230

Radiation

Beam

CPT

0073T

Radiation

Beam

CPT

0082T

Radiation

Beam

CPT

0083T

Radiation

Beam

CPT

0182T

Radiation

Brachytherapy

CPT

0190T

Radiation

Brachytherapy

CPT

0197T

Radiation

Beam

CPT

19296

Radiation

Brachytherapy

CPT

19297

Radiation

Brachytherapy

CPT

19298

Radiation

Brachytherapy

CPT

20555

Radiation

Brachytherapy
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CPT

20660

Radiation

Beam

CPT

31463

Radiation

Brachytherapy

CPT

32553

Radiation

General

CPT

41019

Radiation

Brachytherapy

CPT

49411

Radiation

General

CPT

49412

Radiation

General

CPT

52250

Radiation

Brachytherapy

CPT

55859

Radiation

Brachytherapy

CPT

55860

Radiation

Brachytherapy

CPT

55875

Radiation

Brachytherapy

CPT

55876

Radiation

General

CPT

55920

Radiation

Brachytherapy

CPT

57155

Radiation

Brachytherapy

CPT

57156

Radiation

Brachytherapy

CPT

58346

Radiation

Brachytherapy

CPT

61720

Radiation

Beam

CPT

61735

Radiation

Beam

CPT

61770

Radiation

Beam

CPT

61781

Radiation

Beam

CPT

61782

Radiation

Beam

CPT

61783

Radiation

Beam

CPT

61793

Radiation

Beam

CPT

61795

Radiation

Beam

CPT

61796

Radiation

Beam

CPT

61797

Radiation

Beam

CPT

61798

Radiation

Beam

CPT

61799

Radiation

Beam
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CPT

61800

Radiation

Beam

CPT

63620

Radiation

Beam

CPT

63621

Radiation

Beam

CPT

73670

Radiation

Beam

CPT

76950

Radiation

Beam

CPT

76965

Radiation

Brachytherapy

CPT

77014

Radiation

Beam

CPT

77261

Radiation

Beam

CPT

77262

Radiation

Beam

CPT

77263

Radiation

Beam

CPT

77280

Radiation

Beam

CPT

77285

Radiation

Beam

CPT

77290

Radiation

Beam

CPT

77295

Radiation

Beam

CPT

77299

Radiation

Beam

CPT

77300

Radiation

Beam

CPT

77301

Radiation

Beam

CPT

77305

Radiation

Beam

CPT

77306

Radiation

Beam

CPT

77307

Radiation

Beam

CPT

77310

Radiation

Beam

CPT

77315

Radiation

Beam

CPT

77321

Radiation

Beam

CPT

77326

Radiation

Brachytherapy

CPT

77326

Radiation

Brachytherapy

CPT

77327

Radiation

Brachytherapy

CPT

77327

Radiation

Brachytherapy
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CPT

77328

Radiation

Brachytherapy

CPT

77328

Radiation

Brachytherapy

CPT

77331

Radiation

General

CPT

77332

Radiation

General

CPT

77333

Radiation

General

CPT

77334

Radiation

General

CPT

77336

Radiation

General

CPT

77338

Radiation

Beam

CPT

77370

Radiation

Beam

CPT

77370

Radiation

General

CPT

77371

Radiation

Beam

CPT

77372

Radiation

Beam

CPT

77373

Radiation

Beam

CPT

77380

Radiation

Beam

CPT

77381

Radiation

Beam

CPT

77385

Radiation

Beam

CPT

77386

Radiation

Beam

CPT

77387

Radiation

Beam

CPT

77399

Radiation

General

CPT

77400

Radiation

Beam

CPT

77401

Radiation

Beam

CPT

77402

Radiation

Beam

CPT

77403

Radiation

Beam

CPT

77404

Radiation

Beam

CPT

77405

Radiation

Beam

CPT

77406

Radiation

Beam

CPT

77407

Radiation

Beam
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CPT

77408

Radiation

Beam

CPT

77409

Radiation

Beam

CPT

77410

Radiation

Beam

CPT

77411

Radiation

Beam

CPT

77412

Radiation

Beam

CPT

77413

Radiation

Beam

CPT

77414

Radiation

Beam

CPT

77415

Radiation

Beam

CPT

77416

Radiation

Beam

CPT

77417

Radiation

Beam

CPT

77418

Radiation

Beam

CPT

77419

Radiation

General

CPT

77420

Radiation

General

CPT

77421

Radiation

General

CPT

77422

Radiation

Beam

CPT

77423

Radiation

Beam

CPT

77425

Radiation

General

CPT

77427

Radiation

General

CPT

77430

Radiation

General

CPT

77431

Radiation

General

CPT

77432

Radiation

Beam

CPT

77435

Radiation

Beam

CPT

77469

Radiation

Beam

CPT

77470

Radiation

Beam

CPT

77499

Radiation

General

CPT

77520

Radiation

Beam

CPT

77522

Radiation

Beam
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CPT

77523

Radiation

Beam

CPT

77525

Radiation

Beam

CPT

77750

Radiation

Isotopes

CPT

77761

Radiation

Brachytherapy

CPT

77762

Radiation

Brachytherapy

CPT

77763

Radiation

Brachytherapy

CPT

77776

Radiation

Brachytherapy

CPT

77777

Radiation

Brachytherapy

CPT

77778

Radiation

Brachytherapy

CPT

77781

Radiation

Brachytherapy

CPT

77782

Radiation

Brachytherapy

CPT

77783

Radiation

Brachytherapy

CPT

77784

Radiation

Brachytherapy

CPT

77785

Radiation

Brachytherapy

CPT

77786

Radiation

Brachytherapy

CPT

77787

Radiation

Brachytherapy

CPT

77789

Radiation

Brachytherapy

CPT

77790

Radiation

Brachytherapy

CPT

77799

Radiation

Brachytherapy

CPT

79005

Radiation

Isotopes

CPT

79030

Radiation

Isotopes

CPT

79035

Radiation

Isotopes

CPT

79100

Radiation

Isotopes

CPT

79101

Radiation

Isotopes

CPT

79200

Radiation

Isotopes

CPT

79300

Radiation

Isotopes

CPT

79400

Radiation

Isotopes
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CPT

79403

Radiation

Isotopes

CPT

79420

Radiation

Isotopes

CPT

79440

Radiation

Isotopes

CPT

79445

Radiation

Isotopes

CPT

79900

Radiation

Isotopes

CPT

79999

Radiation

Isotopes

HCPCS

A9606

Radiation

Isotopes

HCPCS

A9699

Radiation

Isotopes

HCPCS

C1715

Radiation

Brachytherapy

HCPCS

C1716

Radiation

Brachytherapy

HCPCS

C1717

Radiation

Brachytherapy

HCPCS

C1718

Radiation

Brachytherapy

HCPCS

C1719

Radiation

Brachytherapy

HCPCS

C1720

Radiation

Brachytherapy

HCPCS

C1728

Radiation

Brachytherapy

HCPCS

C2616

Radiation

Brachytherapy

HCPCS

C2633

Radiation

Brachytherapy

HCPCS

C2634

Radiation

Brachytherapy

HCPCS

C2635

Radiation

Brachytherapy

HCPCS

C2636

Radiation

Brachytherapy

HCPCS

C2637

Radiation

Brachytherapy

HCPCS

C2638

Radiation

Brachytherapy

HCPCS

C2639

Radiation

Brachytherapy

HCPCS

C2640

Radiation

Brachytherapy

HCPCS

C2641

Radiation

Brachytherapy

HCPCS

C2642

Radiation

Brachytherapy

HCPCS

C2643

Radiation

Brachytherapy
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HCPCS

C2698

Radiation

Brachytherapy

HCPCS

C2699

Radiation

Brachytherapy

HCPCS

C9726

Radiation

Brachytherapy

HCPCS

C9728

Radiation

Brachytherapy

HCPCS

G0173

Radiation

Beam

HCPCS

G0174

Radiation

Beam

HCPCS

G0242

Radiation

Beam

HCPCS

G0243

Radiation

Beam

HCPCS

G0251

Radiation

Beam

HCPCS

G0338

Radiation

Beam

HCPCS

G0339

Radiation

Beam

HCPCS

G0340

Radiation

Beam

HCPCS

G6003

Radiation

Beam

HCPCS

G6004

Radiation

Beam

HCPCS

G6005

Radiation

Beam

HCPCS

G6006

Radiation

Beam

HCPCS

G6007

Radiation

Beam

HCPCS

G6008

Radiation

Beam

HCPCS

G6009

Radiation

Beam

HCPCS

G6010

Radiation

Beam

HCPCS

G6011

Radiation

Beam

HCPCS

G6012

Radiation

Beam

HCPCS

G6013

Radiation

Beam

HCPCS

G6014

Radiation

Beam

HCPCS

G6015

Radiation

Beam

HCPCS

G6016

Radiation

Beam

HCPCS

Q3001

Radiation

Brachytherapy
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HCPCS

S2270

Radiation

Brachytherapy

HCPCS

S8049

Radiation

Beam

HCPCS

C1325

Radiation

Brachytherapy

HCPCS

C1348

Radiation

Isotopes

HCPCS

C1350

Radiation

Brachytherapy

HCPCS

C1700

Radiation

Brachytherapy

HCPCS

C1701

Radiation

Brachytherapy

HCPCS

C1702

Radiation

Brachytherapy

HCPCS

C1703

Radiation

Brachytherapy

HCPCS

C1704

Radiation

Brachytherapy

HCPCS

C1705

Radiation

Brachytherapy

HCPCS

C1706

Radiation

Brachytherapy

HCPCS

C1707

Radiation

Brachytherapy

HCPCS

C1708

Radiation

Brachytherapy

HCPCS

C1709

Radiation

Brachytherapy

HCPCS

C1710

Radiation

Brachytherapy

HCPCS

C1711

Radiation

Brachytherapy

HCPCS

C1712

Radiation

Brachytherapy

HCPCS

C1790

Radiation

Brachytherapy

HCPCS

C1791

Radiation

Brachytherapy

HCPCS

C1792

Radiation

Brachytherapy

HCPCS

C1793

Radiation

Brachytherapy

HCPCS

C1794

Radiation

Brachytherapy

HCPCS

C1795

Radiation

Brachytherapy

HCPCS

C1796

Radiation

Brachytherapy

HCPCS

C1797

Radiation

Brachytherapy

HCPCS

C1798

Radiation

Brachytherapy
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HCPCS

C1799

Radiation

Brachytherapy

HCPCS

C1800

Radiation

Brachytherapy

HCPCS

C1801

Radiation

Brachytherapy

HCPCS

C1802

Radiation

Brachytherapy

HCPCS

C1803

Radiation

Brachytherapy

HCPCS

C1804

Radiation

Brachytherapy

HCPCS

C1805

Radiation

Brachytherapy

HCPCS

C1806

Radiation

Brachytherapy

HCPCS

C2632

Radiation

Brachytherapy

HCPCS

C9714

Radiation

Brachytherapy

HCPCS

C9715

Radiation

Beam

HCPCS

G0178

Radiation

Beam

HCPCS

G0256

Radiation

Brachytherapy

HCPCS

G0273

Radiation

Isotopes

HCPCS

G0274

Radiation

Isotopes

HCPCS

G0338

Radiation

Beam

HCPCS

G0339

Radiation

Beam

HCPCS

G0340

Radiation

Beam

HCPCS

G0458

Radiation

Brachytherapy

HCPCS

C2644

Radiation

Brachytherapy

HCPCS

C2645

Radiation

Brachytherapy

CPT

3220

Surgery

CPT

3229

Surgery

CPT

3230

Surgery

CPT

3239

Surgery

CPT

3241

Surgery

CPT

3249

Surgery
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CPT

3250

Surgery

CPT

3259

Surgery

CPT

3260

Surgery

CPT

32095

Surgery

CPT

32096

Surgery

CPT

32097

Surgery

CPT

32098

Surgery

CPT

32100

Surgery

CPT

32124

Surgery

CPT

32140

Surgery

CPT

32141

Surgery

CPT

32150

Surgery

CPT

32402

Surgery

CPT

32440

Surgery

CPT

32445

Surgery

CPT

32480

Surgery

CPT

32480

Surgery

CPT

32482

Surgery

CPT

32484

Surgery

CPT

32486

Surgery

CPT

32488

Surgery

CPT

32491

Surgery

CPT

32500

Surgery

CPT

32503

Surgery

CPT

32504

Surgery

CPT

32505

Surgery

CPT

32506

Surgery

Lobectomy

Segmentectomy

Wedge Resection

184

CPT

32507

Surgery

CPT

32601

Surgery

CPT

32602

Surgery

CPT

32603

Surgery

CPT

32605

Surgery

CPT

32607

Surgery

CPT

32608

Surgery

CPT

32609

Surgery

CPT

32610

Surgery

CPT

32657

Surgery

CPT

32657

Surgery

CPT

32660

Surgery

CPT

32663

Surgery

CPT

32663

Surgery

CPT

32663

Surgery

CPT

32666

Surgery

CPT

32667

Surgery

CPT

32668

Surgery

CPT

32669

Surgery

CPT

32670

Surgery

CPT

32671

Surgery

CPT

32672

Surgery

CPT

32673

Surgery

CPT

32674

Surgery

CPT

38746

Surgery

VATS Wedge Resection

Thoracoscopy
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